start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=167
end-page=176
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This prospective observational study investigated the clinical status of patients with advanced non-small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy+an immune checkpoint inhibitor (chemo + IO) as first-line treatment in a real-world setting. The cases of 98 patients treated with chemo + IO were prospectively collected and analyzed for effectiveness and safety. The response rate to chemo + IO was 46.9%, and the disease control rate was 76.5%. The median progression-free survival and overall survival (OS) in the total population were 5.2 and 22.3 months, respectively. The patients positive for PD-L1 (≥ 1%) showed significantly longer OS than the negative group (<1%) (median 26.7 vs. 18.7 months, p=0.04). Pre-existing interstitial lung disease (ILD) was associated with shorter OS than the absence of ILD (median 9.0 vs. 22.6 months, p<0.01). Immunerelated adverse events (irAEs) were observed in 28 patients (28.6%). The most frequent irAE was ILD (n=11); Grade 1 (n=1 patient), G2 (n=5), G3 (n=4), and only a single patient with a G5 irAE. In this CS-Lung-003 study, first-line chemo + IO in a real-world setting showed good effectiveness, comparable to that observed in international clinical trials. In real-world practice, chemo + IO is a promising and steadfast strategy.
en-copyright=
kn-copyright=

en-aut-name=KanajiNobuhiro
en-aut-sei=Kanaji
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiiKazuya
en-aut-sei=Nishii
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsubataYukari
en-aut-sei=Tsubata
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaoMika
en-aut-sei=Nakao
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkunoTakae
en-aut-sei=Okuno
en-aut-mei=Takae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkawaSachi
en-aut-sei=Okawa
en-aut-mei=Sachi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakataKenji
en-aut-sei=Takata
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KodaniMasahiro
en-aut-sei=Kodani
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiMasahiro
en-aut-sei=Yamasaki
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujitakaKazunori
en-aut-sei=Fujitaka
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaTetsuya
en-aut-sei=Kubota
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CS-Lung-003 Investigator
en-aut-sei=CS-Lung-003 Investigator
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University
kn-affil=

affil-num=9
en-affil=Department of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital
kn-affil=

affil-num=10
en-affil=Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine and Allergology, Kochi University
kn-affil=

affil-num=12
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=14
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=
kn-affil=
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
en-keyword=real-world
kn-keyword=real-world
en-keyword=first-line
kn-keyword=first-line
en-keyword=immune checkpoint inhibitor
kn-keyword=immune checkpoint inhibitor
en-keyword=combined immunotherapy
kn-keyword=combined immunotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=139
end-page=144
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safe Resection of Esophageal Cancer with a Non-Recurrent Inferior Laryngeal Nerve Associated with an Aberrant Right Subclavian Artery Using Intraoperative Nerve Monitoring
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In thoracic esophageal cancer, lymph node dissection around the recurrent laryngeal nerve is crucial but poses a risk of nerve palsy, affecting postoperative quality of life. In cases with an aberrant right subclavian artery (ARSA), the right recurrent laryngeal nerve is absent, and the non-recurrent inferior laryngeal nerve (NRILN) enters the larynx directly from the vagus nerve in the cervical region. Identifying the course of the NRILN is vital to avoid injury. A case of esophageal cancer with an ARSA, in which the course of the NRILN was preserved using the Nerve Integrity Monitoring (NIM) system during surgery, is described.
en-copyright=
kn-copyright=

en-aut-name=TakedaYasushige
en-aut-sei=Takeda
en-aut-mei=Yasushige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaedaNaoaki
en-aut-sei=Maeda
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MizusawaYohei
en-aut-sei=Mizusawa
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatsumotoHijiri
en-aut-sei=Matsumoto
en-aut-mei=Hijiri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KondoYuhei
en-aut-sei=Kondo
en-aut-mei=Yuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KunitomoTomoyoshi
en-aut-sei=Kunitomo
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanoueYukinori
en-aut-sei=Tanoue
en-aut-mei=Yukinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HashimotoMasashi
en-aut-sei=Hashimoto
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanabeShunsuke
en-aut-sei=Tanabe
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=
en-keyword=esophageal cancer
kn-keyword=esophageal cancer
en-keyword=intraoperative nerve monitoring
kn-keyword=intraoperative nerve monitoring
en-keyword=aberrant right subclavian artery
kn-keyword=aberrant right subclavian artery
en-keyword=non-recurrent inferior laryngeal nerve
kn-keyword=non-recurrent inferior laryngeal nerve
en-keyword=thoracoscopic esophagectomy
kn-keyword=thoracoscopic esophagectomy
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=65
end-page=73
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between the Pretreatment Body Mass Index and Anamorelin’s Efficacy in Patients with Cancer Cachexia: A Retrospective Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Anamorelin (ANAM) is used to treat cancer-associated cachexia, a syndrome involving muscle loss and anorexia. The timing of the initiation of ANAM treatment is crucial to its efficacy. Although the body mass index (BMI) is a diagnostic criterion for cancer cachexia, no studies have explored its association with ANAM efficacy. We conducted a single-center, retrospective cohort study to investigate the association between the pre-treatment BMI and ANAM efficacy in patients with cancer-associated cachexia (n=47). The ANAM treatment was considered effective if the patient’s appetite improved within 30 days of treatment initiation. We calculated a BMI cutoff value (19.5 kg/m2) and used it to divide the patients into high- and low-BMI groups. Their background, clinical laboratory values, cancer types, and treatment lines were investigated. Twenty (42.6%) had a high BMI (≥ 19.5 kg/m2) and 27 (57.4%) had a low BMI (< 19.5 kg/m2). High BMI was significantly associated with ANAM effectiveness (odds ratio 7.86, 95% confidence interval 1.99-31.00, p=0.003). Together these results indicate that it is beneficial to initiate ANAM treatment before a patient’s BMI drops below 19.5 kg/m2. Our findings will help advance cancer cachexia treatment and serve as a reference for clinicians to predict ANAM’s efficacy.
en-copyright=
kn-copyright=

en-aut-name=MakiMasatoshi
en-aut-sei=Maki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakadaRyo
en-aut-sei=Takada
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshigoTomoyuki
en-aut-sei=Ishigo
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraMiki
en-aut-sei=Fujiwara
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYoko
en-aut-sei=Takahashi
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaShinya
en-aut-sei=Otsuka
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TamuraKoji
en-aut-sei=Tamura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HamaokaTerutaka
en-aut-sei=Hamaoka
en-aut-mei=Terutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=2
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Sapporo Medical University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Surgery, NHO Fukuyama Medical Center
kn-affil=

affil-num=7
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=8
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=
en-keyword=anamorelin
kn-keyword=anamorelin
en-keyword=cancer-associated cachexia
kn-keyword=cancer-associated cachexia
en-keyword=body mass index
kn-keyword=body mass index
en-keyword=albumin
kn-keyword=albumin
en-keyword=efficacy rate
kn-keyword=efficacy rate
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=
article-no=
start-page=1547222
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250311
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Interleukin-6/soluble IL-6 receptor-induced secretion of cathepsin B and L from human gingival fibroblasts is regulated by caveolin-1 and ERK1/2 pathways
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims: Cathepsins are essential lysosomal enzymes that maintain organismal homeostasis by degrading extracellular substrates. The inflammatory cytokine interleukin-6 (IL-6) increases the production of cathepsins through the caveolin-1 (Cav-1) and c-Jun N-terminal kinase (JNK) signaling pathways, which have been implicated in the destruction of periodontal tissue. This study investigated the effect of the IL-6/soluble IL-6 receptor (sIL-6R) complex on the extracellular secretion of cathepsins in human gingival fibroblasts (HGFs) and examined the function of extracellularly secreted cathepsins B and L under acidic culture conditions in vitro.<br>
Methods: HGFs were isolated from healthy volunteer donors. The expression of Cav-1 was suppressed via transfection with small interfering RNA (siRNA) targeting Cav-1. The expression levels of cathepsins B and L induced by extracellular IL-6/sIL-6R were measured using western blotting and enzyme-linked immunosorbent assay. Extracellular cathepsin activity following IL-6/sIL-6R stimulation was assessed using a methylcoumarylamide substrate in a fluorescence-based assay. IL-6/sIL-6R-induced expression of cathepsins B and L in HGFs was quantified under inhibitory conditions for extracellular signal-regulated kinase (ERK) 1/2 and/or JNK signaling, both of which are transduction pathways activated by IL-6/sIL-6R. This quantification was also performed in HGFs with suppressed Cav-1 expression using western blotting.<br>
Results: Cathepsins B and L were secreted in their precursor forms from HGFs, with significantly elevated protein levels observed at 24, 48, and 72 h post-IL-6/sIL-6R stimulation. Under acidic culture conditions, cathepsin B activity increased at 48 and 72 h. Cav-1 suppression inhibited the secretion of cathepsin B regardless of IL-6/sIL-6R stimulation, whereas the secretion of cathepsin L was reduced only after 48 h of IL-6/sIL-6R stimulation. Inhibition of ERK1/2 and JNK pathways decreased the secretion of cathepsin B after 48 h of IL-6/sIL-6R stimulation, and JNK inhibition reduced the secretion of cathepsin L under similar conditions.<br>
Conclusion: IL-6/sIL-6R stimulation increased the extracellular secretion of cathepsin B and L precursors in HGFs, and these precursors became activated under acidic conditions. Cav-1 and ERK1/2 are involved in regulating the secretion of cathepsin B precursors.
en-copyright=
kn-copyright=

en-aut-name=GotoAyaka
en-aut-sei=Goto
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OmoriKazuhiro
en-aut-sei=Omori
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Yamaguchi-TomikawaTomoko
en-aut-sei=Yamaguchi-Tomikawa
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiHiroya
en-aut-sei=Kobayashi
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Shinoda-ItoYuki
en-aut-sei=Shinoda-Ito
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HiraiKimito
en-aut-sei=Hirai
en-aut-mei=Kimito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IkedaAtsushi
en-aut-sei=Ikeda
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakashibaShogo
en-aut-sei=Takashiba
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Periodontics & Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=cathepsin B
kn-keyword=cathepsin B
en-keyword=cathepsin L
kn-keyword=cathepsin L
en-keyword=human gingival fibroblast
kn-keyword=human gingival fibroblast
en-keyword=interleukin-6
kn-keyword=interleukin-6
en-keyword=caveolin
kn-keyword=caveolin
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=19
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gastrectomy Causes an Imbalance in the Trunk Muscles
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Muscle loss negatively affects gastrectomy prognosis. However, muscle loss is recognized as a systemic change, and individual muscle function is often overlooked. We investigated changes in the muscle volume of individual muscles after gastrectomy to identify clues for prognostic factors and optimal rehabilitation programs. Patients who underwent R0 gastrectomy for Stage I gastric cancer at our hospital from 2015 to 2021 were retrospectively selected to minimize the effects of malignancy and chemotherapy. Trunk muscle volume was measured by computed tomography to analyze body composition changes. Statistical analysis was performed to identify risk factors related to body composition changes. We compared the preoperative and 6-month postoperative conditions of 59 patients after gastrectomy. There was no difference in the psoas major muscle, a conventional surrogate marker of sarcopenia. There were significant decreases in the erector spinae (p=0.01) and lateral abdominal (p=0.01) muscles, and a significant increase in the rectus abdominis muscle (p=0.02). No significant correlation was found between these muscle changes and nutritional status. Body composition imbalance may serve as a new indicator of the general condition of patients after gastrectomy. Rehabilitation to correct this imbalance may improve prognosis after gastrectomy.
en-copyright=
kn-copyright=

en-aut-name=IkeyaNanami
en-aut-sei=Ikeya
en-aut-mei=Nanami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkitaAtsushi
en-aut-sei=Okita
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HashidaShinsuke
en-aut-sei=Hashida
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoSumiharu
en-aut-sei=Yamamoto
en-aut-mei=Sumiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaHirokuni
en-aut-sei=Ikeda
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsukudaKazunori
en-aut-sei=Tsukuda
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=sarcopenia
kn-keyword=sarcopenia
en-keyword=skeletal muscle
kn-keyword=skeletal muscle
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=gastrectomy
kn-keyword=gastrectomy
en-keyword=erector spinae muscle
kn-keyword=erector spinae muscle
END

start-ver=1.4
cd-journal=joma
no-vol=121
cd-vols=
no-issue=35
article-no=
start-page=e2320189121
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240821
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8+ T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic mutations in TILs, their effect on antitumor immunity remains unclear. In this study, we successfully established 18 cancer-specific T cell clones, which have an exhaustion phenotype, from the TILs of four patients with melanoma. We conducted whole-genome sequencing for these T cell clones and identified various somatic mutations in them with high clonality. Among the somatic mutations, an SH2D2A loss-of-function frameshift mutation and TNFAIP3 deletion could activate T cell effector functions in vitro. Furthermore, we generated CD8+ T cell–specific Tnfaip3 knockout mice and showed that Tnfaip3 function loss in CD8+ T cell increased antitumor immunity, leading to remarkable response to PD-1 blockade in vivo. In addition, we analyzed bulk CD3+ T cells from TILs in additional 12 patients and identified an SH2D2A mutation in one patient through amplicon sequencing. These findings suggest that somatic mutations in TILs can affect antitumor immunity and suggest unique biomarkers and therapeutic targets.
en-copyright=
kn-copyright=

en-aut-name=MukoharaFumiaki
en-aut-sei=Mukohara
en-aut-mei=Fumiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwataKazuma
en-aut-sei=Iwata
en-aut-mei=Kazuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshinoTakamasa
en-aut-sei=Ishino
en-aut-mei=Takamasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InozumeTakashi
en-aut-sei=Inozume
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagasakiJoji
en-aut-sei=Nagasaki
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UedaYouki
en-aut-sei=Ueda
en-aut-mei=Youki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzawaKen
en-aut-sei=Suzawa
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UenoToshihide
en-aut-sei=Ueno
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IkedaHideki
en-aut-sei=Ikeda
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawaseKatsushige
en-aut-sei=Kawase
en-aut-mei=Katsushige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SaekiYuka
en-aut-sei=Saeki
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KawashimaShusuke
en-aut-sei=Kawashima
en-aut-mei=Shusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamashitaKazuo
en-aut-sei=Yamashita
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KawaharaYu
en-aut-sei=Kawahara
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NakamuraYasuhiro
en-aut-sei=Nakamura
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Honobe-TabuchiAkiko
en-aut-sei=Honobe-Tabuchi
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=WatanabeHiroko
en-aut-sei=Watanabe
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=DansakoHiromichi
en-aut-sei=Dansako
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KawamuraTatsuyoshi
en-aut-sei=Kawamura
en-aut-mei=Tatsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SuzukiYutaka
en-aut-sei=Suzuki
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HondaHiroaki
en-aut-sei=Honda
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ManoHiroyuki
en-aut-sei=Mano
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KawazuMasahito
en-aut-sei=Kawazu
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=TogashiYosuke
en-aut-sei=Togashi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

affil-num=1
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University
kn-affil=

affil-num=8
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=9
en-affil=Division of Cell Therapy, Chiba Cancer Research Institute
kn-affil=

affil-num=10
en-affil=Division of Cell Therapy, Chiba Cancer Research Institute
kn-affil=

affil-num=11
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=KOTAI Biotechnologies, Inc.
kn-affil=

affil-num=14
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center
kn-affil=

affil-num=16
en-affil=Department of Dermatology, University of Yamanashi
kn-affil=

affil-num=17
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=18
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=19
en-affil=Department of Dermatology, University of Yamanashi
kn-affil=

affil-num=20
en-affil=Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa
kn-affil=

affil-num=21
en-affil=Department of Pathology, Tokyo Women's Medical University
kn-affil=

affil-num=22
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=23
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University
kn-affil=

affil-num=24
en-affil=Division of Cell Therapy, Chiba Cancer Research Institute
kn-affil=

affil-num=25
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=cancer immunology
kn-keyword=cancer immunology
en-keyword=somatic mutation
kn-keyword=somatic mutation
en-keyword=T cell
kn-keyword=T cell
en-keyword=tumor-infiltrating lymphocytes
kn-keyword=tumor-infiltrating lymphocytes
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=459
end-page=464
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Traumatic Neuroma Arising from Surgical Trauma during Conversion from Laparoscopic to Open Cholecystectomy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Traumatic neuroma is an abnormal proliferation of injured nerves resulting from trauma or surgery. We present a case of traumatic neuroma arising in the cystic duct after cholecystectomy. A 66-year-old man was referred to our department due to a biliary tumor. He had undergone cholecystectomy 20 years prior. Cholangioscopy showed an elevated lesion covered with smooth mucosa. Histological examination revealed normal bile duct mucosa. Although benign disease was suspected, the possibilities of malignant disease could not be excluded. Extrahepatic bile duct resection was planned to include intraoperative rapid-freezing of a biopsy specimen followed by histopathological examination. These intraoperative histology results showed proliferation of nerve and fibrous tissue only, resulting in the diagnosis of traumatic neuroma, so no lymph nodes were removed. To avoid excessive surgical intervention, histopathological examination of an intraoperative rapid-frozen biopsy specimen may be important for diagnosing traumatic neuroma.
en-copyright=
kn-copyright=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshimatsuRika
en-aut-sei=Yoshimatsu
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=traumatic neuroma
kn-keyword=traumatic neuroma
en-keyword=biliary stricture
kn-keyword=biliary stricture
en-keyword=cholecystectomy
kn-keyword=cholecystectomy
en-keyword=cholangiography
kn-keyword=cholangiography
en-keyword=intraoperative rapid-frozen biopsy
kn-keyword=intraoperative rapid-frozen biopsy
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=439
end-page=447
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk Factors for Gangrenous Cholecystitis and the Outcomes of Early Cholecystectomy: A Retrospective Study of a Single-Center City General Hospital
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Gangrenous cholecystitis (GC) is classified as moderate acute cholecystitis according to the Tokyo Guidelines from 2018 (TG18). We evaluated the risk factors for GC and the outcomes of early cholecystectomy. A total of 136 patients who underwent emergency cholecystectomy for acute cholecystitis were retrospectively analyzed; 58 of these patients (42.6%) were diagnosed with GC (GC group) based on our retrospective pathologic diagnosis. We comparatively evaluated the patient backgrounds and surgical outcomes between the GC group and non-GC group. The GC group was significantly older and included more hypertensive patients than the non-GC group. The GC group was prescribed more antibiotics as initial treatment than the non-GC group, and they had more days between onset and surgery. The preoperative white blood cell count and C-reactive protein values were significantly higher in the GC group than in the non-GC group, and these values were predictive factors for GC. Cholecystectomy required a longer operation time and caused greater blood loss in the GC group. The GC group also had longer hospitalization times than the non-GC group; however, no significant differences were observed in terms of postoperative complications. In conclusion, gangrenous changes should be assessed when diagnosing cholecystitis, and appropriate treatment, such as surgery or drainage, should be undertaken.
en-copyright=
kn-copyright=

en-aut-name=YamashitaMampei
en-aut-sei=Yamashita
en-aut-mei=Mampei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakayuki
en-aut-sei=Tanaka
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SumidaYorihisa
en-aut-sei=Sumida
en-aut-mei=Yorihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamazakiShoto
en-aut-sei=Yamazaki
en-aut-mei=Shoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaraYuki
en-aut-sei=Hara
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukudaAkiko
en-aut-sei=Fukuda
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HisanagaMakoto
en-aut-sei=Hisanaga
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WakataKoki
en-aut-sei=Wakata
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ArakiMasato
en-aut-sei=Araki
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=EguchiSusumu
en-aut-sei=Eguchi
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=2
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Nagasaki University Graduate School of Biomedical Science
kn-affil=
en-keyword=gangrenous
kn-keyword=gangrenous
en-keyword=cholecystitis
kn-keyword=cholecystitis
en-keyword=acute cholecystitis
kn-keyword=acute cholecystitis
en-keyword=laparoscopic cholecystectomy
kn-keyword=laparoscopic cholecystectomy
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=429
end-page=437
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Partial versus Radical Nephrectomy for Small Renal Cancer: Comparative Propensity Score-Matching Analysis of Cardiovascular Event Risk
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although partial nephrectomy (PN) is preferred over radical nephrectomy (RN) for preserving renal function in patients with cT1 renal cancer, its impact on cardiovascular events (CVe) remains controversial. This study aimed to compare PN and RN in regard to the occurrence of CVe, including cerebrovascular events and exacerbation of hypertension (HT). We retrospectively analyzed 418 consecutive patients who underwent PN or RN for cT1 renal cancer. Propensity score-matching analysis was used to adjust for imbalances between patients who underwent PN and RN, leaving 102 patients in each group. The 5-year probability of cumulative CVe incidence was 6% in the PN group and 12% in the RN group (p=0.03), with a median follow-up of 73.5 months. The statistical significance was retained after propensity score matching for patients without preoperative proteinuria (p=0.03). For all CVe including cerebrovascular events and exacerbation of HT analyzed, PN provided a lower probability of occurrence than RN in patients with small renal cancers.
en-copyright=
kn-copyright=

en-aut-name=KubotaRisa
en-aut-sei=Kubota
en-aut-mei=Risa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=chronic kidney disease
kn-keyword=chronic kidney disease
en-keyword=hypertension
kn-keyword=hypertension
en-keyword=nephrectomy
kn-keyword=nephrectomy
en-keyword=proteinuria
kn-keyword=proteinuria
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=5
article-no=
start-page=377
end-page=386
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We previously found that “albumin grade”, formerly called the “ALBS grade,” demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present study was to compare the performance of the albumin grade with that of the modified albumin-bilirubin (mALBI) grade in predicting overall survival of HCC patients with different BCLC stages and treatment types. We enrolled 7,645 Japanese patients newly diagnosed with HCC using the Akaike information criteria (AIC), likelihood ratio, and C-index in different Barcelona Clinic Liver Cancer (BCLC) stages and treatments. The albumin grade showed similar and slightly better performance than the mALBI grade for BCLC stage 0 and A and especially for patients who underwent curative surgery and ablation. In patients treated with transcatheter arterial chemoembolization, molecular targeted agents, and the best supportive care, the mALBI grade had better performance than the albumin grade. However, the differences of the indices were very small in all scenarios. Overall, the albumin grade was comparable in efficacy to the mALBI grade, showing particular benefit for patients with early-stage HCC.
en-copyright=
kn-copyright=

en-aut-name=HiranoYuichi
en-aut-sei=Hirano
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KariyamaKazuya
en-aut-sei=Kariyama
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiraokaAtsushi
en-aut-sei=Hiraoka
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShiotaShohei
en-aut-sei=Shiota
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WakutaAkiko
en-aut-sei=Wakuta
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YasudaSatoshi
en-aut-sei=Yasuda
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ToyodaHidenori
en-aut-sei=Toyoda
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TsujiKunihiko
en-aut-sei=Tsuji
en-aut-mei=Kunihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HatanakaTakeshi
en-aut-sei=Hatanaka
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KakizakiSatoru
en-aut-sei=Kakizaki
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NaganumaAtsushi
en-aut-sei=Naganuma
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TadaToshifumi
en-aut-sei=Tada
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ItobayashiEi
en-aut-sei=Itobayashi
en-aut-mei=Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaToru
en-aut-sei=Ishikawa
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaNoritomo
en-aut-sei=Shimada
en-aut-mei=Noritomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakaguchiKoichi
en-aut-sei=Takaguchi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TsutsuiAkemi
en-aut-sei=Tsutsui
en-aut-mei=Akemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NaganoTakuya
en-aut-sei=Nagano
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ImaiMichitaka
en-aut-sei=Imai
en-aut-mei=Michitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NakamuraShinichiro
en-aut-sei=Nakamura
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KumadaTakashi
en-aut-sei=Kumada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=Real-Life Practice Experts for HCC (RELPEC) Study Group in Japan
en-aut-sei=Real-Life Practice Experts for HCC (RELPEC) Study Group in Japan
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

affil-num=1
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Gastroenterology Center, Ehime Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
kn-affil=

affil-num=9
en-affil=Center of Gastroenterology, Teine Keijinkai Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Saiseikai Maebashi Hospital
kn-affil=

affil-num=11
en-affil=Department of Clinical Research, NHO Takasaki General Medical Center
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology, NHO Takasaki General Medical Center
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Asahi General Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Saiseikai Niigata Hospital
kn-affil=

affil-num=16
en-affil=Division of Gastroenterology and Hepatology, Otakanomori Hospital
kn-affil=

affil-num=17
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=18
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=19
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology, Niigata Cancer Center Hospital
kn-affil=

affil-num=21
en-affil=Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=22
en-affil=Department of Nursing, Gifu Kyoritsu University
kn-affil=

affil-num=23
en-affil=
kn-affil=
en-keyword=albumin grade
kn-keyword=albumin grade
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=modified albumin-bilirubin grade
kn-keyword=modified albumin-bilirubin grade
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=331
end-page=335
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Rare Subglottic Pleomorphic Adenoma: Magnetic Resonance Findings
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=No previous study has published magnetic resonance imaging (MRI) findings for a subglottic pleomorphic adenoma. Here, we describe the case of a 62-year-old man with a subglottic pleomorphic adenoma. Endoscopic findings revealed a smooth-surfaced tumor arising from the subglottic posterior wall. MRI revealed the lesion as an isointense region on T1-weighted images, which was homogeneously enhanced. This lesion showed a heterogeneously hyperintense region on T2-weighted images. Diffusion-weighted imaging (DWI) showed slightly high intensity in the same area, with a normal or only slightly high apparent diffusion coefficient (ADC). Laryngomicrosurgery was performed for transoral excision of the subglottic tumor, resulting in a postsurgical diagnosis of pleomorphic adenoma.
en-copyright=
kn-copyright=

en-aut-name=FurukawaChieko
en-aut-sei=Furukawa
en-aut-mei=Chieko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TachibanaTomoyasu
en-aut-sei=Tachibana
en-aut-mei=Tomoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NobuhisaTetsuji
en-aut-sei=Nobuhisa
en-aut-mei=Tetsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanieYuichiro
en-aut-sei=Kanie
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WaniYoji
en-aut-sei=Wani
en-aut-mei=Yoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoJun-Ya
en-aut-sei=Matsumoto
en-aut-mei=Jun-Ya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KariyaAkifumi
en-aut-sei=Kariya
en-aut-mei=Akifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SatoAsuka
en-aut-sei=Sato
en-aut-mei=Asuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshikawaIichiro
en-aut-sei=Ishikawa
en-aut-mei=Iichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaoiYuto
en-aut-sei=Naoi
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=4
en-affil=Department of Radiology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=5
en-affil=Department of Pathology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=7
en-affil=Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=10
en-affil=Department of Otolaryngology Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Otolaryngology Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=subglottis
kn-keyword=subglottis
en-keyword=pleomorphic adenoma
kn-keyword=pleomorphic adenoma
en-keyword=MRI
kn-keyword=MRI
en-keyword=transoral surgery
kn-keyword=transoral surgery
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=1
article-no=
start-page=121
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240731
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Pure argyrophilic grain disease revisited: independent effects on limbic, neocortical, and striato-pallido-nigral degeneration and the development of dementia in a series with a low to moderate Braak stage
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Agyrophilic grains (AGs) are age-related limbic-predominant lesions in which four-repeat tau is selectively accumulated. Because previous methodologically heterogeneous studies have demonstrated inconsistent findings on the relationship between AGs and dementia, whether AGs affect cognitive function remains unclear. To address this question, we first comprehensively evaluated the distribution and quantity of Gallyas-positive AGs and the severity of neuronal loss in the limbic, neocortical, and subcortical regions in 30 cases of pure argyrophilic grain disease (pAGD) in Braak stages I-IV and without other degenerative diseases, and 34 control cases that had only neurofibrillary tangles with Braak stages I-IV and no or minimal A beta deposits. Then, we examined whether AGs have independent effects on neuronal loss and dementia by employing multivariate ordered logistic regression and binomial logistic regression. Of 30 pAGD cases, three were classified in diffuse form pAGD, which had evident neuronal loss not only in the limbic region but also in the neocortex and subcortical nuclei. In all 30 pAGD cases, neuronal loss developed first in the amygdala, followed by temporo-frontal cortex, hippocampal CA1, substantia nigra, and finally, the striatum and globus pallidus with the progression of Saito AG stage. In multivariate analyses of 30 pAGD and 34 control cases, the Saito AG stage affected neuronal loss in the amygdala, hippocampal CA1, temporo-frontal cortex, striatum, globus pallidus, and substantia nigra independent of the age, Braak stage, and limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) stage. In multivariate analyses of 23 pAGD and 28 control cases that lacked two or more lacunae and/or one or more large infarctions, 100 or more AGs per x 400 visual field in the amygdala (OR 10.02, 95% CI 1.12-89.43) and hippocampal CA1 (OR 12.22, 95% CI 1.70-87.81), and the presence of AGs in the inferior temporal cortex (OR 8.18, 95% CI 1.03-65.13) affected dementia independent of age, moderate Braak stages (III-IV), and LATE-NC. Given these findings, the high density of limbic AGs and the increase of AGs in the inferior temporal gyrus may contribute to the occurrence of dementia through neuronal loss, at least in cases in a low to moderate Braak stage.
en-copyright=
kn-copyright=

en-aut-name=YokotaOsamu
en-aut-sei=Yokota
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MikiTomoko
en-aut-sei=Miki
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Nakashima-YasudaHanae
en-aut-sei=Nakashima-Yasuda
en-aut-mei=Hanae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshizuHideki
en-aut-sei=Ishizu
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaraguchiTakashi
en-aut-sei=Haraguchi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaChikako
en-aut-sei=Ikeda
en-aut-mei=Chikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HasegawaMasato
en-aut-sei=Hasegawa
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MiyashitaAkinori
en-aut-sei=Miyashita
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IkeuchiTakeshi
en-aut-sei=Ikeuchi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishikawaNaoto
en-aut-sei=Nishikawa
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TakenoshitaShintaro
en-aut-sei=Takenoshita
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SudoKoichiro
en-aut-sei=Sudo
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TeradaSeishi
en-aut-sei=Terada
en-aut-mei=Seishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TakakiManabu
en-aut-sei=Takaki
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Okayama University Medical School 
kn-affil=

affil-num=4
en-affil=Okayama University Medical School 
kn-affil=

affil-num=5
en-affil=Department of Neurology, National Hospital Organization Minami Okayama Medical Center
kn-affil=

affil-num=6
en-affil=Okayama University Medical School 
kn-affil=

affil-num=7
en-affil=Dementia Research Project, Tokyo Metropolitan Institute of Medical Science
kn-affil=

affil-num=8
en-affil=Department of Molecular Genetics, Brain Research Institute, Niigata University
kn-affil=

affil-num=9
en-affil=Department of Molecular Genetics, Brain Research Institute, Niigata University
kn-affil=

affil-num=10
en-affil=Department of Neuropsychiatry, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Neuropsychiatry, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Psychiatry, Tosa Hospital
kn-affil=

affil-num=13
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Argyrophilic grain
kn-keyword=Argyrophilic grain
en-keyword=Globus pallidus
kn-keyword=Globus pallidus
en-keyword=Hippocampal sclerosis
kn-keyword=Hippocampal sclerosis
en-keyword=Striatum
kn-keyword=Striatum
en-keyword=Substantia nigra
kn-keyword=Substantia nigra
en-keyword=Subthalamic nucleus
kn-keyword=Subthalamic nucleus
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=5
article-no=
start-page=3322
end-page=3331
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240702
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prediction of heart failure events based on physiologic sensor data in HINODE defibrillator patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims Hospitalizations are common in patients with heart failure and are associated with high mortality, readmission and economic burden. Detecting early signs of worsening heart failure may enable earlier intervention and reduce hospitalizations. The HeartLogic algorithm is designed to predict worsening heart failure using diagnostic data from multiple device sensors. The main objective of this analysis was to evaluate the sensitivity of the HeartLogic alert calculation in predicting worsening heart failure events (HFEs). We also evaluated the false positive alert rate (FPR) and compared the incidence of HFEs occurring in a HeartLogic alert state to those occurring out of an alert state. <br>
Methods The HINODE study enrolled 144 patients (81 ICD and 63 CRT-D) with device sensor data transmitted via a remote monitoring system. HeartLogic alerts were then retrospectively simulated using relevant sensor data. Clinicians and patients were blinded to calculated alerts. Reported adverse events with HF symptoms were adjudicated and classified by an independent HFE committee. Sensitivity was defined as the ratio of the number of detected usable HFEs (true positives) to the total number of usable HFEs. A false positive alert was defined as an alert with no usable HFE between the alert onset date and the alert recovery date plus 30 days. The patient follow-up period was categorized as in alert state or out of alert state. The event rate ratio was the HFE rate calculated in alert to out of alert. <br>
Results The patient cohort was 79% male and had an average age of 68 +/- 12 years. This analysis yielded 244 years of follow-up data with 73 HFEs from 37 patients. A total of 311 HeartLogic alerts at the nominal threshold (16) occurred across 106 patients providing an alert rate of 1.27 alerts per patient-year. The HFE rate was 8.4 times greater while in alert compared with out of alert (1.09 vs. 0.13 events per patient-year; P < 0.001). At the nominal alert threshold, 80.8% of HFEs were detected by a HeartLogic alert [95% confidence interval (CI): 69.9%-89.1%]. The median time from first true positive alert to an adjudicated clinical HFE was 53 days. The FPR was 1.16 (95% CI: 0.98-1.38) alerts per patient-year. <br>
Conclusions Results suggest that signs of worsening HF can be detected successfully with remote patient follow-up. The use of HeartLogic may predict periods of increased risk for HF or clinically significant events, allowing for early intervention and reduction of hospitalization in a vulnerable patient population.
en-copyright=
kn-copyright=

en-aut-name=NishiiNobuhiro
en-aut-sei=Nishii
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakataYasushi
en-aut-sei=Sakata
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MuroharaToyoaki
en-aut-sei=Murohara
en-aut-mei=Toyoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AndoKenji
en-aut-sei=Ando
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaTakanori
en-aut-sei=Ikeda
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MitsuhashiTakeshi
en-aut-sei=Mitsuhashi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NogamiAkihiko
en-aut-sei=Nogami
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimizuWataru
en-aut-sei=Shimizu
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SchwartzTorri
en-aut-sei=Schwartz
en-aut-mei=Torri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KayserTorsten
en-aut-sei=Kayser
en-aut-mei=Torsten
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BeaudointCaroline
en-aut-sei=Beaudoint
en-aut-mei=Caroline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AonumaKazutaka
en-aut-sei=Aonuma
en-aut-mei=Kazutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=for HINODE Investigators
en-aut-sei=for HINODE Investigators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Cardiology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Cardiology, Kokura Memorial Hospital
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Toho University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Cardiology, Hoshi General Hospital 
kn-affil=

affil-num=7
en-affil=Department of Cardiology, Faculty of Medicine, University of Tsukuba
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, Nippon Medical School
kn-affil=

affil-num=9
en-affil=Boston Scientific
kn-affil=

affil-num=10
en-affil=Boston Scientific
kn-affil=

affil-num=11
en-affil=Boston Scientific
kn-affil=

affil-num=12
en-affil=Department of Cardiology, Faculty of Medicine, University of Tsukuba
kn-affil=

affil-num=13
en-affil=
kn-affil=
en-keyword=HeartLogic
kn-keyword=HeartLogic
en-keyword=heart failure
kn-keyword=heart failure
en-keyword=remote monitoring
kn-keyword=remote monitoring
en-keyword=ICD
kn-keyword=ICD
en-keyword=CRT
kn-keyword=CRT
en-keyword=hospitalization
kn-keyword=hospitalization
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=2
article-no=
start-page=16
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Harderian Gland Development and Degeneration in the Fgf10-Deficient Heterozygous Mouse
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The mouse Harderian gland (HG) is a secretory gland that covers the posterior portion of the eyeball, opening at the base of the nictitating membrane. The HG serves to protect the eye surface from infection with its secretions. Mice open their eyelids at about 2 weeks of age, and the development of the HG primordium mechanically opens the eye by pushing the eyeball from its rear. Therefore, when HG formation is disturbed, the eye exhibits enophthalmos (the slit-eye phenotype), and a line of Fgf10(+/-) heterozygous loss-of-function mice exhibits slit-eye due to the HG atrophy. However, it has not been clarified how and when HGs degenerate and atrophy in Fgf10(+/-) mice. In this study, we observed the HGs in embryonic (E13.5 to E19), postnatal (P0.5 to P18) and 74-week-old Fgf10(+/-) mice. We found that more than half of the Fgf10(+/-) mice had markedly degenerated HGs, often unilaterally. The degenerated HG tissue had a melanized appearance and was replaced by connective tissue, which was observed by P10. The development of HGs was delayed or disrupted in the similar proportion of Fgf10(+/-) embryos, as revealed via histology and the loss of HG-marker expression. In situ hybridization showed Fgf10 expression was observed in the Harderian mesenchyme in wild-type as well as in the HG-lacking heterozygote at E19. These results show that the Fgf10 haploinsufficiency causes delayed or defective HG development, often unilaterally from the unexpectedly early neonatal period.
en-copyright=
kn-copyright=

en-aut-name=IkedaShiori
en-aut-sei=Ikeda
en-aut-mei=Shiori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SatoKeita
en-aut-sei=Sato
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujitaHirofumi
en-aut-sei=Fujita
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=Ono-MinagiHitomi
en-aut-sei=Ono-Minagi
en-aut-mei=Hitomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyaishiSatoru
en-aut-sei=Miyaishi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NohnoTsutomu
en-aut-sei=Nohno
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhuchiHideyo
en-aut-sei=Ohuchi
en-aut-mei=Hideyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Cytology and Histology, Medical School, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Cytology and Histology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Legal Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Cytology and Histology, Medical School, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Harderian gland
kn-keyword=Harderian gland
en-keyword=Fgf10
kn-keyword=Fgf10
en-keyword=haploinsufficiency
kn-keyword=haploinsufficiency
en-keyword=mouse
kn-keyword=mouse
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=9869
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240430
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (ER + HER2 - ABC). However, markers predicting the outcomes of CDK4/6i treatment have yet to be identified. This study was a single-center retrospective cohort study. We retrospectively evaluated 101 patients with ER + HER2 - ABC receiving CDK4/6i in combination with endocrine therapy at Fukuyama City Hospital between November 2017 and July 2021. We investigated the clinical outcomes and the safety of CDK4/6i treatment, and the absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) as predictive markers for CDK4/6i. We defined the cut-off values as 1000/mu L for ALC and 3 for NLR, and divided into "low" and "high" groups, respectively. We evaluated 43 and 58 patients who received abemaciclib and palbociclib, respectively. Patients with high ALC and low NLR had significantly longer overall survival than those with low ALC and high NLR (high vs. low; ALC: HR 0.29; 95% CI 0.12-0.70; NLR: HR 2.94; 95% CI 1.21-7.13). There was no significant difference in efficacy between abemaciclib and palbociclib and both had good safety profiles. We demonstrated that ALC and NLR might predict the outcomes of CDK4/6i treatment in patients with ER + HER2 - ABC.
en-copyright=
kn-copyright=

en-aut-name=NakamotoShogo
en-aut-sei=Nakamoto
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoMari
en-aut-sei=Yamamoto
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamashitaTetsumasa
en-aut-sei=Yamashita
en-aut-mei=Tetsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KuwaharaChihiro
en-aut-sei=Kuwahara
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=ASL 撮影ができない MRI 装置における再燃時の脳卒中発作を伴う小児 MELAS を対象とした FLAIR 画像を用いた診断の提案
kn-title=Proposal for diagnosis using FLAIR image aimed for pediatric MELAS with recurrent stroke-like episodes on MRI system cannot take ASL imaging.
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=SHIMADAMakoto
en-aut-sei=SHIMADA
en-aut-mei=Makoto
kn-aut-name=島田真
kn-aut-sei=島田
kn-aut-mei=真
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=岡山大学大学院保健学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=核内SphK2/S1Pシグナルによるアストロサイト制御機構の解析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KOMAIMasato
en-aut-sei=KOMAI
en-aut-mei=Masato
kn-aut-name=駒井真人
kn-aut-sei=駒井
kn-aut-mei=真人
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=非アルコール性脂肪性肝炎の併発はマウスモデルにおけるアディポネクチン発現低下に関連し乾癬を悪化させる
kn-title=Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKEZAKIDaiki
en-aut-sei=TAKEZAKI
en-aut-mei=Daiki
kn-aut-name=竹﨑大輝
kn-aut-sei=竹﨑
kn-aut-mei=大輝
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=2
article-no=
start-page=323
end-page=331
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Selective activator protein (AP)-1 inhibitors are potentially promising therapeutic agents for atopic dermatitis (AD) because AP-1 is an important regulator of skin inflammation. However, few studies have investigated the effect of topical application of AP-1 inhibitors in treating inflammatory skin disorders. <br>
Methods: Immunohistochemistry was conducted to detect phosphorylated AP-1/c-Jun expression of skin lesions in AD patients. In the in vivo study, 1 % T-5224 ointment was topically applied for 8 days to the ears of 2,4 dinitrofluorobenzene challenged AD-like dermatitis model mice. Baricitinib, a conventional therapeutic agent Janus kinase (JAK) inhibitor, was also topically applied. In the in vitro study, human epidermal keratinocytes were treated with T-5224 and stimulated with AD-related cytokines. <br>
Results: AP-1/c-Jun was phosphorylated at skin lesions in AD patients. In vivo, topical T-5224 application inhibited ear swelling (P < 0.001), restored filaggrin (Flg) expression (P < 0.01), and generally suppressed immune-related pathways. T-5224 significantly suppressed Il17a and l17f expression, whereas baricitinib did not.Baricitinib suppressed Il4, Il19, Il33 and Ifnb expression, whereas T-5224 did not. Il1a, Il1b, Il23a, Ifna, S100a8, and S100a9 expression was cooperatively downregulated following the combined use of T5224 and baricitinib. In vitro, T-5224 restored the expression of FLG and loricrin (LOR) (P < 0.05) and suppressed IL33 expression (P < 0.05) without affecting cell viability and cytotoxicity. <br>
Conclusions: Topical T-5224 ameliorates clinical manifestations of AD-like dermatitis in mice. The effect of this inhibitor is amplified via combined use with JAK inhibitors.
en-copyright=
kn-copyright=

en-aut-name=SasakuraMinori
en-aut-sei=Sasakura
en-aut-mei=Minori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UrakamiHitoshi
en-aut-sei=Urakami
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TachibanaKota
en-aut-sei=Tachibana
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaKenta
en-aut-sei=Ikeda
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HasuiKen-Ichi
en-aut-sei=Hasui
en-aut-mei=Ken-Ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsudaYoshihiro
en-aut-sei=Matsuda
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SunagawaKo
en-aut-sei=Sunagawa
en-aut-mei=Ko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MorizaneShin
en-aut-sei=Morizane
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=AP-1 inhibitor
kn-keyword=AP-1 inhibitor
en-keyword=Atopic dermatitis
kn-keyword=Atopic dermatitis
en-keyword=Baricitinib
kn-keyword=Baricitinib
en-keyword=T-5224
kn-keyword=T-5224
en-keyword=Topical application
kn-keyword=Topical application
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=201
end-page=204
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Gallbladder Cancer with Trousseau Syndrome Successfully Treated Using Radical Resection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Trousseau syndrome is characterized by cancer-associated systemic thrombosis. We describe the first case of a successfully treated gallbladder adenocarcinoma accompanied by Trousseau syndrome. A 66-year-old woman presented with right hemiplegia. Magnetic resonance imaging identified multiple cerebral infarctions. Her serum carbohydrate antigen 19-9 and D-dimer levels were markedly elevated, and a gallbladder tumor was detected via abdominal computed tomography. Venous ultrasonography of the lower limbs revealed a deep venous thrombus in the right peroneal vein. These findings suggested that the brain infarctions were likely caused by Trousseau syndrome associated with her gallbladder cancer. Radical resection of the gallbladder tumor was performed. The resected gallbladder was filled with mucus and was pathologically diagnosed as an adenocarcinoma. Her postoperative course was uneventful, and she received a one-year course of adjuvant therapy with oral S-1. No cancer recurrence or thrombosis was noted 26 months postoperatively. Despite concurrent Trousseau syndrome, a radical cure of the primary tumor and thrombosis could be achieved with the appropriate treatment.
en-copyright=
kn-copyright=

en-aut-name=MasunagaAkari
en-aut-sei=Masunaga
en-aut-mei=Akari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshimatsuRika
en-aut-sei=Yoshimatsu
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=gallbladder cancer
kn-keyword=gallbladder cancer
en-keyword=Trousseau syndrome
kn-keyword=Trousseau syndrome
en-keyword=radical surgery
kn-keyword=radical surgery
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=171
end-page=184
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Relationships among Internalized Stigma, Sense of Coherence, and Personal Recovery of Persons with Schizophrenia Living in the Community
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated (i) the relationships among internalized stigma (IS), sense of coherence (SOC), and the personal recovery (PR) of persons with schizophrenia living in the community, and (ii) how to improve the support for these individuals. A questionnaire survey on IS, SOC, and PR was sent by mail to 270 persons with schizophrenia living in the community who were using psychiatric daycare services, of whom 149 responded and 140 were included in the analysis. We established a hypothetical model in which IS influences PR, and SOC influences IS and PR, and we used structural equation modeling to examine the relationships among these concepts. The goodness of fit was acceptable. Our findings suggest that rather than directly promoting PR, SOC promotes PR by mitigating the impact of IS. It is important for nurses/supporters to support individuals with schizophrenia living in the community so that they have opportunities to reflect on their own experiences through their activities and to share their experiences with peers. Nurses/supporters themselves should also reflect on their own support needs. Our findings suggest that this will lead to a reduction of IS and the improvement of SOC, which will in turn promote personal recovery.
en-copyright=
kn-copyright=

en-aut-name=KuramotoAya
en-aut-sei=Kuramoto
en-aut-mei=Aya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeKumi
en-aut-sei=Watanabe
en-aut-mei=Kumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=School of Nursing, Faculty of Medicine, Kagawa University
kn-affil=
en-keyword=schizophrenia
kn-keyword=schizophrenia
en-keyword=internalized stigma
kn-keyword=internalized stigma
en-keyword=sense of coherence
kn-keyword=sense of coherence
en-keyword=personal recovery
kn-keyword=personal recovery
en-keyword=community
kn-keyword=community
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=95
end-page=106
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Roles of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The lungs are very complex organs, and the respiratory system performs the dual roles of repairing tissue while protecting against infection from various environmental stimuli. Persistent external irritation disrupts the immune responses of tissues and cells in the respiratory system, ultimately leading to respiratory disease. Neuropeptide Y (NPY) is a 36-amino-acid polypeptide and a neurotransmitter that regulates homeostasis. The NPY receptor is a seven-transmembrane-domain G-protein-coupled receptor with six subtypes (Y1, Y2, Y3, Y4, Y5, and Y6). Of these receptors, Y1, Y2, Y4, and Y5 are functional in humans, and Y1 plays important roles in the immune responses of many organs, including the respiratory system. NPY and the Y1 receptor have critical roles in the pathogenesis of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The effects of NPY on the airway immune response and pathogenesis differ among respiratory diseases. This review focuses on the involvement of NPY in the airway immune response and pathogenesis of various respiratory diseases.
en-copyright=
kn-copyright=

en-aut-name=ItanoJunko
en-aut-sei=Itano
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyaharaNobuaki
en-aut-sei=Miyahara
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=neuropeptide y
kn-keyword=neuropeptide y
en-keyword=Y1 receptor
kn-keyword=Y1 receptor
en-keyword=airway immune response
kn-keyword=airway immune response
en-keyword=bronchial epithelial cells
kn-keyword=bronchial epithelial cells
en-keyword=respiratory disease
kn-keyword=respiratory disease
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=89
end-page=93
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ectopic Breast Cancer Arising within an Axillary Lymph Node
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report our experience with the diagnosis and treatment of an ectopic breast cancer arising within an axillary lymph node. The patient was a 65-year-old woman diagnosed breast cancer and axillary lymph node metastasis. We performed a partial mastectomy and axillary lymph node dissection. Postoperative pathology revealed no malignant lesions in the breast; however, a nodule in one of axillary lymph nodes had mixed benign and malignant components, leading to a diagnosis of invasive ductal carcinoma derived from ectopic mammary tissue. This case represents a very rare form of breast cancer, and the malignancy was difficult to distinguish from metastasis.
en-copyright=
kn-copyright=

en-aut-name=ToshimaKei
en-aut-sei=Toshima
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishimuraMidori Filiz
en-aut-sei=Nishimura
en-aut-mei=Midori Filiz
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiYoko
en-aut-sei=Suzuki
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakamotoShogo
en-aut-sei=Nakamoto
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UnoMaya
en-aut-sei=Uno
en-aut-mei=Maya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshiokaRyo
en-aut-sei=Yoshioka
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsukiokiTakahiro
en-aut-sei=Tsukioki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakahashiYuko
en-aut-sei=Takahashi
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IwataniTsuguo
en-aut-sei=Iwatani
en-aut-mei=Tsuguo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YanaiHiroyuki
en-aut-sei=Yanai
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Molecular Hematopathology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Diagnostic Pathology, Okayama University Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=ectopic breast cancer
kn-keyword=ectopic breast cancer
en-keyword=axillary lymph node
kn-keyword=axillary lymph node
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=15
end-page=20
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lung Oligometastasis of Breast Cancer: Prospective Cohort Study of Treatment Strategies (SBP-06)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=While local treatment of metastases is considered to be unrelated to prognosis, previous studies have suggested that local treatment of isolated lung metastases may have positive prognostic impact. We designed this prospective cohort study to investigate the clinical situation and its outcomes. We enrolled patients with fewer than 3 lung nodules suspected of being oligometastases after curative breast cancer surgery. Treatments, including local and systemic therapy, were selected by the physician and patient in consultation. The primary outcome was overall survival (OS); secondary outcomes were the efficacy and the safety of the surgery for lung oligometastases. Between May 2015 and May 2019, 14 patients were enrolled. Resection of lung nodules (metastasectomy) was performed in 11 (78.6%) of 14 patients, and one of these cases was diagnosed as primary lung cancer. Metastasectomies were all performed employing video-assisted thoracic surgery (VATS) without perioperative complications. Systemic therapies were administered to all patients except one. The respective 3-year and 5-year OS rates of patients with lung oligometastases were 91.6% and 81.5%, respectively. Progression occurred in 6 patients: 3 of the 10 with metastasectomy and all 3 without this surgical procedure. Lung metastasectomy was worthwhile as a diagnostic evaluation and may provide long-term benefit in some patients.
en-copyright=
kn-copyright=

en-aut-name=MaedaReina
en-aut-sei=Maeda
en-aut-mei=Reina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiMina
en-aut-sei=Takahashi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawadaKengo
en-aut-sei=Kawada
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakabatakeDaisuke
en-aut-sei=Takabatake
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsuokaKinya
en-aut-sei=Matsuoka
en-aut-mei=Kinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HikinoHajime
en-aut-sei=Hikino
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OsumiShozo
en-aut-sei=Osumi
en-aut-mei=Shozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast and Thyroid Surgery, Ehime Prefectural Central Hospital
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, Matsue Red Cross Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School
kn-affil=

affil-num=13
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=15
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=oligometastasis
kn-keyword=oligometastasis
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=lung
kn-keyword=lung
en-keyword=metastasectomy
kn-keyword=metastasectomy
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=10
article-no=
start-page=100573
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Unresectable or recurrent thymic epithelial tumors (TETs) have a poor prognosis, and treatment options are limited. This study aimed to investigate the immunologic significance of CD80/CD86 or major histocompatibility complex class II (MHC-II) expression in TETs, as potential predictive biomarkers for immune checkpoint inhibitors (ICIs).<br>
Methods: We analyzed CD80, CD86, MHC class I (MHC-I), and MHC-II expression in TETs using immunohistochemistry and investigated their association with T-cell infiltration or ICI efficacy. In addition, we generated CD80- or MHC-II–expressing mouse tumors, evaluated the effects of ICIs, and analyzed tumor-infiltrating lymphocytes. We also performed tumor-rechallenge experiments in vivo.<br>
Results: We found that approximately 50% and 30% of TETs had high expression of CD80/CD86 and MHC-II in tumor cells, respectively, and that this expression was related to T-cell infiltration in clinical samples. In mouse models, both CD80 and MHC-II increase the effects of ICIs. In addition, senescent T cells and long-lived memory precursor effector T cells were significantly decreased and increased, respectively, in tumor-infiltrating lymphocytes from CD80-expressing tumors, and rechallenged tumors were completely rejected after the initial eradication of CD80-expressing tumors by programmed cell death protein 1 blockade. Indeed, patients with CD80-high thymic carcinoma had longer progression-free survival with anti–programmed cell death protein 1 monoclonal antibody.<br>
Conclusions: Half of the TETs had high expression of CD80/CD86 or MHC-II with high T-cell infiltration. These molecules could potentially increase the effects of ICIs, particularly inducing a durable response. CD80/CD86 and MHC-II can be predictive biomarkers of ICIs in TETs, promoting the development of drugs for such TETs.
en-copyright=
kn-copyright=

en-aut-name=IkedaHideki
en-aut-sei=Ikeda
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NagasakiJoji
en-aut-sei=Nagasaki
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShimizuDaiki
en-aut-sei=Shimizu
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsuyaYuki
en-aut-sei=Katsuya
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HorinouchiHidehito
en-aut-sei=Horinouchi
en-aut-mei=Hidehito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HosomiYukio
en-aut-sei=Hosomi
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanjiEtsuko
en-aut-sei=Tanji
en-aut-mei=Etsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IwataTakekazu
en-aut-sei=Iwata
en-aut-mei=Takekazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ItamiMakiko
en-aut-sei=Itami
en-aut-mei=Makiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawazuMasahito
en-aut-sei=Kawazu
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OheYuichiro
en-aut-sei=Ohe
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SuzukiTakuji
en-aut-sei=Suzuki
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TogashiYosuke
en-aut-sei=Togashi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Chiba Cancer Center, Research Institute
kn-affil=

affil-num=2
en-affil=Chiba Cancer Center, Research Institute
kn-affil=

affil-num=3
en-affil=Division of Thoracic Surgery, Chiba Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Experimental Therapeutics, National Cancer Center Hospital
kn-affil=

affil-num=5
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=6
en-affil=Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=7
en-affil=Chiba Cancer Center, Research Institute
kn-affil=

affil-num=8
en-affil=Division of Thoracic Surgery, Chiba Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Surgical Pathology, Chiba Cancer Center
kn-affil=

affil-num=10
en-affil=Chiba Cancer Center, Research Institute
kn-affil=

affil-num=11
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=12
en-affil=Department of Respirology, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=13
en-affil=Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Thymic epithelial tumor
kn-keyword=Thymic epithelial tumor
en-keyword=Cancer immunotherapy
kn-keyword=Cancer immunotherapy
en-keyword=CD80/CD86
kn-keyword=CD80/CD86
en-keyword=MHC
kn-keyword=MHC
en-keyword=Memory precursor effector T cell
kn-keyword=Memory precursor effector T cell
END

start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=3
article-no=
start-page=106
end-page=108
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2022 Incentive Award of the Okayama Medical Association in General Medical Science (2022 Yuuki Prize)
kn-title=令和４年度岡山医学会賞　総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=松本尚美
kn-aut-sei=松本
kn-aut-mei=尚美
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科　疫学・衛生学
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=11
article-no=
start-page=1562
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231024
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Novel Iron Chelators, Super-Polyphenols, Show Antimicrobial Effects against Cariogenic Streptococcus mutans
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Dental caries are an oral infectious disease that can affect human health both orally and systemically. It remains an urgent issue to establish a novel antibacterial method to prevent oral infection for a healthy life expectancy. The aim of this study was to evaluate the inhibitory effects of novel iron chelators, super-polyphenols (SPs), on the cariogenic bacterium Streptococcus mutans, in vitro. SPs were developed to reduce the side effects of iron chelation therapy and were either water-soluble or insoluble depending on their isoforms. We found that SP6 and SP10 inhibited bacterial growth equivalent to povidone-iodine, and viability tests indicated that their effects were bacteriostatic. These results suggest that SP6 and SP10 have the potential to control oral bacterial infections such as Streptococcus mutans.
en-copyright=
kn-copyright=

en-aut-name=Shinoda-ItoYuki
en-aut-sei=Shinoda-Ito
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OmoriKazuhiro
en-aut-sei=Omori
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItoTakashi
en-aut-sei=Ito
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakayamaMasaaki
en-aut-sei=Nakayama
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaAtsushi
en-aut-sei=Ikeda
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItoMasahiro
en-aut-sei=Ito
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OharaToshiaki
en-aut-sei=Ohara
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakashibaShogo
en-aut-sei=Takashiba
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Oral Microbiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Periodontics & Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Pathology and Experimental Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=antimicrobial
kn-keyword=antimicrobial
en-keyword=iron chelator
kn-keyword=iron chelator
en-keyword=oral infection
kn-keyword=oral infection
en-keyword=Streptococcus mutans
kn-keyword=Streptococcus mutans
en-keyword=super-polyphenols
kn-keyword=super-polyphenols
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=635
end-page=645
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Nutritional Support Combined with Neuromuscular Electrical Stimulation on Muscle Strength and Thickness: A Randomized Controlled Trial in Healthy Young Adult Males
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In the management of post-injury patients with activity limitations, methods to prevent musculoskeletal disorders and hasten recovery are important. This randomized controlled, single-blinded study was a preliminary investigation of the combined effect of nutritional support with neuromuscular electrical stimulation (NMES) on muscle strength and thickness. Healthy young adult males (median age, 21 years) were enrolled; each of their hands was randomly assigned to one of the following four groups: Placebo, Nutrition, NMES, and Nutrition + NMES. All participants received whey protein or placebo (3x/week for 6 weeks) and NMES training (3x/week for 6 weeks) on the abductor digiti minimi (ADM) muscle of either the left or right hand. ADM muscle strength and thickness were analyzed at baseline and at week 7. We analyzed 38 hands (9 Placebo, 10 Nutrition, 9 NMES, 10 Nutrition + NMES). There was significantly greater muscle strengthening in the Nutrition + NMES group compared to the Placebo group or the NMES group, but no significant difference in gain of muscle thickness. The combined intervention may be effective in improving muscle strength. Future clinical trials targeting various muscles after sports-related injuries are warranted.
en-copyright=
kn-copyright=

en-aut-name=IkedaTomohiro
en-aut-sei=Ikeda
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkamuraKazunori
en-aut-sei=Okamura
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HasegawaMasaki
en-aut-sei=Hasegawa
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanakaSatoshi
en-aut-sei=Tanaka
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanaiShusaku
en-aut-sei=Kanai
en-aut-mei=Shusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Rehabilitation Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Physical Therapy, Faculty of Health and Welfare, Prefectural University of Hiroshima
kn-affil=

affil-num=3
en-affil=Department of Physical Therapy, Faculty of Health and Welfare, Prefectural University of Hiroshima
kn-affil=

affil-num=4
en-affil=Department of Physical Therapy, Faculty of Health and Welfare, Prefectural University of Hiroshima
kn-affil=

affil-num=5
en-affil=Department of Physical Therapy, Faculty of Health and Welfare, Prefectural University of Hiroshima
kn-affil=
en-keyword=whey protein
kn-keyword=whey protein
en-keyword=electrical stimulation
kn-keyword=electrical stimulation
en-keyword=muscle strength
kn-keyword=muscle strength
en-keyword=healthy volunteers
kn-keyword=healthy volunteers
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=595
end-page=605
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR (95% confidence interval [CI]) 1.67 [1.51-1.85]; VCM + ≥2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN.
en-copyright=
kn-copyright=

en-aut-name=BandoTakashi
en-aut-sei=Bando
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChumaMasayuki
en-aut-sei=Chuma
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkadaNaoto
en-aut-sei=Okada
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KondoMasateru
en-aut-sei=Kondo
en-aut-mei=Masateru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IzumiYuki
en-aut-sei=Izumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshidaShunsuke
en-aut-sei=Ishida
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshiokaToshihiko
en-aut-sei=Yoshioka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AsadaMizuho
en-aut-sei=Asada
en-aut-mei=Mizuho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakechiKenshi
en-aut-sei=Takechi
en-aut-mei=Kenshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MiyataKoji
en-aut-sei=Miyata
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YagiKenta
en-aut-sei=Yagi
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Izawa-IshizawaYuki
en-aut-sei=Izawa-Ishizawa
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AzumaMomoyo
en-aut-sei=Azuma
en-aut-mei=Momoyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=YanagawaHiroaki
en-aut-sei=Yanagawa
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TasakiYoshikazu
en-aut-sei=Tasaki
en-aut-mei=Yoshikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=2
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=4
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=5
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=8
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=9
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=10
en-affil=Department of Medical Molecular Informatics, Meiji Pharmaceutical University
kn-affil=

affil-num=11
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=12
en-affil=Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University
kn-affil=

affil-num=13
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=

affil-num=14
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=15
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=16
en-affil=Department of Pharmacology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=17
en-affil=Department of Infection Control and Prevention, Tokushima University Hospital
kn-affil=

affil-num=18
en-affil=Department of Nursing, Faculty of Health and Welfare, Tokushima Bunri University
kn-affil=

affil-num=19
en-affil=Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University
kn-affil=

affil-num=20
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
en-keyword=vancomycin-associated nephrotoxicity
kn-keyword=vancomycin-associated nephrotoxicity
en-keyword=polypharmacy
kn-keyword=polypharmacy
en-keyword=nephrotoxin
kn-keyword=nephrotoxin
en-keyword=spontaneous adverse event reporting database
kn-keyword=spontaneous adverse event reporting database
en-keyword=electronic medical records
kn-keyword=electronic medical records
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=517
end-page=525
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the effect of modified FOLFIRINOX (mFFX) in unresectable pancreatic cancer by retrospectively analyzing the cases of 43 patients who underwent BRCA testing (germline, n=11; somatic, n=26; both germline and somatic, n=6). The association between BRCA mutations and therapeutic effect was clarified. Six patients tested positive for germline pathogenic variants. Familial pancreatic cancer (33% vs. 3%, p=0.006) and peritoneal disseminated lesions (66% vs. 8%, p<0.001) were significantly more common in patients with germline pathogenic variants. The partial response (PR) rate was 100% in the germline BRCA-positive patients, and 27% in the germline BRCA-negative patients (p<0.001). The median progression-free survival (PFS) was not reached for any germline BRCA-positive patients but was 9.0 months for the germline BRCA-negative patients (p=0.042). Patients with stage IV BRCA-associated pancreatic cancer had better overall survival than those with non-BRCA-associated pancreatic cancer, although the difference was nonsignificant (not reached vs. 655 days, p=0.061). Our results demonstrate that a PR and prolonged PFS can be expected in germline BRCA-positive patients after treatment with mFFX. Our findings also suggest that germline BRCA pathogenic variants may be useful as biomarkers for the therapeutic effect of mFFX in patients with pancreatic cancer.
en-copyright=
kn-copyright=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorimotoKosaku
en-aut-sei=Morimoto
en-aut-mei=Kosaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumiAkihiro
en-aut-sei=Matsumi
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TerasawaHiroyuki
en-aut-sei=Terasawa
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamazakiTatsuhiro
en-aut-sei=Yamazaki
en-aut-mei=Tatsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsutsumiKoichiro
en-aut-sei=Tsutsumi
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=BRCA
kn-keyword=BRCA
en-keyword=FOLFIRINOX
kn-keyword=FOLFIRINOX
en-keyword=pancreatic cancer
kn-keyword=pancreatic cancer
en-keyword=progression-free survival
kn-keyword=progression-free survival
en-keyword=pathogenic variant
kn-keyword=pathogenic variant
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=491
end-page=497
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Participation in the Setouchi Triennale and the Health of Residents in Naoshima: A Cross-Sectional Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Arts festivals have become increasingly popular in various parts of Japan in recent years. The purpose of this study was to investigate the relationships between arts festival activities participation at the Setouchi Triennale and the health of residents in the town of Naoshima. This was a cross-sectional study. Questionnaires were distributed to all residents of Naoshima who were 20 years old or older (n=2,588). We analyzed responses from 708 people. The associations between arts festival activities participation and health (measured by self-rated health) were analyzed using logistic regression analysis as the primary outcome. Kessler’s psychological distress scale scores were also analyzed in the same manner as the primary outcome. The participating group had an adjusted odds ratio of 1.86 (95% confidence interval: 1.03-3.33) for higher self-rated health compared with those who did not participate. Kessler’s psychological distress scale results showed that the participating group had an adjusted odds ratio of 3.23 (95% confidence interval: 1.19-8.81) for lower psychological distress compared with those who did not participate. In conclusion, arts festival activities participation was associated with higher self-rated health and lower psychological distress. However, caution must be taken in regard to generalizability and causality when interpreting these results.
en-copyright=
kn-copyright=

en-aut-name=HabuHiroshi
en-aut-sei=Habu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyajiChikara
en-aut-sei=Miyaji
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AooKen
en-aut-sei=Aoo
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NishitaYosuke
en-aut-sei=Nishita
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsuriMasao
en-aut-sei=Tsuri
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Graduate School of Humanities and Social Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Humanities and Social Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Economics, Musashi University
kn-affil=

affil-num=8
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=art
kn-keyword=art
en-keyword=arts in public health
kn-keyword=arts in public health
en-keyword=arts festival
kn-keyword=arts festival
en-keyword=self-rated health
kn-keyword=self-rated health
en-keyword=Setouchi Triennale
kn-keyword=Setouchi Triennale
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=4
article-no=
start-page=377
end-page=385
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202308
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Liver fibrosis is an important phenomenon in non-alcoholic fatty liver disease (NAFLD) progression. Standard markers reflecting liver fibrosis, including the FIB-4 index, increase with age. This study aimed to identify fibrosis progression-related markers that are diagnostically beneficial even in aged individuals. Serum levels of pro- and anti-inflammatory cytokines were measured by multiple enzyme-linked immunosorbent assay. Two standard NAFLD or fibrosis progression-related markers — the FIB-4 index and APRI score — were analyzed along with cytokine levels to define the best approach to discriminate advanced fibrosis. Ninety-eight NAFLD patients were enrolled: 59 and 39 patients with fibrosis stages 1-2 and 3-4 respectively. In addition to the FIB-4 index and APRI score, the following factors showed significant differences between stages 1-2 and stages 3-4 in a multivariate analysis: platelet counts, IP-10, and RANTES. The fibrosis stage, FIB-4, APRI, PDGF-BB, and RANTES were related to the prognosis. In aged patients, IP-10, GM-CSF, and RANTES differed between stages 1-2 and stages 3-4. FIB-4 and APRI were beneficial for their correlation with fibrosis. However, to stratify either young or elderly advanced fibrosis patients, and to identify patients likely to have a bad outcome, RANTES was the best marker.
en-copyright=
kn-copyright=

en-aut-name=MorimotoKosaku
en-aut-sei=Morimoto
en-aut-mei=Kosaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OyamaAtsushi
en-aut-sei=Oyama
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OnishiHideki
en-aut-sei=Onishi
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=NAFLD
kn-keyword=NAFLD
en-keyword=NASH
kn-keyword=NASH
en-keyword=liver fibrosis
kn-keyword=liver fibrosis
en-keyword=chemokine
kn-keyword=chemokine
en-keyword=FIB-4
kn-keyword=FIB-4
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=3
article-no=
start-page=301
end-page=309
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202306
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Associations between Comorbidities and Acute Exacerbation of Interstitial Lung Disease after Primary Lung Cancer Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Acute exacerbation (AE) of interstitial lung disease (ILD) is a severe complication of lung resection in lung cancer patients with ILD (LC-ILD). This study aimed to assess the predictive value of comorbidities other than ILD for postoperative AE in patients with LC-ILD. We retrospectively evaluated 68 patients with LC-ILD who had undergone lung resection. We classified them into two groups: those who had developed postoperative AE within 30 days after resection and those who had not. We analyzed patient characteristics, high-resolution computed tomography findings, clinical data, pulmonary function, and intraoperative data. The incidence of postoperative AEs was 11.8%. In univariate analysis, performance status (PS), honeycombing, forced vital capacity (FVC), and high hemoglobin A1c (HbA1c) levels without comorbidities were significantly associated with postoperative AE. Patients were divided into two groups according to cutoff levels of those four variables as determined by receiver operating characteristic curves, revealing that the rates of patients without postoperative AE differed significantly between groups. The present results suggested that preoperative comorbidities other than ILD were not risk factors for postoperative AE in patients with LC-ILD. However, a high preoperative HbA1c level, poor PS, low FVC, and honeycombing may be associated with postoperative AE of LC-ILD.
en-copyright=
kn-copyright=

en-aut-name=KatoTakahide
en-aut-sei=Kato
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyoshiSeigo
en-aut-sei=Miyoshi
en-aut-mei=Seigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamadaChizuru
en-aut-sei=Hamada
en-aut-mei=Chizuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SanoYoshifumi
en-aut-sei=Sano
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NogamiNaoyuki
en-aut-sei=Nogami
en-aut-mei=Naoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamaguchiOsamu
en-aut-sei=Yamaguchi
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HamaguchiNaohiko
en-aut-sei=Hamaguchi
en-aut-mei=Naohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Community Medicine, Pulmonology and Cardiology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine
kn-affil=
en-keyword=lung cancer
kn-keyword=lung cancer
en-keyword=interstitial lung disease
kn-keyword=interstitial lung disease
en-keyword=acute exacerbation
kn-keyword=acute exacerbation
en-keyword=comorbidity
kn-keyword=comorbidity
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=3
article-no=
start-page=291
end-page=299
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202306
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Comparison of the Efficacy of Plastic Stent Placement Above and Across the Sphincter of Oddi for Benign Biliary Hilar Stricture
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the efficacy and safety of endoscopic plastic stent (PS) placement for hilar benign biliary strictures (BBSs) and compared cases with PS placement above (inside stent, IS) and across (usual stent, US) the sphincter of Oddi. Patients who underwent initial endoscopic PS placement for hilar BBSs between August 2012 and December 2021 were retrospectively analyzed. Hilar BBSs in 88 patients were investigated. Clinical success was achieved in 81 of these cases (92.0%), including 38 patients in the IS group and 43 patients in the US group. Unexpected stent exchange (uSE) before the first scheduled PS exchange occurred in 18 cases (22.2%). The median time from first stent placement to uSE was 35 days. There was no significant difference in the rate and median time to uSE between the two groups. The rates of adverse events such as pancreatitis or cholangitis in the two groups did not significantly differ. However, the rate of difficult stent removal in the IS group (15.8%) was significantly higher than that in the US group (0%) (p=0.0019). US placement is preferable to IS placement for scheduled stent exchange, as it offers the same effectiveness and risk of adverse events with easier stent removal.
en-copyright=
kn-copyright=

en-aut-name=HimeiHitomi
en-aut-sei=Himei
en-aut-mei=Hitomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SaragaiYosuke
en-aut-sei=Saragai
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamazakiTatsuhiro
en-aut-sei=Yamazaki
en-aut-mei=Tatsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TsutsumiKoichiro
en-aut-sei=Tsutsumi
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=benign biliary stricture
kn-keyword=benign biliary stricture
en-keyword=inside stent
kn-keyword=inside stent
en-keyword=plastic stent
kn-keyword=plastic stent
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230324
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=肥満・高脂血症は相乗的に乾癬様皮疹を悪化させる
kn-title=Obesity and Dyslipidemia Synergistically Exacerbate Psoriatic Skin Inflammation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IKEDAKenta
en-aut-sei=IKEDA
en-aut-mei=Kenta
kn-aut-name=池田賢太
kn-aut-sei=池田
kn-aut-mei=賢太
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=2
article-no=
start-page=193
end-page=197
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202304
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Validity of the 30-Second Chair-Stand Test to Assess Exercise Tolerance and Clinical Outcomes in Patients with Esophageal Cancer: A Retrospective Study with Reference to 6-Minute Walk Test Results
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This retrospective study aimed to investigate the validity of a 30-sec chair stand test (CS-30) as a simple test to assess exercise tolerance and clinical outcomes in 53 Japanese patients with esophageal cancer. There was a strong correlation between the results of CS-30 and the 6-min walk test (6MWT), the gold standard for assessing exercise tolerance (r=0.759). Furthermore, fewer patients whose CS-30 score was greater than 16 (the cutoff value defined based on 6MWT) experienced pneumonia in their postoperative course. These results suggest that exercise tolerance could be assessed using CS-30, and its cutoff value may be useful in predicting postoperative pneumonia risk.
en-copyright=
kn-copyright=

en-aut-name=IkedaTomohiro
en-aut-sei=Ikeda
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkuraKazuki
en-aut-sei=Okura
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatayamaSho
en-aut-sei=Katayama
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYusuke
en-aut-sei=Takahashi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaedaNaoaki
en-aut-sei=Maeda
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanabeShunsuke
en-aut-sei=Tanabe
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WakitaAkiyuki
en-aut-sei=Wakita
en-aut-mei=Akiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HamadaMasanori
en-aut-sei=Hamada
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SendaMasuo
en-aut-sei=Senda
en-aut-mei=Masuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Rehabilitation Medicine, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Rehabilitation, Akita University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Rehabilitation Medicine, Okayama University
kn-affil=

affil-num=5
en-affil=Division of Rehabilitation, Akita University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Esophageal Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Rehabilitation Medicine, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Rehabilitation Medicine, Okayama University
kn-affil=
en-keyword=esophageal cancer
kn-keyword=esophageal cancer
en-keyword=exercise tolerance
kn-keyword=exercise tolerance
en-keyword=rehabilitation
kn-keyword=rehabilitation
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=1
article-no=
start-page=75
end-page=80
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202302
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Scattered Tiny Whitish Protrusions in the Stomach Are a Clue to the Diagnosis of Autoimmune Gastritis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Herein, we report two patients with autoimmune gastritis who had undergone multiple esophagogastroduodenoscopy procedures for 17 and 9 years, respectively, before their diagnosis. Instead, they had been diagnosed with and treated for Helicobacter pylori-associated gastritis. The correct diagnosis was made when scatterings of tiny whitish protrusions in the gastric mucosa were detected on esophagogastroduodenoscopy. Our findings suggest that scattered tiny whitish bumps may be a clue to the diagnosis of autoimmune gastritis.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamadaKenta
en-aut-sei=Hamada
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KonoYoshiyasu
en-aut-sei=Kono
en-aut-mei=Yoshiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanzakiHiromitsu
en-aut-sei=Kanzaki
en-aut-mei=Hiromitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KawanoSeiji
en-aut-sei=Kawano
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawaharaYoshiro
en-aut-sei=Kawahara
en-aut-mei=Yoshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Practical Gastrointestinal Endoscopy, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=autoimmune gastritis
kn-keyword=autoimmune gastritis
en-keyword=esophagogastroduodenoscopy
kn-keyword=esophagogastroduodenoscopy
en-keyword=scattered lesions
kn-keyword=scattered lesions
en-keyword=small white protrusions
kn-keyword=small white protrusions
en-keyword=mucosal lesions
kn-keyword=mucosal lesions
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=36
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202302
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Increased Glycine-conjugated and Unconjugated Bile Acid Levels Associated with Aggravation of Nonalcoholic Steatohepatitis and Cardiovascular Disease in SHRSP5/Dmcr Rat
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The SHRSP5/Dmcr is a useful animal model for the development of nonalcoholic steatohepatitis (NASH) pathology when fed a high-fat, high-cholesterol diet, and further drug interventions can lead to concomitant cardiovascular disease. While SHRSP5/Dmcr rats have been used for basic research related to NASH, details of their bile acid metabolism in this condition are unknown. In this study, we aimed to clarify the changes in the serum bile acid (BA) fractions associated with NASH and found that glycine-conjugated and unconjugated bile acid increased with worsening NASH and cardiovascular disease while taurine-conjugated BA relatively decreased.
en-copyright=
kn-copyright=

en-aut-name=YamamotoShusei
en-aut-sei=Yamamoto
en-aut-mei=Shusei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SatoIkumi
en-aut-sei=Sato
en-aut-mei=Ikumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiiMoe
en-aut-sei=Fujii
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KakimotoMai
en-aut-sei=Kakimoto
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HonmaKoki
en-aut-sei=Honma
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkiyamaNatsumi
en-aut-sei=Akiyama
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakaiMiku
en-aut-sei=Sakai
en-aut-mei=Miku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FukuhamaNatsuki
en-aut-sei=Fukuhama
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KumazakiShota
en-aut-sei=Kumazaki
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HirohataSatoshi
en-aut-sei=Hirohata
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KitamoriKazuya
en-aut-sei=Kitamori
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamoriYukio
en-aut-sei=Yamori
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeShogo
en-aut-sei=Watanabe
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Academic Field of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Medical Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Medical Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Medical Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Academic Field of Health Sciences, Okayama University
kn-affil=

affil-num=11
en-affil=College of Human Life and Environment, Kinjo Gakuin University
kn-affil=

affil-num=12
en-affil=Institute for World Health Development, Mukogawa Women's University
kn-affil=

affil-num=13
en-affil=Academic Field of Health Sciences, Okayama University
kn-affil=
en-keyword=SHRSP5/Dmc
kn-keyword=SHRSP5/Dmc
en-keyword=nonalcoholic steatohepatitis
kn-keyword=nonalcoholic steatohepatitis
en-keyword=cardiovascular disease
kn-keyword=cardiovascular disease
en-keyword=glycine-conjugated bile acids
kn-keyword=glycine-conjugated bile acids
en-keyword=unconjugated bile acids
kn-keyword=unconjugated bile acids
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=6
article-no=
start-page=743
end-page=748
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Posterolateral Floating Technique for the Thoracic Ossification of the Posterior Longitudinal Ligament with Navigation: A Technical Note
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We describe a floating technique via a posterolateral approach with intraoperative O-arm navigation to facilitate decompression of the spinal cord in thoracic myelopathy due to severe ossification of the posterior longitudinal ligament (OPLL). A 62-year-old man with myelopathy due to thoracic OPLL had left-leg muscle weakness, urinary disturbance, and spastic gait. Bilateral leg pain and gait disturbance had persisted for 2 years. He was successfully treated by the posterolateral OPLL floating procedure and posterior pedicle fixation under O-arm navigation. At a 2-year follow-up, manual muscle testing results and sensory function of the left leg had recovered fully. His cervical Japanese Orthopedic Association score had improved from 5/12 to 11/12. The novel intraoperative O-arm navigation-guided posterolateral floating procedure for thoracic OPLL is effective for achieving precise decompression and strong fixation with a posterior approach only and can provide an excellent result for severe thoracic OPLL without the risk of adverse events from intraoperative radiation.
en-copyright=
kn-copyright=

en-aut-name=TanakaMasato
en-aut-sei=Tanaka
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SutharHardik
en-aut-sei=Suthar
en-aut-mei=Hardik
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=DesaiDhvanit
en-aut-sei=Desai
en-aut-mei=Dhvanit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamauchiTaro
en-aut-sei=Yamauchi
en-aut-mei=Taro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AratakiShinya
en-aut-sei=Arataki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraYoshihiro
en-aut-sei=Fujiwara
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UotaniKoji
en-aut-sei=Uotani
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OdaYoshiaki
en-aut-sei=Oda
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MisawaHaruo
en-aut-sei=Misawa
en-aut-mei=Haruo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=
en-keyword=ossification of the posterior longitudinal ligament
kn-keyword=ossification of the posterior longitudinal ligament
en-keyword=floating method
kn-keyword=floating method
en-keyword= navigation surgery
kn-keyword= navigation surgery
en-keyword=C-arm free
kn-keyword=C-arm free
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=6
article-no=
start-page=705
end-page=713
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The sodium glucose transporter 2 (SGLT2) inhibitor tofogliflozin is a glucose-lowering drug that causes the excretion of surplus glucose by inhibiting SGLT2. Because of tofogliflozin’s osmotic diuresis mechanism, patients’ serum electrolytes, body fluid levels, and cardiac function must be monitored. We retrospectively analyzed the cases of 64 elderly Japanese patients with type 2 diabetes mellitus (T2DM) who received tofogliflozin for 3 months. Their HbA1c, serum electrolytes (sodium, potassium, chloride), hematocrit, brain natriuretic peptide (cardiac volume load marker) and renin and aldosterone (RAA; an index of regulatory hormones involved in body fluid retention) were continuously monitored during the investigation period. Renal function and cardiac function (by echocardiography) were assessed throughout the period. HbA1c significantly decreased (β1=−0.341, p<0.0001, linear regression analysis [LRA]). Most of the hormonal, electrolyte, and physiological parameters were maintained throughout the study period. In these circumstances, E/e’ tended to decrease (β1=−0.382, p=0.13, LRA). Compared to the baseline, E/e’ was significantly decreased at 1 and 3 months (p<0.01, p<0.05). In the higher E/e’ group (E/e’≥10, n=34), E/e’ decreased significantly (β1=−0.63, p<0.05, LRA). ΔE/e’ was correlated with body-weight change during treatment (r=0.64, p<0.01). The 3-month tofogliflozin treatment improved glycemic control and diastolic function represented by E/e’ in T2DM patients, without affecting serum electrolytes, renal function, or RAA. No negative impacts on the patients were observed. Three-month tofogliflozin treatment lowered glucose and improved cardiac diastolic function.
en-copyright=
kn-copyright=

en-aut-name=HigashikawaToshihiro
en-aut-sei=Higashikawa
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ItoTomohiko
en-aut-sei=Ito
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MizunoTakurou
en-aut-sei=Mizuno
en-aut-mei=Takurou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshigamiKeiichiro
en-aut-sei=Ishigami
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KurokiKengo
en-aut-sei=Kuroki
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaekawaNaoto
en-aut-sei=Maekawa
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UsudaDaisuke
en-aut-sei=Usuda
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IzumidaToshihide
en-aut-sei=Izumida
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamadaShinya
en-aut-sei=Yamada
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SangenRyusho
en-aut-sei=Sangen
en-aut-mei=Ryusho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HamadaKazu
en-aut-sei=Hamada
en-aut-mei=Kazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KiyosawaJun
en-aut-sei=Kiyosawa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SaitoAtsushi
en-aut-sei=Saito
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IguchiMasaharu
en-aut-sei=Iguchi
en-aut-mei=Masaharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KasamakiYuji
en-aut-sei=Kasamaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NakahashiTakeshi
en-aut-sei=Nakahashi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=FukudaAkihiro
en-aut-sei=Fukuda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SaitoHitoshi
en-aut-sei=Saito
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KandaTsugiyasu
en-aut-sei=Kanda
en-aut-mei=Tsugiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=OkuroMasashi
en-aut-sei=Okuro
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=2
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=3
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=4
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=5
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=6
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=7
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=8
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=9
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=10
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=11
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=12
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=13
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=14
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=15
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=16
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=17
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=18
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=19
en-affil=Kanazawa Medical University Himi Municipal Hospital
kn-affil=

affil-num=20
en-affil=Department of Geriatric Medicine, Kanazawa Medical University
kn-affil=
en-keyword=tofogliflozin
kn-keyword=tofogliflozin
en-keyword=SGLT2 inhibitor
kn-keyword=SGLT2 inhibitor
en-keyword=elderly patient
kn-keyword=elderly patient
en-keyword=HbA1c
kn-keyword=HbA1c
en-keyword=cardiac diastolic function
kn-keyword=cardiac diastolic function
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=6
article-no=
start-page=695
end-page=703
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=History of Transcatheter Arterial Chemoembolization Predicts the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study sought to identify factors that are predictive of a therapeutic response to hepatic arterial infusion chemotherapy (HAIC) by focusing on the number of prior transcatheter arterial chemoembolization (TACE) sessions. To determine the parameters predicting a good response to HAIC, we retrospectively analyzed 170 patients with hepatocellular carcinoma (HCC) who received HAIC regimens comprising low-dose cisplatin combined with 5-fluorouracil (LFP) or cisplatin (CDDP) for the first time. In both the LFP and CDDP regimens, the response rates were significantly lower in patients with three or more prior TACE sessions than in those with two or fewer prior TACE sessions (LFP 57% versus 28%; p=0.01, CDDP 27% versus 6%; p=0.01). Multivariable logistic regression analysis revealed that the number of prior TACE sessions (≥ 3) was significantly associated with non-responder status (odds ratio 4.17, 95% Confidence Interval (CI) 1.76-9.86) in addition to the HAIC regimen. Multivariable analysis using the Cox proportional hazards model revealed that a larger number of prior TACE sessions (≥ 3) was a significant risk factor for survival (hazard ratio 1.60, 95% CI 1.12-2.29) in addition to Child-Pugh class, serum alpha-fetoprotein concentration, and maximum diameter of HCC. HCC patients who receive fewer prior TACE sessions (≤ 2) were found to be better responders to HAIC.
en-copyright=
kn-copyright=

en-aut-name=OnishiHideki
en-aut-sei=Onishi
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OyamaAtsushi
en-aut-sei=Oyama
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=hepatic arterial infusion chemotherapy
kn-keyword=hepatic arterial infusion chemotherapy
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=refractory
kn-keyword=refractory
en-keyword=transcatheter arterial chemoembolization
kn-keyword=transcatheter arterial chemoembolization
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=6
article-no=
start-page=679
end-page=688
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy and Safety of Three-dimensional Conformal Radiotherapy for Macroscopic Vascular Invasion of Hepatocellular Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chemotherapy is insufficient to treat macroscopic vascular invasion (MVI) of hepatocellular carcinoma (HCC). We retrospectively investigated the treatment outcomes of patients who underwent three-dimensional conformal radiotherapy (3D-CRT) for HCC MVI and analyzed prognostic factors by multivariate analysis using a Cox proportional hazard model. Sixty-five patients were studied. MVI sites were the portal vein (n=48 patients), portal and hepatic veins (n=8), and hepatic vein (n=9). The median irradiation dose was 50 Gy. The median survival time (MST) was 7.5 months. Performance status 2 or 3, modified albumin-bilirubin grade 2b or 3, and massive/diffuse type were poor prognostic factors. Nineteen patients (29%) with a treatment effect of 3 or 4 (≥ 50% of tumor necrosis or regression) at the irradiation sites according to the Response Evaluation Criteria in Cancer of the Liver showed longer survival than those with an effect of 1 or 2 (MST 18.7 vs. 5.9 months, p<0.001). No treatment-related death occurred. The hepatic function reserve was preserved in more than 70% of patients. 3D-CRT controlled HCC MVI safely and was suggested to be a good treatment option.
en-copyright=
kn-copyright=

en-aut-name=AsagiAkinori
en-aut-sei=Asagi
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakaguchiChihiro
en-aut-sei=Sakaguchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NadanoSeijin
en-aut-sei=Nadano
en-aut-mei=Seijin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishinaTomohiro
en-aut-sei=Nishina
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HamamotoYasushi
en-aut-sei=Hamamoto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KataokaMasaaki
en-aut-sei=Kataoka
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamashitaNatsumi
en-aut-sei=Yamashita
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanimizuMasahito
en-aut-sei=Tanimizu
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HyodoIchinosuke
en-aut-sei=Hyodo
en-aut-mei=Ichinosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=2
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=3
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=6
en-affil=Department of Radiology, Saiseikai Imabari Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Research Center, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=8
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=macroscopic vascular invasion
kn-keyword=macroscopic vascular invasion
en-keyword=portal vein tumor thrombosis
kn-keyword=portal vein tumor thrombosis
en-keyword=hepatic vein tumor thrombosis
kn-keyword=hepatic vein tumor thrombosis
en-keyword=three-dimensional conformal radiotherapy
kn-keyword=three-dimensional conformal radiotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=6
article-no=
start-page=661
end-page=671
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chemotherapy-induced peripheral neuropathy (CIPN) is an important clinical challenge that threatens patients’ quality of life. This sub-study of the ABROAD trial investigated the influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data from a randomized study to determine the optimal dose of a 3-week-cycle regimen of nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). Patients with HER2-negative MBC were randomly assigned to three doses of q3w nab-PTX (SD: 260 mg/m2 vs. MD: 220 mg/m2 vs. LD: 180 mg/m2). Five SNPs (EPHA4-rs17348202, EPHA5-rs7349683, EPHA6-rs301927, LIMK2-rs5749248, and XKR4-rs4737264) were analyzed based on the results of a previous genome-wide association study. Per-allele SNP associations were assessed by a Cox regression to model the cumulative dose of nab-PTX up to the onset of severe or worsening sensory neuropathy. A total of 141 patients were enrolled in the parent study; 91(65%) were included in this sub-study. Worsening of CIPN was significantly greater in the cases with XKR4 AC compared to those with a homozygote AA (HR 1.86, 95%CI: 1.00001−3.46, p=0.049). There was no significant correlation of CIPN with any other SNP. A multivariate analysis showed that the cumulative dose of nab-PTX was most strongly correlated with CIPN (p<0.01).
en-copyright=
kn-copyright=

en-aut-name=AbeYuko
en-aut-sei=Abe
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KashiwabaraKosuke
en-aut-sei=Kashiwabara
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsurutaniJunji
en-aut-sei=Tsurutani
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KitadaMasahiro
en-aut-sei=Kitada
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiMasato
en-aut-sei=Takahashi
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatoHiroaki
en-aut-sei=Kato
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KikawaYuichiro
en-aut-sei=Kikawa
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SakataEiko
en-aut-sei=Sakata
en-aut-mei=Eiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaitoYoichi
en-aut-sei=Naito
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HasegawaYoshie
en-aut-sei=Hasegawa
en-aut-mei=Yoshie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SaitoTsuyoshi
en-aut-sei=Saito
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IwasaTsutomu
en-aut-sei=Iwasa
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TakashimaTsutomu
en-aut-sei=Takashima
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=AiharaTomohiko
en-aut-sei=Aihara
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MukaiHirofumi
en-aut-sei=Mukai
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=3
en-affil=Clinical Research Promotion Center, University of Tokyo Hospital
kn-affil=

affil-num=4
en-affil=Advanced Cancer Translational Research Institute, Showa University
kn-affil=

affil-num=5
en-affil=Breast Disease Center, Asahikawa Medical University Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Breast Surgery, Teine Keijinkai Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery, Kansai Medical University Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast Surgery, Niigata City General Hospital
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=11
en-affil=Department of Breast Surgery, Hachinohe City Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast Surgery, Japanese Red Cross Saitama Hospital
kn-affil=

affil-num=13
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=14
en-affil=Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Breast Center, Aihara Hospital
kn-affil=

affil-num=16
en-affil=Department of Medical Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=17
en-affil=Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=18
en-affil=Department of Breast and Endocrine surgery, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Department of Breast surgery, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=20
en-affil=Department of Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=metastatic breast cancer
kn-keyword=metastatic breast cancer
en-keyword=taxane-induced peripheral neuropathy
kn-keyword=taxane-induced peripheral neuropathy
en-keyword=chemotherapy-induced peripheral neuropathy
kn-keyword=chemotherapy-induced peripheral neuropathy
en-keyword=nab-paclitaxel
kn-keyword=nab-paclitaxel
en-keyword=single nucleotide polymorphism
kn-keyword=single nucleotide polymorphism
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220922
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=早期乳癌患者における術前のメトホルミン内服が免疫応答因子に与える影響の検討
kn-title=Influences of preoperative metformin on immunological factors in early breast cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TSUKIOKITakahiro
en-aut-sei=TSUKIOKI
en-aut-mei=Takahiro
kn-aut-name=突沖貴宏
kn-aut-sei=突沖
kn-aut-mei=貴宏
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=5
article-no=
start-page=609
end-page=615
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Idiopathic Pneumonia Syndrome Refractory to Ruxolitinib after Post-Transplant Cyclophosphamide-based Haploidentical Hematopoietic Stem Cell Transplantation: Lung Pathological Findings from an Autopsy Case
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 69-year-old Japanese man with acute leukemia received post-transplant cyclophosphamide-based haploidentical stem cell transplantation (PTCY-haplo-SCT) but was readmitted with dyspnea and ground-glass-opacities of the lungs. Bronchoscopy showed inflammatory changes with no signs of infection. He received steroids but required intubation as his condition deteriorated. In addition to antithymocyte globulin and cyclophosphamide, we administered ruxolitinib but failed to save him. Autopsy findings revealed fibrotic nonspecific interstitial pneumonia (NSIP) without evidence of organizing pneumonia or infection. Thus, we diagnosed idiopathic pneumonia syndrome (IPS). As far as our knowledge, this is the first case of IPS with NSIP histology after PTCY-haplo-SCT.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoKen
en-aut-sei=Matsumoto
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujishitaKeigo
en-aut-sei=Fujishita
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsudaMasayuki
en-aut-sei=Matsuda
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OkaSatoshi
en-aut-sei=Oka
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujisawaYuka
en-aut-sei=Fujisawa
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ImaiToshi
en-aut-sei=Imai
en-aut-mei=Toshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MachidaTakuya
en-aut-sei=Machida
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=
en-keyword=idiopathic pneumonia syndrome
kn-keyword=idiopathic pneumonia syndrome
en-keyword=ruxolitinib
kn-keyword=ruxolitinib
en-keyword=post-transplant cyclophosphamide-based haploidentical stem cell transplantation
kn-keyword=post-transplant cyclophosphamide-based haploidentical stem cell transplantation
en-keyword=nonspecific interstitial pneumonia
kn-keyword=nonspecific interstitial pneumonia
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=5
article-no=
start-page=585
end-page=591
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surgery Outcomes for Pulmonary Metastases from Renal Cell Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pulmonary metastatic resection is a standard therapy for renal cell carcinoma (RCC). Although patients with pulmonary metastases who do not undergo any treatment have poor prognoses, it has been reported that resection for pulmonary metastases yields good clinical outcomes. We investigated the prognoses of the 10 Japanese patients (eight males, two females) who underwent a surgical resection of pulmonary metastasectomy from RCC at our institution between April 1, 2012 and March 31, 2020 and analyzed the prognostic factors. We determined the prognoses and calculated the 5-year overall survival (OS) and disease-free survival (DFS) rates. To identify prognostic factors, we compared the median DFS duration for each factor. Elderly patients (median age, 75.5 years) were more predominant compared to previous studies, and all 10 patients underwent a complete resection. The 5-year DFS rate was 30.5% (95%CI: 0.045-0.63) and the 5-year OS rate was 80% (95%CI: 0.20-0.97). The following factors were associated with better prognosis: female, disease-free interval≥36 months, and metastases size<12 mm. These results indicate that complete resection for pulmonary metastases from RCC resulted in good clinical outcomes, particularly for patients with better prognostic factors.
en-copyright=
kn-copyright=

en-aut-name=ChoshiHaruki
en-aut-sei=Choshi
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WatanabeMototsugu
en-aut-sei=Watanabe
en-aut-mei=Mototsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FurukawaShinichi
en-aut-sei=Furukawa
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UjikeHiroyuki
en-aut-sei=Ujike
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KataokaKazuhiko
en-aut-sei=Kataoka
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=5
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=
en-keyword=renal cell carcinoma
kn-keyword=renal cell carcinoma
en-keyword=pulmonary metastasis
kn-keyword=pulmonary metastasis
en-keyword=complete resection
kn-keyword=complete resection
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=5
article-no=
start-page=527
end-page=533
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Serum 1,25-dihydroxyvitamin D3 Levels in Patients with Eosinophilic Chronic Rhinosinusitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MakiharaSeiichiro
en-aut-sei=Makihara
en-aut-mei=Seiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyamotoShotaro
en-aut-sei=Miyamoto
en-aut-mei=Shotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UraguchiKensuke
en-aut-sei=Uraguchi
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkaAiko
en-aut-sei=Oka
en-aut-mei=Aiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsumuraMunechika
en-aut-sei=Tsumura
en-aut-mei=Munechika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NodaYohei
en-aut-sei=Noda
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkanoMitsuhiro
en-aut-sei=Okano
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Otorhinolaryngology, International University of Health and Welfare, School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Otorhinolaryngology, International University of Health and Welfare, School of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=5
article-no=
start-page=511
end-page=517
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Model-Based Iterative Reconstruction in Low-Dose Paranasal Computed Tomography: A Comparison with Filtered Back Projection and Hybrid Iterative Reconstruction
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Iterative reconstruction (IR) improves image quality compared with filtered back projection (FBP). This study investigated the usefulness of model-based IR (forward-projected model-based iterative reconstruction solution [FIRST]) in comparison with FBP and hybrid IR (adaptive iterative dose reduction three-dimensional processing [AIDR 3D]) in low-dose paranasal CT. Twenty-four patients with paranasal sinusitis who underwent standard-dose CT (120 kV) and low-dose CT (100 kV) scanning before and after medical treatment were enrolled. Standard-dose CT scans were reconstructed with FBP (FBP120), and low-dose CT scans with FBP (FBP100), AIDR 3D, and FIRST. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in three anatomical 
structures and effective doses were compared using Mann–Whitney U test. Two radiologists independently evaluated the visibility of 16 anatomical structures, overall image quality, and artifacts. Effective doses in lowdose CT were significantly reduced compared with those in standard-dose CT (0.24 vs 0.43 mSv, p<0.001).  FIRST achieved significantly higher SNR (p<0.01, respectively) and CNR (p<0.001, respectively) of evaluated structures and significant improvement in overall image quality (p<0.001), artifacts (p<0.001), and visibility related to muscles (p<0.05) compared to FBP120, FBP100, and AIDR 3D. FIRST allowed radiation-dose reduction, while maintaining objective and subjective image quality in low-dose paranasal CT.
en-copyright=
kn-copyright=

en-aut-name=TomitaHayato
en-aut-sei=Tomita
en-aut-mei=Hayato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuramochiKenji
en-aut-sei=Kuramochi
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujikawaAtsuko
en-aut-sei=Fujikawa
en-aut-mei=Atsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaHirotaka
en-aut-sei=Ikeda
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KomitaMidori
en-aut-sei=Komita
en-aut-mei=Midori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuriharaYoshiko
en-aut-sei=Kurihara
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MimuraHidefumi
en-aut-sei=Mimura
en-aut-mei=Hidefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Radiology, Fujita Health University School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Radiology, Machida Municipal Hospital
kn-affil=

affil-num=7
en-affil=Department of Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=
en-keyword=paranasal sinuses
kn-keyword=paranasal sinuses
en-keyword=iterative reconstruction
kn-keyword=iterative reconstruction
en-keyword=dose reduction
kn-keyword=dose reduction
en-keyword=low dose
kn-keyword=low dose
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=4
article-no=
start-page=479
end-page=483
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202208
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Liquid Biopsy Revealed HBOC Pedigree and Led to Medical Management Among the Relatives
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A hereditary breast and ovarian cancer (HBOC) pedigree was detected via liquid biopsy, and cancer prevention was initiated for the patient’s daughter, after receiving a definitive result from BRCA genetic testing. A 48-yearold woman with ovarian cancer was administered precision medicine, which used cell-free DNA from plasma. The results revealed a pathogenic variant of BRCA1 as a presumed germline pathogenic mutation. We confirmed the germline pathological variant BRCA1 c.81-1G> A and suggested treatment with a PARP inhibitor. One of her three children had the variant, was diagnosed as an unaffected pathogenic variant carrier, and was advised to initiate surveillance.
en-copyright=
kn-copyright=

en-aut-name=OgawaChikako
en-aut-sei=Ogawa
en-aut-mei=Chikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HirasawaAkira
en-aut-sei=Hirasawa
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SogawaReimi
en-aut-sei=Sogawa
en-aut-mei=Reimi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HasuokaKayoko
en-aut-sei=Hasuoka
en-aut-mei=Kayoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FutagawaMashu
en-aut-sei=Futagawa
en-aut-mei=Mashu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UrakawaYusaku
en-aut-sei=Urakawa
en-aut-mei=Yusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KochiMariko
en-aut-sei=Kochi
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamamotoHideki
en-aut-sei=Yamamoto
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Clinical Genetics and Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Nursing, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Center for Comprehensive Genomic Medicine, Okayama University Hospital Biobank, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Genetics and Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Clinical Genetics and Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=hereditary breast and ovarian cancer (HBOC)
kn-keyword=hereditary breast and ovarian cancer (HBOC)
en-keyword=BRCA 1
kn-keyword=BRCA 1
en-keyword=presumed germline pathogenic variants (PGPV)
kn-keyword=presumed germline pathogenic variants (PGPV)
en-keyword=germline findings
kn-keyword=germline findings
en-keyword=cancer precision medicine
kn-keyword=cancer precision medicine
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=4
article-no=
start-page=399
end-page=408
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202208
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=According to a recent report, a low Ki67 level after short-term preoperative hormone therapy (post-Ki67) might suggest a more favorable prognosis compared with a high post-Ki67 level in patients with hormone receptorpositive/human epidermal growth factor 2-negative (HR+/HER2−) breast cancer with high levels of Ki67. This study aimed to evaluate the pre-treatment genetic differences between these two patient groups. Forty-five luminal B-like patients were stratified into two groups, namely, a group with high (H→H) and one with low (H→L) Ki67 levels after short-term preoperative aromatase inhibitor (AI) treatment. We compared pre-treatmentgene expression profiles between the two groups. In gene level analysis, there was no significant difference between the two groups by the class comparison test. In pathway analysis, five metabolism-related gene sets were significantly upregulated in the H→L group (p≤0.05). In the search for novel targets, five genes (PARP, BRCA2, FLT4, CDK6, and PDCD1LG2) showed significantly higher expression in the H→H group (p≤0.05). Several metabolism-related pathways were associated with sensitivity to AI. In the future, it will be necessary to seek out new therapeutic strategies for the poor prognostic group with high post-Ki67.
en-copyright=
kn-copyright=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ZhuYidan
en-aut-sei=Zhu
en-aut-mei=Yidan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KochiMariko
en-aut-sei=Kochi
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=short-term hormone therapy
kn-keyword=short-term hormone therapy
en-keyword=gene expression profiling
kn-keyword=gene expression profiling
en-keyword=Ki-67
kn-keyword=Ki-67
en-keyword=targeted therapy
kn-keyword=targeted therapy
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=8
article-no=
start-page=1253
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220819
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Anti-inflammatory therapy, centered on inhaled steroids, suppresses airway inflammation in asthma, reduces asthma mortality and hospitalization rates, and achieves clinical remission in many pediatric patients. However, the spontaneous remission rate of childhood asthma in adulthood is not high, and airway inflammation and airway remodeling persist after remission of asthma symptoms. Childhood asthma impairs normal lung maturation, interferes with peak lung function in adolescence, reduces lung function in adulthood, and increases the risk of developing chronic obstructive pulmonary disease (COPD). Early suppression of airway inflammation in childhood and prevention of asthma exacerbations may improve lung maturation, leading to good lung function and prevention of adult COPD. Biological drugs that target T-helper 2 (Th2) cytokines are used in patients with severe pediatric asthma to reduce exacerbations and airway inflammation and improve respiratory function. They may also suppress airway remodeling in childhood and prevent respiratory deterioration in adulthood, reducing the risk of COPD and improving long-term prognosis. No studies have demonstrated a suppressive effect on airway remodeling in childhood severe asthma, and further clinical trials using airway imaging analysis are needed to ascertain the inhibitory effect of biological drugs on airway remodeling in severe childhood asthma. In this review, we describe the natural prognosis of lung function in childhood asthma and the risk of developing adult COPD, the pathophysiology of allergic airway inflammation and airway remodeling via Th2 cytokines, and the inhibitory effect of biological drugs on airway remodeling in childhood asthma.
en-copyright=
kn-copyright=

en-aut-name=TsugeMitsuru
en-aut-sei=Tsuge
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaMasanori
en-aut-sei=Ikeda
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Pediatric Acute Diseases, Okayama University Academic Field of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Okayama University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Pediatrics, Okayama University Academic Field of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=bronchial asthma
kn-keyword=bronchial asthma
en-keyword=chronic obstructive pulmonary disease
kn-keyword=chronic obstructive pulmonary disease
en-keyword=lung function trajectory
kn-keyword=lung function trajectory
en-keyword=type 2 inflammation
kn-keyword=type 2 inflammation
en-keyword=airway remodeling
kn-keyword=airway remodeling
en-keyword=omalizumab
kn-keyword=omalizumab
en-keyword=mepolizumab
kn-keyword=mepolizumab
en-keyword=benralizumab
kn-keyword=benralizumab
en-keyword=dupilumab
kn-keyword=dupilumab
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=3
article-no=
start-page=339
end-page=342
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202206
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rhabdomyolysis with Multiple Electrolyte Imbalances under Proton Pump Inhibitor Treatment after Total Thyroidectomy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 90-year-old man presented with muscle weakness, difficulty concentrating, and dysphagia. About eighteen months prior to presentation, lansoprazole had been initiated to prevent stress ulcers; he also had a history of total thyroidectomy due to papillary thyroid cancer ten years prior. Laboratory findings were as follows: K 2.4 mEq/L, Ca 3.7 mg/dL, Mg 1.3 mg/dL, CK 5386 U/L, and intact PTH (iPTH) 14 pg/mL. Rhabdomyolysis with multiple electrolyte imbalances under proton pump inhibitor (PPI) treatment was diagnosed. We initiated intravenous hydration and electrolyte supplementation with discontinuation of PPI. After discontinuing PPI, the patient’s serum magnesium, potassium, and calcium levels normalised with oral vitamin D and calcium supplementation. PPIs can cause hypocalcaemia and hypokalaemia via hypomagnesemia; hypocalcaemia is also a common postoperative complication of thyroidectomy. Careful monitoring of electrolyte levels is required in patients with long-term PPI treatment, especially in post-thyroidectomy cases.
en-copyright=
kn-copyright=

en-aut-name=YanoAkihiko
en-aut-sei=Yano
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SadaKen-ei
en-aut-sei=Sada
en-aut-mei=Ken-ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SawadaTsutomu
en-aut-sei=Sawada
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ItoHideki
en-aut-sei=Ito
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YanoHiroko
en-aut-sei=Yano
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaTatsuya
en-aut-sei=Ikeda
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=
en-keyword=hypocalcaemia
kn-keyword=hypocalcaemia
en-keyword=thyroidectomy
kn-keyword=thyroidectomy
en-keyword=proton pump inhibitors
kn-keyword=proton pump inhibitors
en-keyword=hypomagnesemia
kn-keyword=hypomagnesemia
en-keyword=rhabdomyolysis
kn-keyword=rhabdomyolysis
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=3
article-no=
start-page=307
end-page=315
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202206
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Factors Associated with Work Efficiency in Home Health Care by Pharmacists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In recent years, medical staff including physicians and nurses have been participating in home health care, reflecting the needs of an aging society in Japan. Pharmacists are also asked to work on home health care teams to ensure the medical safety of patients. It currently remains unclear whether direct communication, i.e. a meeting, between home-visiting physicians and pharmacists contributes to the proper use of medications and continuous medical care. We retrospectively analyzed the medication management guidance records of home-visited patients who received their first home visit between April 2014 and March 2017. We collected data on pharmacist inquiries, the duration of visits, and details from a meeting between home-visiting physicians and pharmacists. Thirty-five patients were included. At the first visit, the inquiry rate by pharmacists was 65.7%. The prescription question rate was significantly lower in patients with a meeting than in those without (p=0.033). The average duration of visits was significantly shorter for home-visited patients whose health care providers had a meeting (p=0.007). These results suggest that pharmacists who held a meeting with the home-visiting physician before the first patient visit were able to resolve drug-related issues earlier, which increased the work efficiency of home-visiting pharmacists.
en-copyright=
kn-copyright=

en-aut-name=SugiuraSatoshi
en-aut-sei=Sugiura
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IzushiYasuhisa
en-aut-sei=Izushi
en-aut-mei=Yasuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pharmacotherapy, School of Pharmacy, Shujitsu University
kn-affil=

affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=home visit
kn-keyword=home visit
en-keyword=pharmacist
kn-keyword=pharmacist
en-keyword=meeting
kn-keyword=meeting
en-keyword=inquiry
kn-keyword=inquiry
en-keyword=home health care
kn-keyword=home health care
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=2
article-no=
start-page=167
end-page=172
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=202204
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating Febrile Neutropenia during Chemotherapy in Patients with Lung Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN.
en-copyright=
kn-copyright=

en-aut-name=HigashionnaTsukasa
en-aut-sei=Higashionna
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MurakawaKiminaka
en-aut-sei=Murakawa
en-aut-mei=Kiminaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
en-keyword=febrile neutropenia
kn-keyword=febrile neutropenia
en-keyword=cefozopran
kn-keyword=cefozopran
en-keyword=cefepime
kn-keyword=cefepime
en-keyword=lung cancer
kn-keyword=lung cancer
en-keyword=retrospective
kn-keyword=retrospective
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=3
article-no=
start-page=103869
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Endosomal anomalies because of vesicular traffic impairment have been indicated as an early pathology of Alzheimer'vertical bar disease (AD). However, the mechanisms and therapeutic targets remain unclear. We previously reported thatbCTF, one of the pathogenic metabolites of APP, interacts with TMEM30A. TMEM30A constitutes a lipid flippase with P4-ATPase and regulates vesicular trafficking through the asymmetric distribution of phospholipids. Therefore, the alteration of lipid flippase activity in AD pathology has got attention. Herein, we showed that the interaction between beta CTF and TMEM30A suppresses the physiological formation and activity of lipid flippase in AD model cells, A7, and App(NLG-F/NLG-F) model mice. Furthermore, the T-RAP peptide derived from the beta CTF binding site of TMEM30A improved endosomal anomalies, which could be a result of the restored lipid flippase activity. Our results provide insights into the mechanisms of vesicular traffic impairment and suggest a therapeutic target for AD.
en-copyright=
kn-copyright=

en-aut-name=KaneshiroNanaka
en-aut-sei=Kaneshiro
en-aut-mei=Nanaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KomaiMasato
en-aut-sei=Komai
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ImaokaRyosuke
en-aut-sei=Imaoka
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaAtsuya
en-aut-sei=Ikeda
en-aut-mei=Atsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KamikuboYuji
en-aut-sei=Kamikubo
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SaitoTakashi
en-aut-sei=Saito
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaidoTakaomi C.
en-aut-sei=Saido
en-aut-mei=Takaomi C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TomitaTaisuke
en-aut-sei=Tomita
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HashimotoTadafumi
en-aut-sei=Hashimoto
en-aut-mei=Tadafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwatsuboTakeshi
en-aut-sei=Iwatsubo
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SakuraiTakashi
en-aut-sei=Sakurai
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UeharaTakashi
en-aut-sei=Uehara
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TakasugiNobumasa
en-aut-sei=Takasugi
en-aut-mei=Nobumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Neurocognitive Science, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=7
en-affil=Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science
kn-affil=

affil-num=8
en-affil=Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Department of Neuropathology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Neuropathology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=
kn-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University

affil-num=13
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=162
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Valence control of charge and orbital frustrated system YbFe2O4 with electrochemical Li+ intercalation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report an attempt valence control of the mixed valence iron triangular oxide YbFe2O4 to develop an effective technique controling the frustration of charges in strongly correlated electron systems. The electrochemical doping of Li + into YbFe2O4 was examined on a cell-type sample similar to the Li-ion secondary battery cell. Systematic changes in the lattice constant and Fe – Fe and Fe–Yb distance were observed with Li doping. Maximum value of the doping was over 300 mAh/g. An EXAFS experiment indicated that Li positioned between Yb octahedron layer (U-layer) and Fe-bipyramidal layer (W-layer). However, detailed change of iron valence state of YbFe2O4was not clearly observed because of the superimpose of the signal from iron metal nano particles in XANES observation. We discuss that the uncertainty might arise from the inhomogeneous distribution of the sample particle size, which might prevent the homogeneous doping of Li because the doping occurs on the surface of each nano-particles.
en-copyright=
kn-copyright=

en-aut-name=MuraseS.
en-aut-sei=Murase
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshikawaY.
en-aut-sei=Yoshikawa
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiwaraK.
en-aut-sei=Fujiwara
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukadaY.
en-aut-sei=Fukada
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TeranishiT.
en-aut-sei=Teranishi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KanoJ.
en-aut-sei=Kano
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujiiT.
en-aut-sei=Fujii
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=InadaY.
en-aut-sei=Inada
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatayamaM.
en-aut-sei=Katayama
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YoshiiK.
en-aut-sei=Yoshii
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TsujiT.
en-aut-sei=Tsuji
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MatsumuraD.
en-aut-sei=Matsumura
en-aut-mei=D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IkedaN.
en-aut-sei=Ikeda
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=8
en-affil=College of Life Sciences, Ritsumeikan University
kn-affil=

affil-num=9
en-affil=College of Life Sciences, Ritsumeikan University
kn-affil=

affil-num=10
en-affil=Japan Atomic Energy Agency
kn-affil=

affil-num=11
en-affil=Japan Atomic Energy Agency
kn-affil=

affil-num=12
en-affil=Japan Atomic Energy Agency
kn-affil=

affil-num=13
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=
en-keyword=RFe2O4 
kn-keyword=RFe2O4 
en-keyword=YbFe2O4 
kn-keyword=YbFe2O4 
en-keyword=Triangular lattice 
kn-keyword=Triangular lattice 
en-keyword=Charge frustration 
kn-keyword=Charge frustration 
en-keyword=Spin frustration 
kn-keyword=Spin frustration 
en-keyword=Orbital frustration 
kn-keyword=Orbital frustration 
en-keyword=Frustration control
kn-keyword=Frustration control
en-keyword=Li doping
kn-keyword=Li doping
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=6
article-no=
start-page=755
end-page=758
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Left Hemihepatectomy for Hepatocellular Carcinoma Following Esophagectomy with Retrosternal Gastric Tube Reconstruction for Esophageal Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Approximately 4% of patients with esophageal cancer develop a second primary malignancy in the upper gastrointestinal trunk. However, hepatectomy following esophagectomy for esophageal cancer has rarely been reported. We report the case of a 70-year-old man who underwent an esophagectomy for esophageal cancer with retrosternal gastric tube reconstruction. Nine years later, he developed hepatocellular carcinoma with tumor thrombus involving the left portal vein, and was successfully treated with left hemihepatectomy. Special attention should be paid to avoiding incidental injury of the gastric tube as well as the right gastroepiploic artery during the hepatectomy.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuiseTakashi
en-aut-sei=Kuise
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UmedaYuzo
en-aut-sei=Umeda
en-aut-mei=Yuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshidaRyuichi
en-aut-sei=Yoshida
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshidaKazuhiro
en-aut-sei=Yoshida
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanabeShunsuke
en-aut-sei=Tanabe
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MaedaNaoaki
en-aut-sei=Maeda
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YagiTakahito
en-aut-sei=Yagi
en-aut-mei=Takahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=liver resection, 
kn-keyword=liver resection, 
en-keyword=esophagectomy, 
kn-keyword=esophagectomy, 
en-keyword=retrosternal gastric tube reconstruction
kn-keyword=retrosternal gastric tube reconstruction
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=6
article-no=
start-page=719
end-page=724
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Significance of Age and Causative Bacterial Morphology in the Choice of an Antimicrobial Agent to Treat Acute Uncomplicated Cystitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Differentiating patients by age and causative bacterial morphology might aid in making the appropriate choice of antimicrobial agent when treating acute uncomplicated cystitis. In this retrospective analysis, the non-susceptibility rates of the causative bacteria to cefcapene-pivoxil (CFPN-PI) and levofloxacin (LVFX) were determined after dividing patients with acute uncomplicated cystitis by age group (15-54 and 55-74 years old) and by bacterial morphology: gram-positive cocci (GPC) or gram-negative rod (GNR). The overall non-susceptibility rates for CFPN-PI and LVFX were 19.4% and 15.3%, respectively. When the subjects were divided by age, only the non-susceptibility rate for LVFX in the younger group significantly decreased (to 8.7%). When the groups were divided by both age and bacterial morphology, the younger GNR group had non-susceptibility rates of 6.9% to CFPN-PI and 7.8% to LVFX, whereas the younger GPC group showed 10.2% non-susceptibility to LVFX. The older GNR group showed 9.8% non-susceptibility to CFPN-PI, while the older GPC group showed 7.2% non-susceptibility to LVFX. All the non-susceptibility rates were lower than 10.2% in the sub-divided groups. Differentiating patients by age and the morphology of causative bacteria can aid in making the appropriate choice of antimicrobial agent and may improve treatment outcomes in patients with acute uncomplicated cystitis.
en-copyright=
kn-copyright=

en-aut-name=UeharaShinya
en-aut-sei=Uehara
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujioKei
en-aut-sei=Fujio
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamasakiTomoya
en-aut-sei=Yamasaki
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtsukiHideo
en-aut-sei=Otsuki
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Urology, Abiko Toho Hospital
kn-affil=

affil-num=2
en-affil=Department of Urology, Abiko Toho Hospital
kn-affil=

affil-num=3
en-affil=Department of Urology, Abiko Toho Hospital
kn-affil=

affil-num=4
en-affil=Department of Urology, Abiko Toho Hospital
kn-affil=
en-keyword=acute uncomplicated cystitis
kn-keyword=acute uncomplicated cystitis
en-keyword=oral antimicrobial agents
kn-keyword=oral antimicrobial agents
en-keyword=antimicrobial susceptibility
kn-keyword=antimicrobial susceptibility
en-keyword=menopause
kn-keyword=menopause
en-keyword=Gram stain
kn-keyword=Gram stain
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=6
article-no=
start-page=699
end-page=704
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Guideline-based Treatment of Glucocorticoid-induced Osteoporosis in Patients with Rheumatoid Arthritis: A Retrospective Study with the AORA Registry
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Glucocorticoid-induced osteoporosis (GIOP) is one of the side effects associated with glucocorticoid (GC) therapy. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) provided new guidelines for the management and treatment of GIOP. The aim of the present study was to clarify the prevalence of patients with rheumatoid arthritis (RA) requiring treatment according to the new guidelines and to identify risk factors associated with lack of treatment in these patients. Patients in the 2018 Akita Orthopedic group on Rheumatoid Arthritis (AORA) database were enrolled. Of 2,234 patients with RA in the database, 683 (30.6%) met the 2014 JSBMR guideline treatment criteria, and 480 (70.3%) had been treated. The untreated group included a larger number of males, younger patients, and patients treated in clinics rather than hospital (p<0.001, p=0.015, and p<0.001, respectively). Multivariate analyses found that male sex, younger age, and clinic-based RA care were significant risk factors associated with lack of treatment (p<0.001, p=0.013, and p<0.001, respectively). Thus, male sex, younger age, and clinic-based care were identified as risk factors
en-copyright=
kn-copyright=

en-aut-name=KawanoTetsuya
en-aut-sei=Kawano
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyakoshiNaohisa
en-aut-sei=Miyakoshi
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsuchieHiroyuki
en-aut-sei=Tsuchie
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KashiwaguraTakeshi
en-aut-sei=Kashiwagura
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KobayashiMoto
en-aut-sei=Kobayashi
en-aut-mei=Moto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AonumaHiroshi
en-aut-sei=Aonuma
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SugimuraYusuke
en-aut-sei=Sugimura
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimadaYoichi
en-aut-sei=Shimada
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Akita City Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Hiraka General Hospital Yokote City
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Ogachi Central Hospital Yuzawa City
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Nakadori General Hospital Akita City
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=
en-keyword=glucocorticoid
kn-keyword=glucocorticoid
en-keyword=glucocorticoid-induced osteoporosis
kn-keyword=glucocorticoid-induced osteoporosis
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=osteoporosis
kn-keyword=osteoporosis
en-keyword=osteopenia
kn-keyword=osteopenia
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=5
article-no=
start-page=557
end-page=565
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202110
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relationship between Pressure Ulcers in Elderly People and Physiological Indices of the Skin
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study examined the relationship between skin physiological indices and pressure ulcers in elderly people. The subjects were 55 bedridden elderly Japanese patients with a median age of 85 years. The following parame-ters were measured using non-invasive devices: skin surface temperature, moisture content in the stratum corneum, moisture content in the dermis, transepidermal water loss as an index of skin barrier function, skin erythema and skin elasticity. The sacral and 2 heel areas were observed as sites predisposed to pressure ulcers. Within one month after measuring the skin physiological indices, we confirmed pressure ulcers of National Pressure Ulcer Advisory Panel classification Stage II or worse based on medical records. Among the 55 patients, 4 (7.3%) prospectively developed a total of 5 pressure ulcers within 16 days. Only the skin erythema score was significantly higher with than without pressure ulcers (p < 0.001). We performed a binary logistic regression analysis and confirmed a significant relationship between pressure-ulcer development and the level of erythema (odds ratio = 1.026; 95% confidence interval: 1.011-1.042). Skin erythema increased before the development of pressure ulcers. Taken together, our results show that the high skin erythema score can be a predictive indicator of pressure ulcers.
en-copyright=
kn-copyright=

en-aut-name=Takeshima KoharaHiroko
en-aut-sei=Takeshima Kohara
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaMitsunori 
en-aut-sei=Ikeda
en-aut-mei=Mitsunori 
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkawaMasami
en-aut-sei=Okawa
en-aut-mei=Masami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Nursing, University of Kochi
kn-affil=

affil-num=2
en-affil=Department of Nursing, University of Kochi
kn-affil=

affil-num=3
en-affil=Shiragikuen Hospital
kn-affil=
en-keyword=elderly people
kn-keyword=elderly people
en-keyword=erythema
kn-keyword=erythema
en-keyword=pressure ulcer
kn-keyword=pressure ulcer
en-keyword=skin
kn-keyword=skin
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=4
article-no=
start-page=505
end-page=509
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association Between Eosinophilia and Late-onset Circulatory Collapse in Preterm Infants: A case-Control Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Late-onset circulatory collapse (LCC) in preterm infants is presumably caused by relative adrenal insufficiency. Because eosinophilia is known to be associated with adrenal insufficiency, we attempted to clarify the relation-ship between eosinophilia and LCC in preterm infants. We divided the cases of the infants (born at < 28 weeks’ gestation) admitted to our neonatal intensive care unit in 2008-2010 into 2 groups: those diagnosed with LCC that received glucocorticoids (LCC group), and those who did not receive glucocorticoids (control group). We compared eosinophil counts between the 2 groups and between before and after glucocorticoid treatment in the LCC group. A total of 28 infants were examined: LCC group (n = 12); control group (n = 16). The peak eosin-ophil counts of the LCC group were significantly higher than those of the control group (median: 1.392 × 109/L vs. 1.033 × 109/L, respectively; p = 0.02). Additionally, in the LCC group, the eosinophil counts declined significantly after glucocorticoid treatment (0.877 × 109/L vs. 0.271 × 109/L, p = 0.003). Eosinophil counts in the LCC group were significantly higher than in the control group and decreased rapidly after gluco-corticoid treatment. These results indicate that eosinophilia may be a factor associated with LCC caused by adrenal insufficiency.
en-copyright=
kn-copyright=

en-aut-name=OkamuraTomoka
en-aut-sei=Okamura
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WashioYosuke
en-aut-sei=Washio
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeHirokazu
en-aut-sei=Watanabe
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakanishiHidehiko
en-aut-sei=Nakanishi
en-aut-mei=Hidehiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=UchiyamaAtsushi
en-aut-sei=Uchiyama
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name= TsukaharaHirokazu
en-aut-sei= Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KusudaSatoshi
en-aut-sei=Kusuda
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=

affil-num=2
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=

affil-num=3
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=

affil-num=4
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=

affil-num=5
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=

affil-num=6
en-affil=Department of Pediatrics, Graduate school of Medicine, Dentistry and Pharmaceutical Science
kn-affil=

affil-num=7
en-affil=Department of Neonatology, Maternal and Perinatal Center, Tokyo Women's Medical University
kn-affil=
en-keyword=late-onset circulatory collapse
kn-keyword=late-onset circulatory collapse
en-keyword=preterm infant
kn-keyword=preterm infant
en-keyword=eosinophilia
kn-keyword=eosinophilia
en-keyword=steroid
kn-keyword=steroid
en-keyword=adrenal insufficiency
kn-keyword=adrenal insufficiency
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=4
article-no=
start-page=403
end-page=413
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surgical Treatment of Epiretinal Membrane
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Epiretinal membrane (ERM) is a common retinal disease characterized by cellular proliferation and metaplasia that lead to the formation of a pathological fibrocellular membrane immediately superjacent to the inner retinal surface. The vast majority of ERMs are considered idiopathic. However, ERM formation can result from various primary intraocular diseases, including retinal breaks and detachment, retinal vascular diseases, and vitreoretinal inflammatory conditions. Although ERMs are generally asymptomatic or cause mild metamorphopsia and/or a modest decrease in visual acuity, some can cause severe macular distortion and macular edema, resulting in significantly impaired function. Surgical removal of ERM is the only treatment, and improvements in vitrectomy systems have enabled less invasive treatment. However, there are currently no standardized criteria for ERM surgery, and the indications for surgery are determined from the patient’s subjective symptoms. Another problem with ERM surgery is that not all patients show satisfactory postoperative recovery of visual function. Thus, further research is needed to determine the criteria for ERM surgery and methods to improve the postoperative prognosis.
en-copyright=
kn-copyright=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=epiretinal membrane
kn-keyword=epiretinal membrane
en-keyword=vitrectomy
kn-keyword=vitrectomy
en-keyword=optical coherence tomography
kn-keyword=optical coherence tomography
en-keyword=internal limiting membrane
kn-keyword=internal limiting membrane
en-keyword=lamellar macular hole
kn-keyword=lamellar macular hole
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=363
end-page=372
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202106
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Role of the Transcription Factor BTB and CNC Homology 1 in a Rat Model of Acute Liver Injury Induced by Experimental Endotoxemia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Hepatic oxidative stress plays an important role in the pathogenesis of several acute liver diseases, and free heme is thought to contribute to endotoxemia-induced acute liver injury. The heme oxygenase 1 (HO-1) gene is upregulated and the δ-aminolevulinate synthase (ALAS1) gene is downregulated in the rat liver following lipopolysaccharide (LPS) treatment. BTB and CNC homology 1 (Bach1) is a heme-responsive transcription factor that normally represses HO-1 expression. In this study, we evaluated the changes in HO-1, ALAS1, and Bach1 expression and nuclear Bach1 expression in rat livers following intravenous LPS administration (10 mg/kg body weight). LPS significantly upregulated HO-1 mRNA and downregulated ALAS1 mRNA in the rat livers, suggesting that hepatic free heme concentrations are increased after LPS treatment. Bach1 mRNA was strongly induced after LPS injection. In contrast, nuclear Bach1 was significantly but transiently decreased after LPS treatment. Rats were also administered hemin (50 mg/kg body weight) intravenously to elevate heme concentrations, which decreased nuclear Bach1 levels. Our results suggest that elevated hepatic free heme may be associated with a decline of nuclear Bach1, and induction of Bach1 mRNA may compensate for the decreased nuclear Bach1 after LPS treatment in the rat liver.
en-copyright=
kn-copyright=

en-aut-name=TaniokaNohito
en-aut-sei=Tanioka
en-aut-mei=Nohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShimizuHiroko
en-aut-sei=Shimizu
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OmoriEmiko
en-aut-sei=Omori
en-aut-mei=Emiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakahashiToru
en-aut-sei=Takahashi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamaokaMasakazu
en-aut-sei=Yamaoka
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MorimatsuHiroshi
en-aut-sei=Morimatsu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Faculty of Health and Welfare Science, Okayama Prefectural University
kn-affil=

affil-num=5
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=heme oxygenase-1
kn-keyword=heme oxygenase-1
en-keyword=BTB and CNC homology 1
kn-keyword=BTB and CNC homology 1
en-keyword= heme, 
kn-keyword= heme, 
en-keyword=lipopolysaccharide
kn-keyword=lipopolysaccharide
en-keyword= liver injury
kn-keyword= liver injury
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=357
end-page=362
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202106
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment for high-risk breast cancer. We explored the optimal timing of administration of 3.6 mg Peg, the dose approved in Japan. In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively). Among the 52 women enrolled, 13 were aged > 60 years. The anthracycline sequence was administered to P2 (n=33), P3 (n=5), and P4 (n=14) patients, and the taxane sequence to P2 (n=38) and P3 (n=6) patients. Both sequences showed no interaction between Peg administration timing and treatment discontinuation, treatment delay, or dose reduction. However, the relative dose intensity (RDI) was significantly different among the groups. The neutrophil count transition differed significantly among the groups receiving the anthracycline sequence. However, the neutrophil count remained in the appropriate range for both sequences in the P2 group. The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT.
en-copyright=
kn-copyright=

en-aut-name=TakabatakeDaisuke
en-aut-sei=Takabatake
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiYoko
en-aut-sei=Suzuki
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoMari
en-aut-sei=Yamamoto
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakahashiMina
en-aut-sei=Takahashi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AogiKenjiro
en-aut-sei=Aogi
en-aut-mei=Kenjiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OhsumiShozo
en-aut-sei=Ohsumi
en-aut-mei=Shozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishiyamaYoshitaka
en-aut-sei=Nishiyama
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HikinoHajime
en-aut-sei=Hikino
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MatsuokaKinya
en-aut-sei=Matsuoka
en-aut-mei=Kinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Kochi Health Science Center
kn-affil=

affil-num=2
en-affil=Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Fukuyama Citizens Hospital
kn-affil=

affil-num=6
en-affil=Fukuyama Citizens Hospital
kn-affil=

affil-num=7
en-affil=Fukuyama Citizens Hospital
kn-affil=

affil-num=8
en-affil=Shikoku Cancer Center
kn-affil=

affil-num=9
en-affil=Cancer Institute Hospital
kn-affil=

affil-num=10
en-affil=Shikoku Cancer Center
kn-affil=

affil-num=11
en-affil=Shikoku Cancer Center
kn-affil=

affil-num=12
en-affil=Kagawa Prefectural Center Hospital
kn-affil=

affil-num=13
en-affil=Okayama Saiseikai General Hospital
kn-affil=

affil-num=14
en-affil=Matsue Red Cross General Hospital
kn-affil=

affil-num=15
en-affil=Ehime Prefectural Central Hospital
kn-affil=

affil-num=16
en-affil=Okayama University Hospital
kn-affil=

affil-num=17
en-affil=Okayama University Hospital
kn-affil=

affil-num=18
en-affil=Okayama University Hospital
kn-affil=
en-keyword=dose-dense chemotherapy
kn-keyword=dose-dense chemotherapy
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=pegfilgrastim
kn-keyword=pegfilgrastim
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=335
end-page=343
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202106
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC) has a poor prognosis. Although nivolumab is approved in Japan for treating R/MHNSCC, the response rate is low. Therefore, identifying pretreatment prognostic factors is necessary. This study assessed the utility of the neutrophil-to-lymphocyte ratio (NLR) and Glasgow Prognostic Score (GPS) as biomarkers of response to nivolumab. We retrospectively collected the data of 56 R/MHNSCC patients treated with nivolumab between May 2017 and December 2019. The Kaplan–Meier method and log-rank test were used to estimate overall survival (OS) and progression-free survival (PFS), and multivariate Cox hazard regression analysis was used to identify independent predictors of survival. Patients with a low pretreatment NLR had prolonged OS, and patients with a low pretreatment GPS had increased OS and PFS. A performance score (PS) of 0-1, development of immune-related adverse events, and GPS of 0-1 were significantly associated with OS in multivariate analysis. In summary, baseline pretreatment NLR and GPS are independently associated with OS in R/MHNSCC patients treated with nivolumab. Administration of nivolumab while maintaining the PS reflects a immune status of the host and leads to a good OS.
en-copyright=
kn-copyright=

en-aut-name=ChikuieNobuyuki
en-aut-sei=Chikuie
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamamotoTakao
en-aut-sei=Hamamoto
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UedaTsutomu
en-aut-sei=Ueda
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TaruyaTakayuki
en-aut-sei=Taruya
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KonoTakashi
en-aut-sei=Kono
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FuruieHiromi
en-aut-sei=Furuie
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IshinoTakashi
en-aut-sei=Ishino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakenoSachio
en-aut-sei=Takeno
en-aut-mei=Sachio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=2
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=3
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=4
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=5
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=6
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Kure Medical Center and Chugoku Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=8
en-affil=Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=
en-keyword=neutrophil-to-lymphocyte ratio
kn-keyword=neutrophil-to-lymphocyte ratio
en-keyword=nivolumab
kn-keyword=nivolumab
en-keyword=Glasgow Prognostic Score
kn-keyword=Glasgow Prognostic Score
en-keyword=recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC)
kn-keyword=recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC)
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=323
end-page=334
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202106
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gender Expression among Transgender Women in Japan: Support Is Needed to Improve Social Passing as a Woman
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Gender expression is important for transgender women to improve their social passing as women. Herein, a questionnaire about the status of gender expression and support needs was distributed to 54 transgender women aged 17-71 in Japan. Most of the respondents noted that they had found it relatively difficult to handle physical changes and weight gain due to hormone treatment. They also found it difficult to enact and sustain practices such as a feminine use of voice and to use women-only services, whereas practicing and continuing with routine skin and hair care and feminine mannerisms were relatively easy for them. In the questionnaire regarding the support for gender transitioning, many items showed only a small percentage of the transgender women had received the support that they were looking for, and most of their needs for support were not addressed. Some of the factors that increased the respondents’ needs and achievement of gender expression as women included estrogen treatment, sex reassignment surgery, and living as a woman; these aspects met their support needs as well. Gender support professionals need to coordinate and collaborate with specialists in areas such as nutritional guidance and voice training to enable transgender women to improve the extent to which they can socially ‘pass’ as women.
en-copyright=
kn-copyright=

en-aut-name=FurutaniMichiyo
en-aut-sei=Furutani
en-aut-mei=Michiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YuZhou
en-aut-sei=Yu
en-aut-mei=Zhou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=transgender
kn-keyword=transgender
en-keyword=gender expression
kn-keyword=gender expression
en-keyword=social passing as a woman
kn-keyword=social passing as a woman
en-keyword=real life experience
kn-keyword=real life experience
en-keyword=gender transition
kn-keyword=gender transition
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=289
end-page=297
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202106
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy and Safety of Early Intravenous Landiolol on Myocardial Salvage in Patients with ST-segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention: A Randomized Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Early treatment with an oral β-blocker is recommended in patients with a ST-segment–elevation myocardial infarction (STEMI). In this multicenter study, we evaluated the effects of a continuous administration of landiolol, an ultrashort-acting β-blocker, before primary percutaneous coronary intervention (PCI) on myocardial salvage and its safety in STEMI patients. A total of 47 Japanese patients with anterior or lateral STEMI undergoing a primary PCI within 12 h of symptom onset were randomized to receive intravenous landiolol (started at 3 μg/min/kg dose and continued to a total of 50 mg; n=23) or not (control; n=24). Patients with Killip class III or more were excluded. The primary outcome was the myocardial salvage index on cardiac magnetic resonance imaging (MRI) performed 5-7 days after the PCI. Cardiac MRI was performed in 35 patients (74%). The myocardial salvage index in the landiolol group was significantly greater than that in the control group (44.4±14.6% vs. 31.7±18.9%, respectively; p=0.04). There were no significant differences in adverse events at 24 h between the landiolol and control groups. A continuous administration of landiolol before a primary PCI may increase the degree of myocardial salvage without additional hemodynamic adverse effects within the first 24 h after STEMI.
en-copyright=
kn-copyright=

en-aut-name=MiyamotoMasakazu
en-aut-sei=Miyamoto
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OsawaKazuhiro
en-aut-sei=Osawa
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriAtsushi
en-aut-sei=Mori
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshikawaMasaki
en-aut-sei=Yoshikawa
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkaTakefumi
en-aut-sei=Oka
en-aut-mei=Takefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IchikawaKeishi
en-aut-sei=Ichikawa
en-aut-mei=Keishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Cardiology, Tsuyama Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Cardiology, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Cardiology, Tsuyama Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=myocardial infarction
kn-keyword=myocardial infarction
en-keyword=landiolol
kn-keyword=landiolol
en-keyword= magnetic resonance imaging
kn-keyword= magnetic resonance imaging
en-keyword=STEMI
kn-keyword=STEMI
en-keyword=PCI
kn-keyword=PCI
END

start-ver=1.4
cd-journal=joma
no-vol=231
cd-vols=
no-issue=1
article-no=
start-page=75
end-page=84
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=20210504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Divergence in red light responses associated with thermal reversion of phytochrome B between high‐ and low‐latitude species
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Summary<br>
・Phytochromes play a central role in mediating adaptive responses to light and temperature throughout plant life cycles. Despite evidence for adaptive importance of natural variation in phytochromes, little information is known about molecular mechanisms that modulate physiological responses of phytochromes in nature.<br>
・We show evolutionary divergence in physiological responses relevant to thermal stability of a physiologically active form of phytochrome (Pfr) between two sister species of Brassicaceae growing at different latitudes.<br>
The higher latitude species (Cardamine bellidifolia; Cb) responded more strongly to light‐limited conditions compared with its lower latitude sister (C. nipponica; Cn). Moreover, CbPHYB conferred stronger responses to both light‐limited and warm conditions in the phyB‐deficient mutant of Arabidopsis thaliana than CnPHYB: that is Pfr CbphyB was more stable in nuclei than CnphyB. <br>
・Our findings suggest that fine tuning Pfr stability is a fundamental mechanism for plants to optimise phytochrome‐related traits in their evolution and adapt to spatially varying environments, and open a new avenue to understand molecular mechanisms that fine tune phytochrome responses in nature.
en-copyright=
kn-copyright=

en-aut-name=IkedaHajime
en-aut-sei=Ikeda
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SuzukiTomomi
en-aut-sei=Suzuki
en-aut-mei=Tomomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkaYoshito
en-aut-sei=Oka
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GustafssonA. Lovisa S.
en-aut-sei=Gustafsson
en-aut-mei=A. Lovisa S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BrochmannChristian
en-aut-sei=Brochmann
en-aut-mei=Christian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MochizukiNobuyoshi
en-aut-sei=Mochizuki
en-aut-mei=Nobuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NagataniAkira
en-aut-sei=Nagatani
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Science, Kyoto University
kn-affil=

affil-num=3
en-affil=Graduate School of Science, Kyoto University
kn-affil=

affil-num=4
en-affil=Natural History Museum, University of Oslo
kn-affil=

affil-num=5
en-affil=Natural History Museum, University of Oslo
kn-affil=

affil-num=6
en-affil=Graduate School of Science, Kyoto University
kn-affil=

affil-num=7
en-affil=Graduate School of Science, Kyoto University
kn-affil=
en-keyword=alpine plants
kn-keyword=alpine plants
en-keyword=Brassicaceae
kn-keyword=Brassicaceae
en-keyword=Cardamine
kn-keyword=Cardamine
en-keyword=phytochrome
kn-keyword=phytochrome
en-keyword=thermal reversion
kn-keyword=thermal reversion
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=2
article-no=
start-page=213
end-page=218
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Dual-pathology Hepatocellular Carcinoma (HCC) and Cholangiolocellular Carcinoma (CoCC) after Eradication of Hepatitis C Virus (HCV) Infection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 75-year-old Japanese man visited our hospital for further examination of liver tumors. He had a history of successful hepatitis C virus (HCV) eradication and therapy for hepatocellular carcinoma (HCC) at another hospital. Magnetic resonance imaging (MRI) revealed two tumors in the liver. He underwent anterior inferior (S5) and posterior inferior (S6) subsegmentectomy of the liver. Microscopic examination found that one tumor was HCC while the other was cholangiolocellular carcinoma (CoCC). We experienced a rare case of liver cancer with two synchronous pathologies, HCC and CoCC.
en-copyright=
kn-copyright=

en-aut-name=MiyashitaManabi
en-aut-sei=Miyashita
en-aut-mei=Manabi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaragaiYousuke
en-aut-sei=Saragai
en-aut-mei=Yousuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujimotoTsuyoshi
en-aut-sei=Fujimoto
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanakaShouichi
en-aut-sei=Tanaka
en-aut-mei=Shouichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AokiHideki
en-aut-sei=Aoki
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SatoYumiko 
en-aut-sei=Sato
en-aut-mei=Yumiko 
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Hepatology, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=

affil-num=5
en-affil=Department of Surgery, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=

affil-num=6
en-affil=Department of Pathology, National Hospital Organaization of Iwakuni Clinical Center
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=1
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202102
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Treatment Outcomes of Pulmonary Metastases from Head and Neck Squamous Cell Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although the lung is the most common site of distant metastases from head and neck squamous cell carcinoma (HNSCC), the number of reports about the effects of pulmonary metastasectomy for the treatment of lung metastasis from HNSCC is limited. Metachronous pulmonary metastases were detected in 45 HNSCC patients at Kumamoto University Hospital from 1998 to 2018. Twenty-two patients underwent an operative resection (Ope group) and 23 underwent chemotherapy (Chemo group). The 3-year overall survival (OS) rate and median OS were evaluated. The effects of adjuvant chemotherapy after pulmonary metastasectomy and of new drugs (cetuximab and nivolumab), in the chemo group were also assessed. The 3-year OS rates and median OS were: Ope, 66.1% and 31.5 months; Chemo, 39.7% and 18 months, respectively. In the Ope group, addi-tional recurrences were significantly fewer in the patients who underwent adjuvant chemotherapy post-surgery versus the patients who underwent surgery alone (p = 0.013). In the Chemo group, the 3-year OS rate of the patients who received new drugs was significantly better than that of the patients who did not (p = 0.021). Adjuvant chemotherapy after pulmonary metastasectomy may be a preferable treatment option for preventing recurrences. Cetuximab and nivolumab have a potential to improve OS.
en-copyright=
kn-copyright=

en-aut-name=MiyamaruSatoru
en-aut-sei=Miyamaru
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MurakamiDaizo
en-aut-sei=Murakami
en-aut-mei=Daizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishimotoKohei
en-aut-sei=Nishimoto
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoHaruki
en-aut-sei=Saito
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyamotoYusuke
en-aut-sei=Miyamoto
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HirotaKaoruko
en-aut-sei=Hirota
en-aut-mei=Kaoruko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IseMomoko
en-aut-sei=Ise
en-aut-mei=Momoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OritaYorihisa
en-aut-sei=Orita
en-aut-mei=Yorihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=5
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=7
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
kn-affil=
en-keyword=pulmonary metastasis
kn-keyword=pulmonary metastasis
en-keyword=head and neck squamous cell carcinoma
kn-keyword=head and neck squamous cell carcinoma
en-keyword=pulmonary metastasectomy
kn-keyword=pulmonary metastasectomy
en-keyword=adjuvant chemotherapy
kn-keyword=adjuvant chemotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=1
article-no=
start-page=15
end-page=23
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202102
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.
en-copyright=
kn-copyright=

en-aut-name=KatsuiKuniaki
en-aut-sei=Katsui
en-aut-mei=Kuniaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OgataTakeshi
en-aut-sei=Ogata
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TadaAkihiro
en-aut-sei=Tada
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SugiyamaSoichi
en-aut-sei=Sugiyama
en-aut-mei=Soichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshioKotaro
en-aut-sei=Yoshio
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KurodaMasahiro
en-aut-sei=Kuroda
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanazawaSusumu
en-aut-sei=Kanazawa
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Radiology, Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Radiology, Okayama Diagnostic Imaging Center
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Radiological Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=volumetric positron emission tomography parameters
kn-keyword=volumetric positron emission tomography parameters
en-keyword=distant metastasis-free survival
kn-keyword=distant metastasis-free survival
en-keyword=chemoradiotherapy
kn-keyword=chemoradiotherapy
en-keyword=cisplatin/docetaxel
kn-keyword=cisplatin/docetaxel
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
END

start-ver=1.4
cd-journal=joma
no-vol=10
cd-vols=
no-issue=1
article-no=
start-page=19959
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20201117
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Follistatin expressed in mechanically-damaged salivary glands of male mice induces proliferation of CD49f(+) cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Salivary glands (SGs) are very important for maintaining the physiological functions of the mouth. When SGs regenerate and repair from various damages, including mechanical, radiological, and immune diseases, acinar and granular duct cells originate from intercalated duct cells. However, the recovery is often insufficient because of SGs' limited self-repair function. Furthermore, the precise repair mechanism has been unclear. Here, we focused on CD49f, one of the putative stem cell markers, and characterized CD49f positive cells (CD49f(+) cells) isolated from male murine SGs. CD49f(+) cells possess self-renewal ability and express epithelial and pluripotent markers. Compared to CD49f negative cells, freshly isolated CD49f(+) cells highly expressed inhibin beta A and beta B, which are components of activin that has anti-proliferative effects. Notably, an inhibitor of activin, follistatin was expressed in mechanically-damaged SGs, meanwhile no follistatin was expressed in normal SGs in vivo. Moreover, sub-cultured CD49f(+) cells highly expressed both Follistatin and a series of proliferative genes, expressions of which were decreased by Follistatin siRNA. These findings indicated that the molecular interaction between activin and follistatin may induce CD49f(+) cells proliferation in the regeneration and repair of mouse SGs.
en-copyright=
kn-copyright=

en-aut-name=IkedaA.
en-aut-sei=Ikeda
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoT.
en-aut-sei=Yamamoto
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MineshibaJ.
en-aut-sei=Mineshiba
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakashibaS.
en-aut-sei=Takashiba
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Periodontics and Endodontics, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology - Periodontal Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Hanamizuki Dental Clinic
kn-affil=

affil-num=4
en-affil=Department of Pathophysiology ‑ Periodontal Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=2020
cd-vols=
no-issue=9
article-no=
start-page=093H02
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200920
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Improved method for measuring low-concentration radium and its application to the Super-Kamiokande Gadolinium project
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chemical extraction using a molecular recognition resin named "Empore Radium Rad Disk" was developed to improve sensitivity for the low concentration of radium (Ra). Compared with the previous method, the extraction process speed was improved by a factor of three and the recovery rate for Ra-226 was also improved from 81 +/- 4% to > 99.9%. The sensitivity on the 10(-1) mBq level was achieved using a high-purity germanium detector. This improved method was applied to determine Ra-226 in Gd-2(SO4)(3)center dot 8H(2)O which will be used in the Super-Kamiokande Gadolinium project. The improvement and measurement results are reported in this paper.
en-copyright=
kn-copyright=

en-aut-name=ItoS.
en-aut-sei=Ito
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IchimuraK.
en-aut-sei=Ichimura
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakuY.
en-aut-sei=Takaku
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AbeK.
en-aut-sei=Abe
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaradaM.
en-aut-sei=Harada
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaM.
en-aut-sei=Ikeda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ItoH.
en-aut-sei=Ito
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KishimotoY.
en-aut-sei=Kishimoto
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakajimaY.
en-aut-sei=Nakajima
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OkadaT.
en-aut-sei=Okada
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SekiyaH.
en-aut-sei=Sekiya
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Okayama University, Faculty of Science
kn-affil=

affil-num=2
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=3
en-affil=Institute for Environmental Sciences, Department of Radioecology
kn-affil=

affil-num=4
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=5
en-affil=Okayama University, Faculty of Science
kn-affil=

affil-num=6
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=7
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=8
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=9
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=10
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=11
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=6
article-no=
start-page=557
end-page=562
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cisplatin and trastuzumab chemotherapy. On day 8, severe diarrhea and mucositis developed; chemotherapy was stopped. On day 14, the patient developed renal dysfunction and febrile neutropenia. He also suffered from pneumonia due to Candida albicans. Systemic symptoms improved after intensive conservative treatment. Best supportive care was continued until the patient died from gastric cancer. The dihydropyrimidine dehydroge-nase protein level was low at 3.18 U/mg protein. The result of DPYD genotyping revealed three variants at posi-tions 1615 (G > A), 1627 (A > G), and 1896 (T > C) in exons 13, 13, and 14, respectively.
en-copyright=
kn-copyright=

en-aut-name=IshiguroMikako
en-aut-sei=Ishiguro
en-aut-mei=Mikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakenakaRyuta
en-aut-sei=Takenaka
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OguraKenichiro
en-aut-sei=Ogura
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiratsukaAkira
en-aut-sei=Hiratsuka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakedaHiromasa
en-aut-sei=Takeda
en-aut-mei=Hiromasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KawaiDaisuke
en-aut-sei=Kawai
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsugenoHirofumi
en-aut-sei=Tsugeno
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujikiShigeatsu
en-aut-sei=Fujiki
en-aut-mei=Shigeatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=2
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=3
en-affil=Department of Drug Metabolism and Molecular Toxicology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
kn-affil=

affil-num=4
en-affil=Department of Drug Metabolism and Molecular Toxicology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=5-fluorouracil
kn-keyword=5-fluorouracil
en-keyword=dihydropyrimidine dehydrogenase deficiency
kn-keyword=dihydropyrimidine dehydrogenase deficiency
en-keyword=DPYD variant
kn-keyword=DPYD variant
en-keyword=gastric cancer
kn-keyword=gastric cancer
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=6
article-no=
start-page=537
end-page=544
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Four Cases with Rare Complications of Intramedullary Screw Fixation for Jones Fracture
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Active treatment with intramedullary screw fixation is now common for athletes with Jones fracture. Outcomes are generally good, but complications can occur. We report 4 rare complications of intramedullary screw fixa-tion. Two cases developed osteomyelitis and pseudarthrosis caused by thermal necrosis. In the other two cases, screw-related complications occurred during the insertion of the tapered headless screw. Although thermal necrosis and screw insertion failures are considered rare complications and not widely reported in the litera-ture, they do occur occasionally. Knowing the mechanisms underlying these complications could help prevent them, and knowing their course could lead caregivers to appropriate interventions when they do occur.
en-copyright=
kn-copyright=

en-aut-name=MorimotoYusuke
en-aut-sei=Morimoto
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KomatsuTaichi
en-aut-sei=Komatsu
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TokuhashiYasuaki
en-aut-sei=Tokuhashi
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=
en-keyword=Jones fracture
kn-keyword=Jones fracture
en-keyword=thermal necrosis
kn-keyword=thermal necrosis
en-keyword=tapered headless screw
kn-keyword=tapered headless screw
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=6
article-no=
start-page=521
end-page=524
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Bilateral Approach for Thoracoscopic Esophagectomy in a Patient with Esophageal Cancer and Solitary Posterior Thoracic Para-aortic Lymph  Node Metastasis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report a successful dissection of metastatic posterior thoracic para-aortic lymph node (No. 112aoP) via bilateral thoracoscopic surgery. With the anesthetized patient (a 73-year-old Japanese woman) in the prone position, two working ports were inserted for the left-side approach, and artificial pneumothorax was created. Thoracoscopic examination revealed a swollen LN posterior to the descending aorta. Fat and metastatic LNs posterior to the aorta were dissected from the aortic arch level to the diaphragm while preserving intercostal arteries. For the right-side approach, two working ports were inserted and a routine thoracoscopic esophagec-tomy was performed. Gastric conduit reconstruction was achieved laparoscopically. Operation time for the left thoracic procedure: 54 min; estimated blood loss: almost none. No recurrence was detected 24 months post-operatively. There are several surgical options for approaching No. 112aoP, including transhiatal, left thora-cotomy, and thoracoscopy. Although a wide dissection of the posterior thoracic para-aortic area has not been reported, it may be feasible and safe if the artery of Adamkiewicz and intercostal arteries are preserved. A min-imally invasive bilateral thoracoscopic approach for a thoracoscopic esophagectomy is safe and useful for esophageal cancer patients with solitary No. 112aoP metastasis.
en-copyright=
kn-copyright=

en-aut-name=ItazakiYujiro
en-aut-sei=Itazaki
en-aut-mei=Yujiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsujimotoHironori
en-aut-sei=Tsujimoto
en-aut-mei=Hironori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SugasawaHidekazu
en-aut-sei=Sugasawa
en-aut-mei=Hidekazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YaguchiYoshihisa
en-aut-sei=Yaguchi
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NomuraShinsuke
en-aut-sei=Nomura
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItoNozomi
en-aut-sei=Ito
en-aut-mei=Nozomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HaradaManabu
en-aut-sei=Harada
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugiharaTakao
en-aut-sei=Sugihara
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TsuchiyaSatoshi
en-aut-sei=Tsuchiya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IshibashiYusuke
en-aut-sei=Ishibashi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KouzuKeita
en-aut-sei=Kouzu
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KishiYoji
en-aut-sei=Kishi
en-aut-mei=Yoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=UenoHideki 
en-aut-sei=Ueno
en-aut-mei=Hideki 
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=2
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=3
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=4
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=5
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=6
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=7
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=8
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=9
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=10
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=11
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=12
en-affil=Department of Surgery, National Defense Medical College
kn-affil=

affil-num=13
en-affil=Department of Surgery, National Defense Medical College
kn-affil=
en-keyword=bilateral approach
kn-keyword=bilateral approach
en-keyword=posterior thoracic para-aortic lymph node
kn-keyword=posterior thoracic para-aortic lymph node
en-keyword=thoracoscopic esophagectomy
kn-keyword=thoracoscopic esophagectomy
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=6
article-no=
start-page=513
end-page=520
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Delay in Emergency Medical Service Transportation Responsiveness during the COVID-19 Pandemic in a Minimally Affected Region
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Few studies have investigated the influence of the Coronavirus Disease 2019 (COVID-19) pandemic on emer-gency medical service (EMS) systems, especially in areas less affected or unaffected by COVID-19. In this study, we investigated changes in prehospital EMS activity and transport times during the COVID-19 pandemic. All patients transported by EMS in the city of Okayama from March–May 2019 or March–May 2020 were included. Interfacility transports were excluded. The primary outcome was the time from a patient’s first emergency call until hospital arrival (total prehospital time). Secondary outcomes included three segments of total prehospital time: the response time, on-scene time, and transportation time. Total prehospital time and the durations of each segment were compared between corresponding months in 2020 (COVID19-affected) and 2019 (control). The results showed that total prehospital times in April 2020 were significantly higher than those in 2019 (33.8 ± 11.6 vs. 32.2 ± 10.8 min, p < 0.001). Increases in total prehospital time were caused by longer response time (9.3 ± 3.8 vs. 8.7 ± 3.7 min, p < 0.001) and on-scene time (14.4 ± 7.9 vs. 13.5 ± 6.2min, p < 0.001). The COVID-19 pandemic was thus shown to affect EMS and delayed arrival/response even in a minimally affected region. A system to minimize transportation delays should be developed for emerging pandemics.
en-copyright=
kn-copyright=

en-aut-name=AgetaKohei
en-aut-sei=Ageta
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamadaTaihei
en-aut-sei=Yamada
en-aut-mei=Taihei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsukaharaKohei
en-aut-sei=Tsukahara
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YakushijiHiromasa
en-aut-sei=Yakushiji
en-aut-mei=Hiromasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=emergency medical services
kn-keyword=emergency medical services
en-keyword=health care system
kn-keyword=health care system
en-keyword=emergency transport
kn-keyword=emergency transport
en-keyword=coronavirus
kn-keyword=coronavirus
en-keyword=infection
kn-keyword=infection
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=5
article-no=
start-page=401
end-page=406
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202010
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution. We retrospectively investigated prognosis and factors including sex, reason for discovery, treatment, pathological factors and treatment progress to clarify the risk factors. All patients underwent curative surgical treatment. Pathologically, lymph node metastasis was identified in 25 patients (75%). Thirteen patients (39%) had bilateral cervical metastasis. In addition, 9 (27%) had more than 10 metastatic lymph nodes. The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI). Five patients (15%) had local recurrences and received surgery. There have been no further recurrences or deaths. However, no factors were determined to significantly predict the recurrence of juvenile DTC. Local recurrent disease was treated with surgery and/or RAI until remission, and survival was excellent in juvenile DTC.
en-copyright=
kn-copyright=

en-aut-name=TsukiokiTakahiro
en-aut-sei=Tsukioki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhtaniYusuke
en-aut-sei=Ohtani
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiharaMiwa
en-aut-sei=Fujihara
en-aut-mei=Miwa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuzukiYoko
en-aut-sei=Suzuki
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KajiharaYukiko
en-aut-sei=Kajihara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HatonoMinami
en-aut-sei=Hatono
en-aut-mei=Minami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawadaKengo
en-aut-sei=Kawada
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KochiMariko
en-aut-sei=Kochi
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IkedaHirokuni
en-aut-sei=Ikeda
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=differentiated thyroid carcinoma
kn-keyword=differentiated thyroid carcinoma
en-keyword=juvenile
kn-keyword=juvenile
en-keyword=children
kn-keyword=children
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=4
article-no=
start-page=285
end-page=291
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202008
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparison of Two Different Intensive Care Unit Systems for Severely Ill Children in Japan: Data from the JaRPAC Registry
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The importance of centralizing treatment services for severely ill children has been well established, but such entralization remains difficult in Japan. We aimed to compare the trauma and illness severity and mortality of children admitted to two common types of ICUs for children. According to the type of management and disposition of the medical provider, we classified ICUs as pediatric ICUs [PICUs] or general ICUs, and analyzed differences in endogenous and exogenous illness settings between them. Overall, 1,333 pediatric patients were included, with 1,143 patients admitted to PICUs and 190 patients to general ICUs. The Pediatric Cerebral Performance Category score (PCPC) at discharge was significantly lower in the PICU group (adjusted OR: 0.45; 95%CI: 0.23-0.88). Death and unfavorable neurological outcomes occurred less often in the PICU group (adjusted OR: 0.29; 95%CI: 0.14-0.60). However, when limited to exogenous illness, PCPC scores (adjusted OR: 0.38; 95%CI: 0.07-1.99) or death/unfavorable outcomes (adjusted OR: 0.72; 95%CI: 0.08-6.34) did not differ between the groups. PCPC deterioration and overall sequelae/death rates were lower in PICUs for children with endogenous illnesses, although the outcomes of exogenous illness were similar between the 2 unit types. Further studies on the necessity of centralization are warranted.
en-copyright=
kn-copyright=

en-aut-name=TsukaharaKohei
en-aut-sei=Tsukahara
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaitouHiromichi
en-aut-sei=Naitou
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NosakaNobuyuki
en-aut-sei=Nosaka
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoHirotsugu
en-aut-sei=Yamamoto
en-aut-mei=Hirotsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OsakoTakaaki
en-aut-sei=Osako
en-aut-mei=Takaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=the JaRPAC Study Group
en-aut-sei=the JaRPAC Study Group
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Emergency, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Emergency, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Cedars-Sinai Medical Center
kn-affil=

affil-num=5
en-affil=Department of Emergency, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Emergency, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Emergency, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=
kn-affil=
en-keyword=kids
kn-keyword=kids
en-keyword=critical care
kn-keyword=critical care
en-keyword=mortality
kn-keyword=mortality
en-keyword=morbidity
kn-keyword=morbidity
en-keyword=centralization
kn-keyword=centralization
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=4
article-no=
start-page=275
end-page=283
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202008
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Decreased Serum Antioxidant Marker is Predictive of Early Recurrence in the Same Segment after Radical Ablation for Hepatocellular Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a promising method for controlling tumors, although it does not entirely eliminate recurrence. Oxidative stress is associated with the progression of hepatocarcinogenesis, while also acting as an anticancer response. The objective of the present study was to investigate the factors influencing post-RFA outcomes. We recruited 235 newly diagnosed HCC patients who received RFA for single tumors. The patients with recurrence were sub-grouped into early and segmental recurrence groups. The characteristics of the sub-grouped patients were evaluated, including by measuring oxidative stress marker reactive oxygen metabolites and antioxidant marker OXY-adsorbent tests. The factors associated with poor survival were a high Child-Pugh score and early recurrence within 2 years in the same segment. The patients who experienced recurrence within 2 years in the same segment showed a larger tumor diameter than did others. According to a multivariate analysis, the OXY values were also significantly low in these patients. In conclusion, maintaining the antioxidant reservoir function with a high OXY value might be necessary to prevent early recurrence within the RFA-treated segment.
en-copyright=
kn-copyright=

en-aut-name=MuroTaiko
en-aut-sei=Muro
en-aut-mei=Taiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraShinichiro
en-aut-sei=Nakamura
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OnishiHideki
en-aut-sei=Onishi
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YasunakaTetsuya
en-aut-sei=Yasunaka
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OyamaAtsushi
en-aut-sei=Oyama
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=oxidative stress
kn-keyword=oxidative stress
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=recurrence,
kn-keyword=recurrence,
en-keyword=radiofrequency ablation
kn-keyword=radiofrequency ablation
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=3
article-no=
start-page=261
end-page=264
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202006
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Randomized Phase 2 Trial of Antibiotic Prophylaxis Versus No Intervention for Muscle Biopsy in A Neurology Department
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Muscle biopsy can be used to confirm the diagnosis of neuromuscular diseases. However, it is unclear whether antibiotic prophylaxis prior to muscle biopsy is needed to prevent surgical site infection (SSI). We are conducting a phase 2, single-center, open-labeled, prospective randomized trial to clarify the need for antibiotic prophylaxis in patients at low risk for SSI undergoing muscle biopsy. Patients will be randomized to an antibiotic prophylaxis group or a control group, and the incidence of SSI will be compared between the groups. Our findings will clarify the need for antibiotic prophylaxis in this patient population.
en-copyright=
kn-copyright=

en-aut-name=NakaharaKeiichi
en-aut-sei=Nakahara
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaTokunori
en-aut-sei=Ikeda
en-aut-mei=Tokunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakamatsuKoutaro
en-aut-sei=Takamatsu
en-aut-mei=Koutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TawaraNozomu
en-aut-sei=Tawara
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaraKentaro
en-aut-sei=Hara
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EnokidaYuki
en-aut-sei=Enokida
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanoueNaomi
en-aut-sei=Tanoue
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NaritaSawana
en-aut-sei=Narita
en-aut-mei=Sawana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiiAkiko
en-aut-sei=Fujii
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamanouchiYoshinori
en-aut-sei=Yamanouchi
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MorinagaJun
en-aut-sei=Morinaga
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamashitaSatoshi
en-aut-sei=Yamashita
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
kn-affil=

affil-num=2
en-affil= Department of Clinical Investigation, Kumamoto University Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
kn-affil=

affil-num=5
en-affil=Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Kumamoto University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmacy, Kumamoto University Hospital
kn-affil=

affil-num=8
en-affil=Department of Clinical Investigation, Kumamoto University Hospital
kn-affil=

affil-num=9
en-affil=Department of Clinical Investigation, Kumamoto University Hospital
kn-affil=

affil-num=10
en-affil=Department of Clinical Investigation, Kumamoto University Hospital
kn-affil=

affil-num=11
en-affil=Department of Clinical Investigation, Kumamoto University Hospital
kn-affil=

affil-num=12
en-affil=Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
kn-affil=
en-keyword=muscle biopsy
kn-keyword=muscle biopsy
en-keyword=antibiotic prophylaxis
kn-keyword=antibiotic prophylaxis
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=3
article-no=
start-page=257
end-page=260
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202006
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Intravenous Vitamin C as Ancillary Treatment for Cranial Polyneuritis and Meningitis due to Varicella Zoster Virus Reactivation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 65-year-old Japanese woman developed vesicular eruptions on her right ear due to varicella zoster virus (VZV) reactivation, followed by cranial polyneuritis and meningitis affecting her right cranial nerves V, VII, VIII, IX, and X. After acyclovir administration, her facial paralysis worsened. Intravenous methylprednisolone and vitamin C were administered on Day 4 post-admission. Her symptoms steadily improved, and by Day 45 she had fully recovered. Cranial polyneuritis is a rare complication of VZV reactivation, and there is no established method of treatment. This is the first report of full recovery from cranial polyneuritis using intravenous vitamin C as ancillary treatment.
en-copyright=
kn-copyright=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiokaShinichi
en-aut-sei=Fujioka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkatsukaRiku
en-aut-sei=Akatsuka
en-aut-mei=Riku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiwaraTosifumi
en-aut-sei=Fujiwara
en-aut-mei=Tosifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamamotoKazuhide
en-aut-sei=Yamamoto
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil= Department of Emergency Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=2
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=5
en-affil=Department of Emergency Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=
en-keyword=varicella zoster virus
kn-keyword=varicella zoster virus
en-keyword=polyneuritis
kn-keyword=polyneuritis
en-keyword=vitamin C
kn-keyword=vitamin C
en-keyword=meningitis
kn-keyword=meningitis
en-keyword=facial nerve palsy
kn-keyword=facial nerve palsy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Reference values for the locomotive syndrome risk test quantifying mobility of 8681 adults aged 20–89 years: A cross-sectional nationwide study in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background<br/>
The locomotive syndrome risk test was developed to quantify the decrease in mobility among adults, which could eventually lead to disability. The purpose of this study was to establish reference values for the locomotive syndrome risk test for adults and investigate the influence of age and sex.<br/>
Methods<br/>
We analyzed 8681 independent community dwellers (3607 men, 5074 women). Data pertaining to locomotive syndrome risk test (the two-step test, the stand-up test, and the 25-question geriatric locomotive function scale [GLFS-25]) scores were collected from seven administrative areas of Japan.<br/>
Results<br/>
The reference values of the three test scores were generated and all three test scores gradually decreased among young-to-middle-aged individuals and rapidly decreased in individuals aged over 60 years. The stand-up test score began decreasing significantly from the age of 30 years. The trajectories of decrease in the two-step test score with age was slightly different between men and women especially among the middle-aged individuals. The two physical test scores were more sensitive to aging than the self-reported test score.<br/>
Conclusion<br/>
The reference values generated in this study could be employed to determine whether an individual has mobility comparable to independent community dwellers of the same age and sex.
en-copyright=
kn-copyright=

en-aut-name=YamadaKeiko
en-aut-sei=Yamada
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ItoYoichi M.
en-aut-sei=Ito
en-aut-mei=Yoichi M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AkagiMasao
en-aut-sei=Akagi
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ChosaEtsuo
en-aut-sei=Chosa
en-aut-mei=Etsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiTakeshi
en-aut-sei=Fuji
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HiranoKenichi
en-aut-sei=Hirano
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IkedaShinichi
en-aut-sei=Ikeda
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshibashiHideaki
en-aut-sei=Ishibashi
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshibashiYasuyuki
en-aut-sei=Ishibashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IshijimaMuneaki
en-aut-sei=Ishijima
en-aut-mei=Muneaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ItoiEiji
en-aut-sei=Itoi
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IwasakiNorimasa
en-aut-sei=Iwasaki
en-aut-mei=Norimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IzumidaRyoichi
en-aut-sei=Izumida
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KadoyaKen
en-aut-sei=Kadoya
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KamimuraMasayuki
en-aut-sei=Kamimura
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KanajiArihiko
en-aut-sei=Kanaji
en-aut-mei=Arihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KatoHiroyuki
en-aut-sei=Kato
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KishidaShunji
en-aut-sei=Kishida
en-aut-mei=Shunji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MashimaNaohiko
en-aut-sei=Mashima
en-aut-mei=Naohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MatsudaShuichi
en-aut-sei=Matsuda
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MatsuiYasumoto
en-aut-sei=Matsui
en-aut-mei=Yasumoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MatsunagaToshiki
en-aut-sei=Matsunaga
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=MiyakoshiNaohisa
en-aut-sei=Miyakoshi
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MizutaHiroshi
en-aut-sei=Mizuta
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NakamuraYutaka
en-aut-sei=Nakamura
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=NakataKen
en-aut-sei=Nakata
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=OmoriGo
en-aut-sei=Omori
en-aut-mei=Go
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=OsukaKoji
en-aut-sei=Osuka
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=UchioYuji
en-aut-sei=Uchio
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=RyuKazuteru
en-aut-sei=Ryu
en-aut-mei=Kazuteru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=SasakiNobuyuki
en-aut-sei=Sasaki
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=SatoKimihito
en-aut-sei=Sato
en-aut-mei=Kimihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=SendaMasuo
en-aut-sei=Senda
en-aut-mei=Masuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=SudoAkihiro
en-aut-sei=Sudo
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=TakahiraNaonobu
en-aut-sei=Takahira
en-aut-mei=Naonobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=TsumuraHiroshi
en-aut-sei=Tsumura
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=YamaguchiSatoshi
en-aut-sei=Yamaguchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=YamamotoNoriaki
en-aut-sei=Yamamoto
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=NakamuraKozo
en-aut-sei=Nakamura
en-aut-mei=Kozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=Takashi Ohe
en-aut-sei=Takashi
en-aut-mei= Ohe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

affil-num=1
en-affil=Departments of Sensory & Motor System Medicine, Faculty of Medicine, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Statistical Data Science, The Institute of Statistical Mathematics
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Kindai University Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, University of Miyazaki
kn-affil=

affil-num=5
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=6
en-affil=Hirano Orthopaedics Clinic
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Oita University,
kn-affil=

affil-num=8
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=11
en-affil=Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=13
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=14
en-affil=Department of Advanced Medicine for Locomotor System, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
kn-affil=

affil-num=15
en-affil=Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=17
en-affil=Department of Orthopaedic Surgery, Shinshu University School of Medicine
kn-affil=

affil-num=18
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=19
en-affil=Department of Bone and Joint Surgery, Ehime University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=Center for Frailty and Locomotive Syndrome, National Center for Geriatrics and Gerontology
kn-affil=

affil-num=22
en-affil=Department of Rehabilitation Medicine, Akita University Hospital
kn-affil=

affil-num=23
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University
kn-affil=

affil-num=25
en-affil=Saiseikai Shonan Hiratsuka Hospital
kn-affil=

affil-num=26
en-affil=Medicine for Sports and Performing Arts, Osaka University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Department of Sports and Health, Faculty of Health and Science, Niigata University of Health and Welfare
kn-affil=

affil-num=28
en-affil=Osuka Clinic
kn-affil=

affil-num=29
en-affil=Department of Orthopaedic Surgery, Shimane University
kn-affil=

affil-num=30
en-affil=Kanai Hospital
kn-affil=

affil-num=31
en-affil=Sasaki Orthopedic and Anesthesiology Clinic
kn-affil=

affil-num=32
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=33
en-affil=Okayama University Hospital, Division of Physical Medicine and Rehabilitation
kn-affil=

affil-num=34
en-affil=Department of Orthopaedic Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=35
en-affil=Department of Rehabilitation, Kitasato University School of Allied Health Sciences
kn-affil=

affil-num=36
en-affil=Department of Orthopaedic Surgery
kn-affil=

affil-num=37
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=38
en-affil=Nigata Rehabilitation Hospital
kn-affil=

affil-num=39
en-affil=“Locomo Challenge!” Promotion Council
kn-affil=

affil-num=40
en-affil=“Locomo Challenge!” Promotion Council, T
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=959
cd-vols=
no-issue=
article-no=
start-page=163549
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200411
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of gadolinium’s action on water Cherenkov detector systems with EGADS
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Used for both proton decay searches and neutrino physics, large water Cherenkov (WC) detectors have been very successful tools in particle physics. They are notable for their large masses and charged particle detection capabilities. While current WC detectors reconstruct charged particle tracks over a wide energy range, they cannot efficiently detect neutrons. Gadolinium (Gd) has the largest thermal neutron capture cross section of all stable nuclei and produces an 8 MeV gamma cascade that can be detected with high efficiency. Because of the many new physics opportunities that neutron tagging with a Gd salt dissolved in water would open up, a large-scale R&D program called EGADS was established to demonstrate this technique’s feasibility. EGADS features all the components of a WC detector, chiefly a 200-ton stainless steel water tank furnished with 240 photo-detectors, DAQ, and a water system that removes all impurities from water while keeping Gd in solution. In this paper we discuss the milestones towards demonstrating the feasibility of this novel technique, and the features of EGADS in detail.
en-copyright=
kn-copyright=

en-aut-name=MartiLl.
en-aut-sei=Marti
en-aut-mei=Ll.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaM.
en-aut-sei=Ikeda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatoY.
en-aut-sei=Kato
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KishimotoY.
en-aut-sei=Kishimoto
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakahataM.
en-aut-sei=Nakahata
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakajimaY.
en-aut-sei=Nakajima
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakanoY.
en-aut-sei=Nakano
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakayamaS.
en-aut-sei=Nakayama
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkajimaY.
en-aut-sei=Okajima
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OriiA.
en-aut-sei=Orii
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=PronostG.
en-aut-sei=Pronost
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SekiyaH.
en-aut-sei=Sekiya
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShiozawaM.
en-aut-sei=Shiozawa
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TanakaH.
en-aut-sei=Tanaka
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=UenoK.
en-aut-sei=Ueno
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YamadaS.
en-aut-sei=Yamada
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YanoT.
en-aut-sei=Yano
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=YokozawaT.
en-aut-sei=Yokozawa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MurdochM.
en-aut-sei=Murdoch
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SchuemannJ.
en-aut-sei=Schuemann
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=VaginsM.R.
en-aut-sei=Vagins
en-aut-mei=M.R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=BaysK.
en-aut-sei=Bays
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=CarminatiG.
en-aut-sei=Carminati
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=GriskevichN.J.
en-aut-sei=Griskevich
en-aut-mei=N.J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KroppW.R.
en-aut-sei=Kropp
en-aut-mei=W.R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=LockeS.
en-aut-sei=Locke
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=RenshawA.
en-aut-sei=Renshaw
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=SmyM.B.
en-aut-sei=Smy
en-aut-mei=M.B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=WeatherlyP.
en-aut-sei=Weatherly
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=ItoS.
en-aut-sei=Ito
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=IshinoH.
en-aut-sei=Ishino
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=KibayashiA.
en-aut-sei=Kibayashi
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=KoshioY.
en-aut-sei=Koshio
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=MoriT.
en-aut-sei=Mori
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=SakudaM.
en-aut-sei=Sakuda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=YamaguchiR.
en-aut-sei=Yamaguchi
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=FernandezP.
en-aut-sei=Fernandez
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=LabargaL.
en-aut-sei=Labarga
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=BandacI.
en-aut-sei=Bandac
en-aut-mei=I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=PerezJ.
en-aut-sei=Perez
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=AmeyJ.
en-aut-sei=Amey
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=LitchfieldR.P.
en-aut-sei=Litchfield
en-aut-mei=R.P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=SztucA.
en-aut-sei=Sztuc
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=UchidaY.
en-aut-sei=Uchida
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=MaW.Y.
en-aut-sei=Ma
en-aut-mei=W.Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=GoldsackA.
en-aut-sei=Goldsack
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=SimpsonC.
en-aut-sei=Simpson
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=WarkD.
en-aut-sei=Wark
en-aut-mei=D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=AnthonyL.H.V.
en-aut-sei=Anthony
en-aut-mei=L.H.V.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=McCauleyN.
en-aut-sei=McCauley
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=PritchardA.
en-aut-sei=Pritchard
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=Di LodovicoF.
en-aut-sei=Di Lodovico
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=RichardsB.
en-aut-sei=Richards
en-aut-mei=B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=ColeA.
en-aut-sei=Cole
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=ThiesseM.
en-aut-sei=Thiesse
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=ThompsonL.
en-aut-sei=Thompson
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=ImberJ.
en-aut-sei=Imber
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=CaoS.V.
en-aut-sei=Cao
en-aut-mei=S.V.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=ItoK.
en-aut-sei=Ito
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=TakeuchiY.
en-aut-sei=Takeuchi
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=AkutsuR.
en-aut-sei=Akutsu
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

en-aut-name=NishimuraY.
en-aut-sei=Nishimura
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=62
ORCID=

en-aut-name=OkumuraK.
en-aut-sei=Okumura
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=63
ORCID=

en-aut-name=HirotaS.
en-aut-sei=Hirota
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=64
ORCID=

en-aut-name=MutoF.
en-aut-sei=Muto
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=65
ORCID=

en-aut-name=YokoyamaM.
en-aut-sei=Yokoyama
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=66
ORCID=

en-aut-name=SudaY.
en-aut-sei=Suda
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=67
ORCID=

en-aut-name=ZhangH.
en-aut-sei=Zhang
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=68
ORCID=

affil-num=1
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=2
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=3
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=4
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=5
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=6
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=7
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=8
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=9
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=10
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=11
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=12
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=13
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=14
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=15
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=16
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=17
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=18
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=19
en-affil= Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study
kn-affil=

affil-num=20
en-affil= Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study
kn-affil=

affil-num=21
en-affil= Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study
kn-affil=

affil-num=22
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=23
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=24
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=25
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=26
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=27
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=28
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=29
en-affil= Department of Physics and Astronomy, University of California
kn-affil=

affil-num=30
en-affil= Department of Physics, Okayama University
kn-affil=

affil-num=31
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=32
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=33
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=34
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=35
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=36
en-affil=Department of Physics, Okayama University
kn-affil=

affil-num=37
en-affil= Department of Theoretical Physics, University Autonoma Madrid
kn-affil=

affil-num=38
en-affil= Department of Theoretical Physics, University Autonoma Madrid
kn-affil=

affil-num=39
en-affil=Laboratorio Subterraneo de Canfranc
kn-affil=

affil-num=40
en-affil=Laboratorio Subterraneo de Canfranc
kn-affil=

affil-num=41
en-affil=Department of Physics, Imperial College London
kn-affil=

affil-num=42
en-affil=Department of Physics, Imperial College London
kn-affil=

affil-num=43
en-affil=Department of Physics, Imperial College London
kn-affil=

affil-num=44
en-affil=Department of Physics, Imperial College London
kn-affil=

affil-num=45
en-affil=Department of Physics, Imperial College London
kn-affil=

affil-num=46
en-affil=Department of Physics, Oxford University
kn-affil=

affil-num=47
en-affil=Department of Physics, Oxford University
kn-affil=

affil-num=48
en-affil=Department of Physics, Oxford University
kn-affil=

affil-num=49
en-affil=Department of Physics, University of Liverpool
kn-affil=

affil-num=50
en-affil=Department of Physics, University of Liverpool
kn-affil=

affil-num=51
en-affil=Department of Physics, University of Liverpool
kn-affil=

affil-num=52
en-affil= Department of Physics, King’s College London
kn-affil=

affil-num=53
en-affil= Department of Physics, King’s College London
kn-affil=

affil-num=54
en-affil=Department of Physics and Astronomy, University of Sheffield
kn-affil=

affil-num=55
en-affil=Department of Physics and Astronomy, University of Sheffield
kn-affil=

affil-num=56
en-affil=Department of Physics and Astronomy, University of Sheffield
kn-affil=

affil-num=57
en-affil= Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet
kn-affil=

affil-num=58
en-affil=High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=59
en-affil=Department of Physics, Tokai University
kn-affil=

affil-num=60
en-affil= Department of Physics, Kobe University
kn-affil=

affil-num=61
en-affil=Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=62
en-affil=Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=63
en-affil=Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=64
en-affil= Department of Physics, Kyoto University
kn-affil=

affil-num=65
en-affil= Institute for Space-Earth Environmental Research, Nagoya University
kn-affil=

affil-num=66
en-affil=Department of Physics, University of Tokyo
kn-affil=

affil-num=67
en-affil=Department of Physics, University of Tokyo
kn-affil=

affil-num=68
en-affil=Department of Engineering Physics, Tsinghua University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=3
article-no=
start-page=470
end-page=480
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=20191113
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Regulation of the Poly(A) Status of Mitochondrial mRNA by Poly(A)-Specific Ribonuclease Is Conserved among Land Plants
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Regulation of the stability and the quality of mitochondrial RNA is essential for the maintenance of mitochondrial and cellular functions in eukaryotes. We have previously reported that the eukaryotic poly(A)-specific ribonuclease (PARN) and the prokaryotic poly(A) polymerase encoded by AHG2 and AGS1, respectively, coordinately regulate the poly(A) status and the stability of mitochondrial mRNA in Arabidopsis. Mitochondrial function of PARN has not been reported in any other eukaryotes. To know how much this PARN-based mitochondrial mRNA regulation is conserved among plants, we studied the AHG2 and AGS1 counterparts of the liverwort, Marchantia polymorpha, a member of basal land plant lineage. We found that M. polymorpha has one ortholog each for AHG2 and AGS1, named MpAHG2 and MpAGS1, respectively. Their Citrine-fused proteins were detected in mitochondria of the liverwort. Molecular genetic analysis showed that MpAHG2 is essential and functionally interacts with MpAGS1 as observed in Arabidopsis. A recombinant MpAHG2 protein had a deadenylase activity in vitro. Overexpression of MpAGS1 and the reduced expression of MpAHG2 caused an accumulation of polyadenylated Mpcox1 mRNA. Furthermore, MpAHG2 suppressed Arabidopsis ahg2-1 mutant phenotype. These results suggest that the PARN-based mitochondrial mRNA regulatory system is conserved in land plants.
en-copyright=
kn-copyright=

en-aut-name=KanazawaMai
en-aut-sei=Kanazawa
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaYoko
en-aut-sei=Ikeda
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishihamaRyuichi
en-aut-sei=Nishihama
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamaokaShohei
en-aut-sei=Yamaoka
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LeeNam-Hee
en-aut-sei=Lee
en-aut-mei=Nam-Hee
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamatoKatsuyuki T
en-aut-sei=Yamato
en-aut-mei=Katsuyuki T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KohchiTakayuk
en-aut-sei=Kohchi
en-aut-mei=Takayuk
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirayamaTakashi
en-aut-sei=Hirayama
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Division of Science for Bioresources, Graduate School of Environment and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Division of Science for Bioresources, Graduate School of Environment and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Biostudies, Kyoto University
kn-affil=

affil-num=4
en-affil=Graduate School of Biostudies, Kyoto University
kn-affil=

affil-num=5
en-affil=Department of Life Sciences, Faculty of Science and Engineering, Sorbonne University
kn-affil=

affil-num=6
en-affil=Department of Biotechnological Science, Faculty of Biology-Oriented Science and Technology, Kindai University
kn-affil=

affil-num=7
en-affil=Graduate School of Biostudies, Kyoto University
kn-affil=

affil-num=8
en-affil=Division of Science for Bioresources, Graduate School of Environment and Life Science, Okayama University
kn-affil=
en-keyword=Arabidopsis
kn-keyword=Arabidopsis
en-keyword=Marchantia polymorpha
kn-keyword=Marchantia polymorpha
en-keyword=Mitochondria
kn-keyword=Mitochondria
en-keyword= Poly(A) polymerase
kn-keyword= Poly(A) polymerase
en-keyword=Poly(A) regulation
kn-keyword=Poly(A) regulation
en-keyword= Poly(A)-specific ribonuclease
kn-keyword= Poly(A)-specific ribonuclease
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=2
article-no=
start-page=103
end-page=108
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202004
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Switching from Treatment with Amlodipine and Atorvastatin Using Two Pills to an Equal Dose of Single-Pill Therapy in Japanese Outpatients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= This study examined whether switching from amlodipine and atorvastatin treatment using two pills to an equal dose of single-pill therapy is useful in Japanese outpatients. We retrospectively reviewed data obtained from 94 outpatients for whom treatment with two pills, namely amlodipine and atorvastatin, was switched to an equal dose of single-pill therapy in 11 hospitals. The criterion for enrollment in this study was that patients had switched their medication without changing other anti-hypertensive or anti-cholesterol drugs. Neither systolic nor diastolic blood pressure changed significantly after switching to an equal dose of single-pill therapy, whereas low-density lipoprotein (LDL) cholesterol levels significantly decreased after the medication was switched from 94±24 mg/dl to 89±17 mg/dl (p=0.015). A switch from medication with two separate pills of amlodipine and atorvastatin to an equal dose of single-pill therapy resulted in an overall decrease in LDL cholesterol. The results indicated that the switch to single-pill therapy might be a useful treatment.
en-copyright=
kn-copyright=

en-aut-name=KawadaYasumasa
en-aut-sei=Kawada
en-aut-mei=Yasumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuboToru
en-aut-sei=Kubo
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BabaYuichi
en-aut-sei=Baba
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HirotaTakayoshi
en-aut-sei=Hirota
en-aut-mei=Takayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TaniokaKatsutoshi
en-aut-sei=Tanioka
en-aut-mei=Katsutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamasakiNaohito
en-aut-sei=Yamasaki
en-aut-mei=Naohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KitaokaHiroaki
en-aut-sei=Kitaoka
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=2
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=3
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=4
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=5
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=6
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=

affil-num=7
en-affil=Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University
kn-affil=
en-keyword=hypertension
kn-keyword=hypertension
en-keyword=dyslipidemia
kn-keyword=dyslipidemia
en-keyword=single-pill therapy
kn-keyword=single-pill therapy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=6
article-no=
start-page=063H03
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=20190629
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a method for measuring rare earth elements in the environment for future experiments with gadolinium-loaded detectors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Demand to use gadolinium (Gd) in detectors is increasing in the field of elementary particle physics, especially in neutrino measurements and dark matter searches. Large amounts of Gd are used in these experiments. To assess the impact of Gd on the environment it is becoming important to measure the baseline concentrations of Gd. Such measurement, however, is not easy due to interference by other elements. In this paper a method for measuring the concentrations of rare earth elements, including Gd, is proposed. In the method, inductively coupled plasma-mass spectrometry is utilized after collecting the dissolved elements in chelating resin. Results of the ability to detect anomalous concentrations of rare earth elements in river water samples in the Kamioka and Toyama areas are also reported.
en-copyright=
kn-copyright=

en-aut-name=ItoS.
en-aut-sei=Ito
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkadaT.
en-aut-sei=Okada
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakuY.
en-aut-sei=Takaku
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaradaM.
en-aut-sei=Harada
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaM.
en-aut-sei=Ikeda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KishimotoY.
en-aut-sei=Kishimoto
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KoshioY.
en-aut-sei=Koshio
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakahataM.
en-aut-sei=Nakahata
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakajimaY.
en-aut-sei=Nakajima
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SekiyaH.
en-aut-sei=Sekiya
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Okayama University, Faculty of Science
kn-affil=

affil-num=2
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=3
en-affil=Institute for Environmental Sciences, Department of Radioecology
kn-affil=

affil-num=4
en-affil=Okayama University, Faculty of Science
kn-affil=

affil-num=5
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=6
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=7
en-affil=Okayama University, Faculty of Science
kn-affil=

affil-num=8
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=9
en-affil=Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo
kn-affil=

affil-num=10
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=1
article-no=
start-page=65
end-page=72
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Metabolic Profiling of the Cerebrospinal Fluid in Pediatric Epilepsy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= To characterize metabolic profiles within the central nervous system in epilepsy, we performed gas chromatography-tandem mass spectrometry (GC-MS/MS)-based metabolome analysis of the cerebrospinal fluid (CSF) in pediatric patients with and without epilepsy. The CSF samples obtained from 64 patients were analyzed by GC-MS/MS. Multivariate analyses were performed for two age groups, 0-5 years of age and 6-17 years of age, to elucidate the effects of epilepsy and antiepileptic drugs on the metabolites. In patients aged 0-5 years (22 patients with epilepsy, 13 without epilepsy), epilepsy patients had reduced 2-ketoglutaric acid and elevated pyridoxamine and tyrosine. In patients aged 6-17 years (12 with epilepsy, 17 without epilepsy), epilepsy patients had reduced 1,5-anhydroglucitol. Valproic acid was associated with elevated 2-aminobutyric acid, 2-ketoisocaproic acid, 4-hydroxyproline, acetylglycine, methionine, N-acetylserine, and serine. Reduced energy metabolism and alteration of vitamin B6 metabolism may play a role in epilepsy in young children. The roles of 1,5-anhydroglucitol in epilepsy in older children and in levetiracetam and zonisamide treatment remain to be explained. Valproic acid influenced the levels of amino acids and related metabolites involved in the metabolism of serine, methionine, and leucine.
en-copyright=
kn-copyright=

en-aut-name=AkiyamaTomoyuki
en-aut-sei=Akiyama
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaigusaDaisuke
en-aut-sei=Saigusa
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HyodoYuki
en-aut-sei=Hyodo
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UmedaKeiko
en-aut-sei=Umeda
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaijoReina
en-aut-sei=Saijo
en-aut-mei=Reina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KoshibaSeizo
en-aut-sei=Koshiba
en-aut-mei=Seizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiKatsuhiro
en-aut-sei=Kobayashi
en-aut-mei=Katsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Child Neurology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=3
en-affil=Department of Child Neurology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=5
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=6
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=7
en-affil=Department of Child Neurology, Okayama University Hospital
kn-affil=
en-keyword=antiepileptic drugs
kn-keyword=antiepileptic drugs
en-keyword=gas chromatography-tandem mass spectrometry
kn-keyword=gas chromatography-tandem mass spectrometry
en-keyword=metabolome analysis
kn-keyword=metabolome analysis
en-keyword=metabolomics
kn-keyword=metabolomics
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=
article-no=
start-page=11934
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=2019815
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Berberine improved experimental chronic colitis by regulating interferon-gamma- and IL-17A-producing lamina propria CD4(+) T cells through AMPK activation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= The herbal medicine berberine (BBR) has been recently shown to be an AMP-activated protein kinase (AMPK) productive activator with various properties that induce anti-inflammatory responses. We investigated the effects of BBR on the mechanisms of mucosal CD4+T cell activation in vitro and on the inflammatory responses in T cell transfer mouse models of inflammatory bowel disease (IBD). We examined the favorable effects of BBR in vitro, using lamina propria (LP) CD4+ T cells in T cell transfer IBD models in which SCID mice had been injected with CD4+CD45RBhigh T cells. BBR suppressed the frequency of IFN-γ- and Il-17A-producing LP CD4+ T cells. This effect was found to be regulated by AMPK activation possibly induced by oxidative phosphorylation inhibition. We then examined the effects of BBR on the same IBD models in vivo. BBR-fed mice showed AMPK activation in the LPCD4+ T cells and an improvement of colitis. Our study newly showed that the BBR-induced AMPK activation of mucosal CD4+ T cells resulted in an improvement of IBD and underscored the importance of AMPK activity in colonic inflammation.
en-copyright=
kn-copyright=

en-aut-name=TakaharaMasahiro
en-aut-sei=Takahara
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AdachTakuya
en-aut-sei=Adach
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimomuraYasuyuki
en-aut-sei=Shimomura
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsushitaHiroshi
en-aut-sei=Matsushita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Nguyen Tien Thi Thuy
en-aut-sei=Nguyen Tien Thi Thuy
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KoikeKazuko
en-aut-sei=Koike
en-aut-mei=Kazuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IkedaAiri
en-aut-sei=Ikeda
en-aut-mei=Airi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakashimaShiho
en-aut-sei=Takashima
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamasakiYasushi
en-aut-sei=Yamasaki
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InokuchiToshihiro
en-aut-sei=Inokuchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KinugasaHideaki
en-aut-sei=Kinugasa
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SugiharaYusaku
en-aut-sei=Sugihara
en-aut-mei=Yusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HaradaKeita
en-aut-sei=Harada
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=EikawaShingo
en-aut-sei=Eikawa
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MoritaHidetoshi
en-aut-sei=Morita
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UdonoHeiichiro
en-aut-sei=Udono
en-aut-mei=Heiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Animal Applied Microbiology, Okayama University Graduate School of Environmental and Life Science
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Graduate School of Environmental and Life Science
kn-affil=

affil-num=18
en-affil=Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=6
article-no=
start-page=537
end-page=542
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201912
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Two Cases of High Tibial Osteotomy in Patients with Rheumatoid Arthritis Treated with Biologic Disease-modifying Anti-rheumatic Drugs
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= High tibial osteotomy (HTO) procedure is generally contraindicated in rheumatoid arthritis (RA) patients because synovial inflammation may exacerbate joint damage post-surgery. The natural course of joint destruction in RA changed dramatically with new treatment strategies and the introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs). We report the cases of two RA patients who underwent HTO and whose disease activities were well controlled by bDMARDs. Despite their short follow-up periods, they showed acceptable objective and subjective clinical results. We believe that the combination of bDMARDs and HTO can be indicated for selected RA patients before total knee arthroplasty.
en-copyright=
kn-copyright=

en-aut-name=TakaharaYasuhiro
en-aut-sei=Takahara
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakashimaHirotaka
en-aut-sei=Nakashima
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OchiNobuaki
en-aut-sei=Ochi
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=UchidaYoichiro
en-aut-sei=Uchida
en-aut-mei=Yoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KatoHisayoshi
en-aut-sei=Kato
en-aut-mei=Hisayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ItaniSatoru
en-aut-sei=Itani
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakamuraMakoto
en-aut-sei=Nakamura
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwasakiYuichi
en-aut-sei=Iwasaki
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsujimuraYoshitaka
en-aut-sei=Tsujimura
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopedic Surgery, Nippon Kokan Fukuyama Hospital
kn-affil=
en-keyword=high tibial osteotomy
kn-keyword=high tibial osteotomy
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=biologic DMARD
kn-keyword=biologic DMARD
en-keyword=knee surgery
kn-keyword=knee surgery
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=5
article-no=
start-page=441
end-page=447
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201910
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk Factors for Postoperative Hematoma after Chest Wall Contouring for Female-to-Male Transsexuals: A Clinical Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Gender dysphoria is a condition in which a discrepancy between biological sex and gender identity causes distress. Many female-to-male transsexuals (FTMTS) are uncomfortable with female breasts. Chest wall contouring surgery is effective for obtaining a male-type chest, reducing mental stress, and increasing sexual satisfaction in such cases. At the Okayama University Hospital Gender Center, we have obtained positive results using an algorithm to determine the most appropriate surgical method for chest wall contouring in FTMTS patients. However, serious complications requiring reoperation, such as hematoma, may still occur. Postoperative hematomas were found in 15 (4.18%) of 358 FTMTS patients who underwent chest contouring surgery at our hospital between 2006 and 2018. Postoperative hematoma was examined retrospectively. The median time to the onset of hematoma was 7 (6-12) h after the initial surgery. The main blood vessels causing bleeding were those in the head-side skin flap region where visual confirmation was difficult and the perforator vessels from the pectoralis major muscle. Intraoperative bleeding and the operation time had a significant impact on the onset of postoperative hematoma. This is the first retrospective study that investigated the blood vessels and other factors contributing to postoperative hematoma development after chest wall contouring.
en-copyright=
kn-copyright=

en-aut-name=WatanabeToshiyuki
en-aut-sei=Watanabe
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakuraiToru
en-aut-sei=Sakurai
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MukaiYuko
en-aut-sei=Mukai
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KimataYoshihiro
en-aut-sei=Kimata
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NambaYuzaburo
en-aut-sei=Namba
en-aut-mei=Yuzaburo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Plastic and Reconstructive Surgery,Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Plastic and Reconstructive Surgery,Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Plastic and Reconstructive Surgery,Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Plastic and Reconstructive Surgery,Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Gender Center, Okayama University Hospital
kn-affil=
en-keyword=female-to-male transsexuals
kn-keyword=female-to-male transsexuals
en-keyword=chest wall contouring
kn-keyword=chest wall contouring
en-keyword=postoperative hematoma
kn-keyword=postoperative hematoma
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=5
article-no=
start-page=387
end-page=392
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201910
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= To assess the efficacy and safety of 2 drugs for overactive bladder (OAB), solifenacin and mirabegron. Fortyseven female OAB patients were randomized into 2 groups. Twenty-three patients were initially prescribed solifenacin for 4 weeks, followed by mirabegron for 4 weeks (group S). The other 24 patients were initially prescribed mirabegron for 4 weeks, followed by solifenacin for 4 weeks (group M). Evaluations included clinical determination of the OAB symptom score (OABSS), International Prostate Symptom Score (IPSS), and Visual Analog Scale. The IPSS significantly improved after the administration of solifenacin in both groups. The OABSS significantly improved in both groups after 4 weeks. In group M, the OABSS after eight weeks was significantly improved compared to that after 4 weeks. However, in group S, it was not significantly improved. Twelve patients experienced adverse events during the solifenacin treatment, while 2 patients experienced adverse events during the mirabegron treatment. Both solifenacin and mirabegron led to improved OAB symptoms. Switching from mirabegron to solifenacin significantly improved the OABSS. However, mirabegron led to fewer adverse events than solifenacin. We recommend that mirabegron be prescribed first for OAB patients. If patients are not satisfied with mirabegron, solifenacin should be used.
en-copyright=
kn-copyright=

en-aut-name=InoueMiyabi
en-aut-sei=Inoue
en-aut-mei=Miyabi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YokoyamaTeruhiko
en-aut-sei=Yokoyama
en-aut-mei=Teruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Miyabi Urogyne Clinic
kn-affil=

affil-num=2
en-affil=Yokoyama Urological Clinic
kn-affil=
en-keyword=overactive bladder,
kn-keyword=overactive bladder,
en-keyword=randomized crossover study
kn-keyword=randomized crossover study
en-keyword=solifenacin
kn-keyword=solifenacin
en-keyword=mirabegron
kn-keyword=mirabegron
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=4
article-no=
start-page=367
end-page=372
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201908
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Patient with Type 3 Autoimmune Polyglandular Syndrome who Developed Systemic Lupus Erythematosus 8 years after the Diagnosis of Autoimmune Hepatitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Eight years prior to her present admission, a 61-year-old Japanese woman was diagnosed with autoimmune hepatitis, slowly progressive insulin-dependent diabetes mellitus, and chronic thyroiditis; she had been treated with oral prednisolone (PSL). After she suddenly discontinued PSL, she newly developed systemic lupus erythematosus. A combination therapy of oral PSL and intravenous cyclophosphamide resulted in remission. She was finally diagnosed with autoimmune polyglandular syndrome (APS) type 3 (3A ,3B, 3D), complicated with four different autoimmune diseases. Since patients with type 3 APS may present many manifestations over a long period of time, they should be carefully monitored.
en-copyright=
kn-copyright=

en-aut-name=Mifune-MoriokaTomoyo
en-aut-sei=Mifune-Morioka
en-aut-mei=Tomoyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=A.  UchidaHaruhito
en-aut-sei=A.  Uchida
en-aut-mei=Haruhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FukushimaKazuhiko
en-aut-sei=Fukushima
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeMayu
en-aut-sei=Watanabe
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OuchiChihiro
en-aut-sei=Ouchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiseKoki
en-aut-sei=Mise
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawakitaChieko
en-aut-sei=Kawakita
en-aut-mei=Chieko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanoYuzuki
en-aut-sei=Kano
en-aut-mei=Yuzuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OnishiAkifumi
en-aut-sei=Onishi
en-aut-mei=Akifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TomaKishio
en-aut-sei=Toma
en-aut-mei=Kishio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=EguchiJun
en-aut-sei=Eguchi
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SasakiErika
en-aut-sei=Sasaki
en-aut-mei=Erika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SuganamiYu
en-aut-sei=Suganami
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KishidaMasayuki
en-aut-sei=Kishida
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SugiyamaHitoshi
en-aut-sei=Sugiyama
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Human Resource Development of Dialysis Therapy for Kidney Disease,  Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of General Internal Medicine and Endocrinology, Okayama City Hospital
kn-affil=

affil-num=15
en-affil=Department of General Internal Medicine and Endocrinology, Okayama City Hospital
kn-affil=

affil-num=16
en-affil=Department of General Internal Medicine and Endocrinology, Okayama City Hospital
kn-affil=

affil-num=17
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=autoimmune polyglandular syndrome type 3
kn-keyword=autoimmune polyglandular syndrome type 3
en-keyword=systemic lupus erythematosus
kn-keyword=systemic lupus erythematosus
en-keyword=autoimmune hepatitis
kn-keyword=autoimmune hepatitis
en-keyword=slowly progressive insulin-dependent diabetes mellitus
kn-keyword=slowly progressive insulin-dependent diabetes mellitus
en-keyword=chronic thyroiditis
kn-keyword=chronic thyroiditis
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=4
article-no=
start-page=333
end-page=339
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201908
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with the expectation of preventing postembolization syndrome. Here we investigated the precise effects of steroids on TACE. We prospectively enrolled 144 HCC patients from 10 hospitals who underwent TACE. Three hospitals used steroids (steroid group, n=77) and the rest did not routinely use steroids (control group, n=67). The occurrence of adverse events and the algetic degree at 1-5 days post-treatment were compared between the groups. Fever (grades 0-2) after TACE was significantly less in the steroid group (56/21/0) compared to the control group (35/29/3, p=0.005, Cochran-Armitage test for trend). The suppressive effect of steroids against fever was prominent in females (p=0.001). Vomiting (G0/G1/ G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3), but not significantly (p=0.106). The algetic degree and the grade of hematological adverse events, including hyperglycemia, did not differ between the groups. We conclude that the administration of steroids was useful for the prevention of adverse events after TACE in patients with HCC.
en-copyright=
kn-copyright=

en-aut-name=KuwakiKenji
en-aut-sei=Kuwaki
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyashitaManabi
en-aut-sei=Miyashita
en-aut-mei=Manabi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MakinoYasuhiro
en-aut-sei=Makino
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HagiharaHiroaki
en-aut-sei=Hagihara
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MoriyaAkio
en-aut-sei=Moriya
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YasunakaYuki
en-aut-sei=Yasunaka
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasunakaTetsuya
en-aut-sei=Yasunaka
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OnishiHideki
en-aut-sei=Onishi
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NakamuraShinichiro
en-aut-sei=Nakamura
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Iwakuni Clinical Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Iwakuni Clinical Center
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Sumitomo Besshi Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Mitoyo General Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=antipyretic
kn-keyword=antipyretic
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=therapeutic chemoembolization
kn-keyword=therapeutic chemoembolization
en-keyword=steroid
kn-keyword=steroid
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=85
end-page=89
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.
en-copyright=
kn-copyright=

en-aut-name=AbeYoshiyuki
en-aut-sei=Abe
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujibayashiKazutoshi
en-aut-sei=Fujibayashi
en-aut-mei=Kazutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishizakiYuji
en-aut-sei=Nishizaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YanagisawaNaotake
en-aut-sei=Yanagisawa
en-aut-mei=Naotake
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NojiriShuko
en-aut-sei=Nojiri
en-aut-mei=Shuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoSoichiro
en-aut-sei=Nakano
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TadaKurisu
en-aut-sei=Tada
en-aut-mei=Kurisu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamajiKen
en-aut-sei=Yamaji
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamuraNaoto
en-aut-sei=Tamura
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=2
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=3
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=4
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=5
en-affil=Clinical Research and Trial Center, Juntendo University Hospital
kn-affil=

affil-num=6
en-affil=Geriatric General Medicine, Juntendo Tokyo Koto Geriatric Medical Center
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=
en-keyword=pneumocystis pneumonia
kn-keyword=pneumocystis pneumonia
en-keyword=prophylaxis
kn-keyword=prophylaxis
en-keyword=systemic rheumatic disease
kn-keyword=systemic rheumatic disease
en-keyword=sulfamethoxazole-trimethoprim
kn-keyword=sulfamethoxazole-trimethoprim
en-keyword=conventional-dose versus half-dose
kn-keyword=conventional-dose versus half-dose
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=81
end-page=84
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparison of Two Electrosurgical Modes for Endoscopic Submucosal Dissection of Superficial Colorectal Neoplasms: A Prospective Randomized Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Endoscopic submucosal dissection (ESD) is reportedly one of the standard treatment strategies for large superficial colorectal neoplasms in Japan because of its high en bloc resection rate. A few technical issues regarding ESD should be considered, one of which is the selection of the Endo-cut I mode versus the Swift-coagulation mode as the electrosurgical unit mode setting during submucosal dissection. We seek to determine which of these two modes is more suitable for submucosal dissections of colorectal tumors with regard to procedure time and safety.
en-copyright=
kn-copyright=

en-aut-name=SugiharaYuusaku
en-aut-sei=Sugihara
en-aut-mei=Yuusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HaradaKeita
en-aut-sei=Harada
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkaShohei
en-aut-sei=Oka
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasutomiEriko
en-aut-sei=Yasutomi
en-aut-mei=Eriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamasakiYasushi
en-aut-sei=Yamasaki
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InokuchiToshihiro
en-aut-sei=Inokuchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KinugasaHideaki
en-aut-sei=Kinugasa
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakaharaMasahiro
en-aut-sei=Takahara
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Division of Endoscopy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=endoscopic submucosal dissection
kn-keyword=endoscopic submucosal dissection
en-keyword=electrosurgical mode
kn-keyword=electrosurgical mode
en-keyword=colorectal tumor
kn-keyword=colorectal tumor
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=41
end-page=50
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.
en-copyright=
kn-copyright=

en-aut-name=IkedaAilee
en-aut-sei=Ikeda
en-aut-mei=Ailee
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasunakaTetsuya
en-aut-sei=Yasunaka
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OyamaAtsushi
en-aut-sei=Oyama
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WadaNozomu
en-aut-sei=Wada
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OnishiHideki
en-aut-sei=Onishi
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YoshidaKazuhiro
en-aut-sei=Yoshida
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KuiseTakashi
en-aut-sei=Kuise
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NobuokaDaisuke
en-aut-sei=Nobuoka
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YoshidaRyuichi
en-aut-sei=Yoshida
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=UmedaYuzo
en-aut-sei=Umeda
en-aut-mei=Yuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YagiTakahito
en-aut-sei=Yagi
en-aut-mei=Takahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=acute liver failure
kn-keyword=acute liver failure
en-keyword=hepatitis B
kn-keyword=hepatitis B
en-keyword=hepatitis B vaccine
kn-keyword=hepatitis B vaccine
en-keyword=liver cirrhosis
kn-keyword=liver cirrhosis
en-keyword=liver transplantation
kn-keyword=liver transplantation
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=39
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Histidine-rich Glycoprotein Could Be an Early Predictor of Vasospasm after Aneurysmal Subarachnoid Hemorrhage
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Cerebral vasospasm (CVS) is a major contributor to the high morbidity and mortality of aneurysmal subarachnoid hemorrhage (aSAH) patients. We measured histidine-rich glycoprotein (HRG), a new biomarker of aSAH, in cerebrospinal fluid (CSF) to investigate whether HRG might be an early predictor of CVS. A total of seven controls and 14 aSAH patients (8 males, 6 females aged 53.4±15.4 years) were enrolled, and serial CSF and serum samples were taken. We allocated these samples to three phases (T1-T3) and measured HRG, interleukin (IL)-6, fibrinopeptide A (FpA), and 8-hydroxy-2’-deoxyguanosine (8OHdG) in the CSF, and the HRG in serum. We also examined the release of HRG in rat blood incubated in artificial CSF. In contrast to the other biomarkers examined, the change in the CSF HRG concentration was significantly different between the nonspasm and spasm groups (p<0.01). The rat blood/CSF model revealed a time course similar to that of the human CSF samples in the non-spasm group. HRG thus appears to have the potential to become an early predictor of CVS. In addition, the interaction of HRG with IL-6, FpA, and 8OHdG may form the pathology of CVS.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoAtsushi
en-aut-sei=Matsumoto
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraTakehiro
en-aut-sei=Nakamura
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShinomiyaAya
en-aut-sei=Shinomiya
en-aut-mei=Aya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawakitaKenya
en-aut-sei=Kawakita
en-aut-mei=Kenya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawanishiMasahiko
en-aut-sei=Kawanishi
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyakeKeisuke
en-aut-sei=Miyake
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KurodaYasuhiro
en-aut-sei=Kuroda
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KeepRichard F.
en-aut-sei=Keep
en-aut-mei=Richard F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamiyaTakashi
en-aut-sei=Tamiya
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Kagawa University Faculty of Medicine
kn-affil=

affil-num=2
en-affil=Department of Medical Technology, Kagawa Prefectural University of Health Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Kagawa University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Emergency Medical Center, Kagawa University Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Kagawa University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Kagawa University Faculty of Medicine
kn-affil=

affil-num=7
en-affil=Emergency Medical Center, Kagawa University Hospital
kn-affil=

affil-num=8
en-affil=Department of Neurosurgery, University of Michigan
kn-affil=

affil-num=9
en-affil=Department of Neurological Surgery, Kagawa University Faculty of Medicine
kn-affil=
en-keyword=biomarker
kn-keyword=biomarker
en-keyword=histidine-rich glycoprotein
kn-keyword=histidine-rich glycoprotein
en-keyword=predictor
kn-keyword=predictor
en-keyword=subarachnoid hemorrhage
kn-keyword=subarachnoid hemorrhage
en-keyword=vasospasm
kn-keyword=vasospasm
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=21
end-page=27
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clitoral Blood Flow Changes after Surgery with Tension-Free Vaginal Mesh for Pelvic Organ Prolapse
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= We measured basal clitoral blood flow by Doppler sonography to determine whether tension-free vaginal mesh(TVM) affects the clitoral blood flow and sexual function in women with pelvic organ prolapse (POP). We performed a prospective study of 22 patients who underwent TVM for POP. Clitoral blood flow was measured by Doppler ultrasound. The resistance index (RI), pulsatility index (PI), peak systolic velocity (PSV), and end-diastolic velocity (EDV) of the clitoral arteries were measured preoperatively and at 1, 3, and 6 months postoperatively. Female sexual function was also investigated with the Female Sexual Function Index (FSFI). The mean PI and RI were increased at 1 month and significantly decreased at 6 months postoperatively (p<0.05). In contrast, the mean PSV and EDV decreased at 1 month postoperatively and increased at 6 months postoperatively. These four parameters recovered to baseline levels at 6 months following surgery. Total FSFI scores improved significantly from 10.2±7.9 at baseline to 18.2±8.9 at 6 months postoperatively. Color Doppler ultrasonography is potentially useful in measuring clitoral blood flow in patients treated with TVM for POP. Prospective long-term studies are needed to evaluate the utility of this modality as a diagnostic and prognostic tool for female sexual dysfunction.
en-copyright=
kn-copyright=

en-aut-name=OiwaYuko
en-aut-sei=Oiwa
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WatanabeToyohiko
en-aut-sei=Watanabe
en-aut-mei=Toyohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshiiAyano
en-aut-sei=Ishii
en-aut-mei=Ayano
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakoTomoko
en-aut-sei=Sako
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueMiyabi
en-aut-sei=Inoue
en-aut-mei=Miyabi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WadaKoichiro
en-aut-sei=Wada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NasuYasutomo
en-aut-sei=Nasu
en-aut-mei=Yasutomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Integrated Support Center for Patients and Self-learning, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Miyabi Urogyne Clinic
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=clitoris
kn-keyword=clitoris
en-keyword=pelvic organ prolapse
kn-keyword=pelvic organ prolapse
en-keyword=Doppler ultrasound
kn-keyword=Doppler ultrasound
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=6
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Role of Kallikrein-Related Peptidases in Atopic Dermatitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Excessive protease activity is a characteristic abnormality that affects the epidermal barrier in patients with atopic dermatitis (AD). Kallikrein-related peptidases (KLKs) are excessively expressed in AD lesions, and it is suggested that the abnormal action of KLKs is involved in the skin barrier dysfunction in AD. In other words, overexpressed KLKs disrupt the normal barrier function, and due to that breakdown, external substances that can become antigens of AD easily invade the epidermis, resulting in dermatitis, coupled with the induction of Th2 cytokines. Further investigations are required to elucidate the role of KLKs in AD; this knowledge could contribute to the design of new therapeutic and prophylactic drugs for AD.
en-copyright=
kn-copyright=

en-aut-name=MorizaneShin
en-aut-sei=Morizane
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=atopic dermatitis
kn-keyword=atopic dermatitis
en-keyword=kallikrein-related peptidases
kn-keyword=kallikrein-related peptidases
en-keyword=epidermal barrier dysfunction
kn-keyword=epidermal barrier dysfunction
END

start-ver=1.4
cd-journal=joma
no-vol=50
cd-vols=
no-issue=1
article-no=
start-page=66
end-page=74
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=20161122
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma. In addition to these findings, regulatory T cells (Treg) showed enhanced function through cell-cell contact and increased secretion of typical soluble factors, interleukin (IL)-10 and transforming growth factor (TGF)-β, in a cell line model using the MT-2 human polyclonal T cells and its sublines exposed continuously to asbestos fibers. Since these sublines showed a remarkable reduction of FoxO1 transcription factor, which regulates various cell cycle regulators in asbestos-exposed sublines, the cell cycle progression in these sublines was examined and compared with that of the original MT-2 cells. Results showed that cyclin D1 expression was markedly enhanced, and various cyclin-dependent kinase-inhibitors were reduced with increased S phases in the sublines. Furthermore, the increase of cyclin D1 expression was regulated by FoxO1. The overall findings indicate that antitumor immunity in asbestos-exposed individuals may be reduced in Treg through changes in the function and volume of Treg.
en-copyright=
kn-copyright=

en-aut-name=LeeSuni
en-aut-sei=Lee
en-aut-mei=Suni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsuzakiHidenori
en-aut-sei=Matsuzaki
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaedaMegumi
en-aut-sei=Maeda
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoShoko
en-aut-sei=Yamamoto
en-aut-mei=Shoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Kumagai-TakeiNaoko
en-aut-sei=Kumagai-Takei
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HatayamaTamayo
en-aut-sei=Hatayama
en-aut-mei=Tamayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IkedaMiho
en-aut-sei=Ikeda
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshitomeKei
en-aut-sei=Yoshitome
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NishimuraYasumitsu
en-aut-sei=Nishimura
en-aut-mei=Yasumitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukiTakemi
en-aut-sei=Otsuki
en-aut-mei=Takemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=2
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=3
en-affil=Department of Biofunctional Chemistry, Division of Bioscience, Okayama University Graduate School of Natural Science and Technology
kn-affil=

affil-num=4
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=
kn-affil=

affil-num=6
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=8
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=9
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=10
en-affil=Department of Hygiene, Kawasaki Medical School
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=50
cd-vols=
no-issue=6
article-no=
start-page=2024
end-page=2032
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2017
dt-pub=20170509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= We have previously reported that chronic, recurrent and low-dose exposure to asbestos fibers causes a reduction in antitumor immunity. Investigation of natural killer (NK) cells using an in vitro cell line model and comprising in vitro activation using freshly isolated NK cells co-cultured with chrysotile fibers, as well as NK cells derived from asbestos-exposed patients with pleural plaque (PP) or malignant mesothelioma (MM), revealed decreased expression of NK cell activating receptors such as NKG2D, 2B4 and NKp46. An in vitro differentiation and clonal expansion model for CD8+ cytotoxic T lymphocytes (CTLs) showed reduced cytotoxicity with decreased levels of cytotoxic molecules such as granzyme B and perforin, as well as suppressed proliferation of CTLs. Additionally, analysis of T helper cells showed that surface CXCR3, chemokine receptor, and the productive potential of interferon (IFN)γ were reduced following asbestos exposure in an in vitro cell line model and in peripheral CD4+ cells of asbestos-exposed patients. Moreover, experiments revealed that asbestos exposure enhanced regulatory T cell (Treg) function. This study also focused on CXCR3 expression and the Th-17 cell fraction. Following activation with T-cell receptor and co-culture with various concentrations of chrysotile fibers using freshly isolated CD4+ surface CXCR3 positive and negative fractions, the intracellular expression of CXCR3, IFNγ and IL-17 remained unchanged when co-cultured with chrysotile. However, subsequent re-stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin resulted in enhanced IL-17 production and expression, particularly in CD4+ surface CXCR3 positive cells. These results indicated that the balance and polarization between Treg and Th-17 fractions play an important role with respect to the immunological effects of asbestos and the associated reduction in antitumor immunity.
en-copyright=
kn-copyright=

en-aut-name=MaedaMegumi
en-aut-sei=Maeda
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChenYing
en-aut-sei=Chen
en-aut-mei=Ying
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LeeSuni
en-aut-sei=Lee
en-aut-mei=Suni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=Kumagai-TakeiNaoko
en-aut-sei=Kumagai-Takei
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshitomeKei
en-aut-sei=Yoshitome
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsuzakiHidenori
en-aut-sei=Matsuzaki
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoShoko
en-aut-sei=Yamamoto
en-aut-mei=Shoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HatayamaTamayo
en-aut-sei=Hatayama
en-aut-mei=Tamayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IkedaMiho
en-aut-sei=Ikeda
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishimuraYasumitsu
en-aut-sei=Nishimura
en-aut-mei=Yasumitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtsukiTakemi
en-aut-sei=Otsuki
en-aut-mei=Takemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Biofunctional Chemistry, Division of Bioscience, Okayama University Graduate School of Natural Science and Technology
kn-affil=

affil-num=2
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=3
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=4
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=8
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=9
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=10
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=

affil-num=11
en-affil= Department of Hygiene, Kawasaki Medical School
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=129
cd-vols=
no-issue=2
article-no=
start-page=115
end-page=121
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2017
dt-pub=20170801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Achalasia treated with per-oral endoscopic myotomy (POEM)
kn-title=POEM (Per-Oral Endoscopic Myotomy) を施行した 食道アカラシアの1例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Esophageal achalasia is a disorder of the lower esophageal sphincter muscle. Patients present with dysphagia, chest pain, vomiting, and aspiration. Esophageal achalasia had traditionally been treated with esophageal achalasia balloon dilatation and the Heller-Dor method, but in recent years, the use of per-oral endoscopic myotomy (POEM) has increased. Our patient, a 39-yr-old male, began experiencing dysphagia 4 years prior to his referral to our hospital. Based on the results of esophagogastroduodenoscopy, esophageal radiography and high-resolution manometry, we made the diagnosis of esophageal achalasia (Chicago classification type I) . After informed consent from the patient and his family and approval from our hospital's ethics committee were obtained, we performed a POEM. The patient was discharged on the 4th day post-surgery. At the 1-year post-operative examination, no worsening of symptoms and no relapse were observed. POEM is an excellent treatment method for esophageal achalasia from the perspective of therapeutic effect and prevention of invasion. We recommend that it be considered as the first-choice treatment for achalasia. However, accessibility to the procedure itself is limited due to the few adequately trained operators worldwide. POEM should thus be performed by an expert operator at a high-volume center.
en-copyright=
kn-copyright=

en-aut-name=SugiharaYuusaku
en-aut-sei=Sugihara
en-aut-mei=Yuusaku
kn-aut-name=杉原雄策
kn-aut-sei=杉原
kn-aut-mei=雄策
aut-affil-num=1
ORCID=

en-aut-name=HaradaKeita
en-aut-sei=Harada
en-aut-mei=Keita
kn-aut-name=原田馨太
kn-aut-sei=原田
kn-aut-mei=馨太
aut-affil-num=2
ORCID=

en-aut-name=KatoRyo
en-aut-sei=Kato
en-aut-mei=Ryo
kn-aut-name=加藤諒
kn-aut-sei=加藤
kn-aut-mei=諒
aut-affil-num=3
ORCID=

en-aut-name=YamauchiKenji
en-aut-sei=Yamauchi
en-aut-mei=Kenji
kn-aut-name=山内健司
kn-aut-sei=山内
kn-aut-mei=健司
aut-affil-num=4
ORCID=

en-aut-name=TakashimaShiho
en-aut-sei=Takashima
en-aut-mei=Shiho
kn-aut-name=高嶋志保
kn-aut-sei=高嶋
kn-aut-mei=志保
aut-affil-num=5
ORCID=

en-aut-name=TakeiDaisuke
en-aut-sei=Takei
en-aut-mei=Daisuke
kn-aut-name=竹井大介
kn-aut-sei=竹井
kn-aut-mei=大介
aut-affil-num=6
ORCID=

en-aut-name=InokuchiaToshihiro
en-aut-sei=Inokuchia
en-aut-mei=Toshihiro
kn-aut-name=井口俊博
kn-aut-sei=井口
kn-aut-mei=俊博
aut-affil-num=7
ORCID=

en-aut-name=TakaharaMasahiro
en-aut-sei=Takahara
en-aut-mei=Masahiro
kn-aut-name=高原政宏
kn-aut-sei=高原
kn-aut-mei=政宏
aut-affil-num=8
ORCID=

en-aut-name=KawanoSeiji
en-aut-sei=Kawano
en-aut-mei=Seiji
kn-aut-name=川野誠司
kn-aut-sei=川野
kn-aut-mei=誠司
aut-affil-num=9
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=平岡佐規子
kn-aut-sei=平岡
kn-aut-mei=佐規子
aut-affil-num=10
ORCID=

en-aut-name=TanabeShunsuke
en-aut-sei=Tanabe
en-aut-mei=Shunsuke
kn-aut-name=田辺俊介
kn-aut-sei=田辺
kn-aut-mei=俊介
aut-affil-num=11
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=野間和宏
kn-aut-sei=野間
kn-aut-mei=和宏
aut-affil-num=12
ORCID=

en-aut-name=ShirakawaYasuhiro
en-aut-sei=Shirakawa
en-aut-mei=Yasuhiro
kn-aut-name=白川靖博
kn-aut-sei=白川
kn-aut-mei=靖博
aut-affil-num=13
ORCID=

en-aut-name=ManabeNoriaki
en-aut-sei=Manabe
en-aut-mei=Noriaki
kn-aut-name=眞部紀明
kn-aut-sei=眞部
kn-aut-mei=紀明
aut-affil-num=14
ORCID=

en-aut-name=InoueHaruhiro
en-aut-sei=Inoue
en-aut-mei=Haruhiro
kn-aut-name=井上晴洋
kn-aut-sei=井上
kn-aut-mei=晴洋
aut-affil-num=15
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=岡田裕之
kn-aut-sei=岡田
kn-aut-mei=裕之
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=2
en-affil=Division of Endoscopy, Okayama University Hospital
kn-affil=岡山大学病院　光学医療診療部

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=6
en-affil=Division of Endoscopy, Okayama University Hospital
kn-affil=岡山大学病院　光学医療診療部

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科

affil-num=11
en-affil=Department of  Gastroenterological Surgery, Okayama University Hospital
kn-affil=岡山大学病院　消化管外科

affil-num=12
en-affil=Department of  Gastroenterological Surgery, Okayama University Hospital
kn-affil=岡山大学病院　消化管外科

affil-num=13
en-affil=Department of  Gastroenterological Surgery, Okayama University Hospital
kn-affil=岡山大学病院　消化管外科

affil-num=14
en-affil=Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School
kn-affil=川崎医科大学　検査診断学

affil-num=15
en-affil=Digestive Diseases Center, Showa University Koto Toyosu Hospital
kn-affil=昭和大学江東豊洲病院　消化器センター

affil-num=16
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=岡山大学病院　消化器内科
en-keyword=POEM
kn-keyword=POEM
en-keyword=食道アカラシア (esophageal achalasia)
kn-keyword=食道アカラシア (esophageal achalasia)
END

start-ver=1.4
cd-journal=joma
no-vol=43
cd-vols=
no-issue=5
article-no=
start-page=648
end-page=652
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=20150903
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Rapid Immunochromatographic Tests for Norovirus in Neonatal and Infant Faecal Specimens
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: To compare the diagnostic performance of two norovirus rapid immunochromatographic kits (QuickNavi(®)-Norovirus [QN] and QuickNavi®-Norovirus 2 [QN2]; Denka Seiken, Niigata, Japan) for neonatal and infant faecal specimens.<br/>
Methods: Monthly faecal samples were collected from infants from birth to 12 months of age, and tested for norovirus using QN and QN2. Real-time reverse transcription polymerase chain reaction (RT-PCR) was used as the gold standard for norovirus detection. The diagnostic performance of the kits was calculated.<br/>
Results: A total of 343 specimens from 81 infants were analysed. In all samples, the specificity of QN and QN2 was 80% (275/343) and 99% (339/343), respectively. In infants aged <1 month, the specificity of QN was 33% (23/70), increasing to 93% at 4 months of age. Specificity of QN2 was ≥94% in infants between 0 and 12 months of age.<br/>
Conclusions: QN2 offers improved performance and is more useful than QN for the diagnosis of norovirus infection in the neonatal and infant period.
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=TakahashiNobumasa
kn-aut-sei=Takahashi
kn-aut-mei=Nobumasa
aut-affil-num=1
ORCID=

en-aut-name=NojimaIkuko
en-aut-sei=Nojima
en-aut-mei=Ikuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ArakiTooru
en-aut-sei=Araki
en-aut-mei=Tooru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakasugiMizue
en-aut-sei=Takasugi
en-aut-mei=Mizue
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakaneTomoko
en-aut-sei=Sakane
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KoderaAya
en-aut-sei=Kodera
en-aut-mei=Aya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IkedaMasanori
en-aut-sei=Ikeda
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=2
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=3
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=4
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=5
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=6
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=7
en-affil=Department of Paediatrics, Fukuyama Medical Centre
kn-affil=

affil-num=8
en-affil=Department of Paediatrics, Okayama University Hospital
kn-affil=
en-keyword=Norovirus
kn-keyword=Norovirus
en-keyword=false positive
kn-keyword=false positive
en-keyword=immunochromatography
kn-keyword=immunochromatography
en-keyword=neonate
kn-keyword=neonate
en-keyword=rapid detection test
kn-keyword=rapid detection test
en-keyword=specificity
kn-keyword=specificity
END

start-ver=1.4
cd-journal=joma
no-vol=66
cd-vols=
no-issue=7
article-no=
start-page=371
end-page=376
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=201607
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy and Safety of Salmeterol/fluticasone Combination Therapy in Infants and Preschool Children with Asthma Insufficiently Controlled by Inhaled Corticosteroids
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Clinical evidences of inhaled salmeterol/fluticasone propionate combination (SFC) therapy are insufficient in early childhood asthma.<br/>
Objectives: To examine the effects of SFC50, a combination product of salmeterol xinafoate (50 μg/day) and fluticasone propionate (100 μg/day), in infants and preschool children with asthma.<br/>
Methods: The study was conducted at 31 sites in Japan. 35 patients (6 months to 5 years old) with asthma insufficiently controlled by inhaled corticosteroids (100 μg/day) were initiated to treat with SFC50 twice a day for 12 weeks with pressurized metered dose inhalers. The efficacy of SFC50 was assessed using nighttime sleep disorder score as the primary endpoint and the other efficacy measurements. The safety measurement included the incidences of adverse event (AE).<br/>
Results: Mean patient age was 3.1 years, and 94.2% had mild-to-moderate persistent asthma (atopic type: 65.7%). Nighttime sleep disorder scores, assessed by a nighttime sleep diary, significantly decreased after treatment with SFC50 throughout the study period (p<0.01). SFC50 also significantly improved other efficacy outcomes including asthma symptom score, frequency of short-acting beta-agonist treatment, frequency of unscheduled visits to clinic, frequency of exacerbation due to virus infection, asthma control score and patient QOL score (p<0.01). AEs of cold, upper respiratory inflammation and asthmatic attack occurred in each of the 3 patients (8.6%); however, these were not regarded as treatment-related AEs.<br/>
Conclusions: SFC50 improved nighttime sleep disorder score and other efficacy outcome measures with no safety concerns. The results suggest that SFC50 treatment is useful to control the mild-to-moderate asthma in infant and preschool-aged children.
en-copyright=
kn-copyright=

en-aut-name=YoshiharaS.
en-aut-sei=Yoshihara
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukudaH.
en-aut-sei=Fukuda
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TamuraM.
en-aut-sei=Tamura
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArisakaO.
en-aut-sei=Arisaka
en-aut-mei=O.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaM.
en-aut-sei=Ikeda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukudaN.
en-aut-sei=Fukuda
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsujiT.
en-aut-sei=Tsuji
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HasegawaS.
en-aut-sei=Hasegawa
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KannoN.
en-aut-sei=Kanno
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TeraokaM.
en-aut-sei=Teraoka
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=WakiguchiH.
en-aut-sei=Wakiguchi
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AokiY.
en-aut-sei=Aoki
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TeradaA.
en-aut-sei=Terada
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HasegawaM.
en-aut-sei=Hasegawa
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MankiA.
en-aut-sei=Manki
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IgarashiH.
en-aut-sei=Igarashi
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Dokkyo Medical University
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Dokkyo Medical University
kn-affil=

affil-num=3
en-affil=Department of Pediatrics, Dokkyo Medical University
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Dokkyo Medical University
kn-affil=

affil-num=5
en-affil=Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Grimm Pediatrics and Allergy Clinic
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, JA Hiroshima General Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, Nishikata Hospital
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Kurashiki Municipal Hospital
kn-affil=

affil-num=11
en-affil=Department of Pediatrics, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Pediatrics, Nagato General Hospital
kn-affil=

affil-num=13
en-affil=Terada Kid’s Allergy & Asthma Clinic
kn-affil=

affil-num=14
en-affil=Department of Pediatrics, Yamaguchi Grand Medical Center
kn-affil=

affil-num=15
en-affil=Department of Pediatrics, Okayama City Hospital
kn-affil=

affil-num=16
en-affil=Department of Pediatrics, Nogi Hospital
kn-affil=
en-keyword=salmeterol/fluticasone combination
kn-keyword=salmeterol/fluticasone combination
en-keyword=asthma
kn-keyword=asthma
en-keyword=infant
kn-keyword=infant
en-keyword=preschool children
kn-keyword=preschool children
en-keyword=nighttime sleep disorder score
kn-keyword=nighttime sleep disorder score
en-keyword=long-acting beta-agonist
kn-keyword=long-acting beta-agonist
en-keyword= inhaled corticosteroid
kn-keyword= inhaled corticosteroid
END

start-ver=1.4
cd-journal=joma
no-vol=71
cd-vols=
no-issue=10
article-no=
start-page=1435
end-page=1443
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=201604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Predictive Values of Egg-Specific IgE by Two Commonly Used Assay Systems for the Diagnosis of Egg Allergy in Young Children: A Prospective Multicenter Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Specific IgE (sIgE) is often used to predict oral food challenge (OFC) outcomes in food allergy, but interpretation of the results may vary depending on the assay method employed and the patient population tested. The aim of this study was to use two commercial assay systems to determine egg-sIgE values predictive of allergy within the most common populations treated at pediatric clinics.<br/>
Methods: In a multicenter prospective study, 433 children with suspected or confirmed egg allergy underwent oral challenge (OFC) using cooked egg (CE) and raw egg (RE) powders to diagnose either true allergy in 1-year-old (group A, n = 220) or tolerance in 2- to 6-year-old (group B, n = 213). Egg white (EW)- and ovomucoid (OM)-sIgE values were measured using the ImmunoCAP(®) sIgE (ImmunoCAP) and the IMMULITE(®) 2000 3 gAllergy(™) (3gAllergy) systems. Children were recruited from six primary care clinics and 18 hospitals in Japan.<br/>
Results: Receiver-operating characteristic (ROC) curve analysis yielded similar areas under the curve (AUC) for the two assays (0.7-0.8). The optimal cutoff values and the probability curves (PCs) of the sIgE by the two assays to predict CE and RE OFC outcomes were determined for both groups. Values for 3gAllergy were higher than for ImmunoCAP; however, correlation of sIgE and predicted probability calculated by PCs were strong between the two methods.<br/>
Conclusions: Cutoff values and PCs for egg-sIgE established using both ImmunoCAP and 3gAllergy may be useful for predicting egg allergy in early childhood patient populations.
en-copyright=
kn-copyright=

en-aut-name=FuruyaK.
en-aut-sei=Furuya
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NagaoM.
en-aut-sei=Nagao
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SatoY.
en-aut-sei=Sato
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ItoS.
en-aut-sei=Ito
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujisawaT.
en-aut-sei=Fujisawa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IPAD3g investigators
en-aut-sei=IPAD3g investigators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Allergy Center and Institute for Clinical Research, Mie National Hospital
kn-affil=

affil-num=2
en-affil=Allergy Center and Institute for Clinical Research, Mie National Hospital
kn-affil=

affil-num=3
en-affil=Department of Global Clinical Research, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=4
en-affil=Department of Food Science and Nutrition, Faculty of Human Life and Science, Doshisha Women's College of Liberal Arts
kn-affil=

affil-num=5
en-affil=Allergy Center and Institute for Clinical Research, Mie National Hospital
kn-affil=

affil-num=6
en-affil=
kn-affil=
en-keyword=egg allergy
kn-keyword=egg allergy
en-keyword=oral food challenge
kn-keyword=oral food challenge
en-keyword=predictive value
kn-keyword=predictive value
en-keyword=probability curve
kn-keyword=probability curve
en-keyword=specific IgE
kn-keyword=specific IgE
END

start-ver=1.4
cd-journal=joma
no-vol=128
cd-vols=
no-issue=2
article-no=
start-page=91
end-page=94
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=20160801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2015 Incentive Award of the Okayama Medical Association in General Medical Science (2015 Yuuki Prize)
kn-title=平成27年度岡山医学会賞 総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KajitaAi
en-aut-sei=Kajita
en-aut-mei=Ai
kn-aut-name=梶田藍
kn-aut-sei=梶田
kn-aut-mei=藍
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Dermatology, Okayama University Hospital
kn-affil=岡山大学病院　皮膚科
END

start-ver=1.4
cd-journal=joma
no-vol=128
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=3
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=20160401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2014 Incentive Award of the Okayama Medical Association in Neuroscience (2014 Niimi Prize)
kn-title=平成26年度岡山医学会賞 脳神経研究奨励賞（新見賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KonoSyoichiro
en-aut-sei=Kono
en-aut-mei=Syoichiro
kn-aut-name=河野祥一郎
kn-aut-sei=河野
kn-aut-mei=祥一郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学病院　神経内科
END

start-ver=1.4
cd-journal=joma
no-vol=127
cd-vols=
no-issue=3
article-no=
start-page=203
end-page=207
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=20151201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Non-high-output cardiac failure in patients undergoing hemodialysis through an arteriovenous shunt
kn-title=透析シャント心不全―非過大シャント心不全 “Non-High-Output Cardiac Failure”の病態―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Hemodialysis-related heart failure has been considered to be associated with excessive blood flow through the arteriovenous (AV) shunt used for vascular access. However, some patients undergoing dialysis have heart failure in the absence of an increase in cardiac output (CO) related to shunt blood-flow loading because the loading cannot be compensated for by increasing CO. This condition may be challenging to manage ; thus, early diagnosis is important.
 Methods and Results: Twelve patients (mean age, 71 years ; 9 men) with end-stage renal disease, dialysis-related heart failure, a high brain natriuretic peptide (BNP) level, and a mean New York Heart Association (NYHA) class of II underwent AV shunt closure. Their cardiac index (CI), pre- and post-dialysis BNP levels, and several cardiac variables were assessed pre- and postoperatively. All patients achieved relief of heart failure symptoms and a reduction in NYHA class after AV closure, but six patients had a postoperative increase in CI (the "non-high-output" cardiac failure group), whereas the other six had a decrease in CI (the "high-output" cardiac failure group). The high-output patients had greater improvements in BNP levels and most cardiac variables compared to the non-high-output group ;
therefore, the heart failure in the non-high-output patients was considered more serious than that in the high-output group.
 Conclusions: The selection of effective strategies for treating dialysis-related heart failure may depend partly on identifying which patients have non-high-output failure. Such identification requires serial measurements of BNP levels and evaluations of cardiac variables other than the ejection fraction.
en-copyright=
kn-copyright=

en-aut-name=UgawaToyomu
en-aut-sei=Ugawa
en-aut-mei=Toyomu
kn-aut-name=鵜川豊世武
kn-aut-sei=鵜川
kn-aut-mei=豊世武
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科
en-keyword=心拍出量（cardiac output）
kn-keyword=心拍出量（cardiac output）
en-keyword=心不全（heart failure）
kn-keyword=心不全（heart failure）
en-keyword=脳性ナトリウム利尿ペプチド（brain natriuretic peptide）
kn-keyword=脳性ナトリウム利尿ペプチド（brain natriuretic peptide）
en-keyword=非過大シャント心不全（non-high-output cardiac failure）
kn-keyword=非過大シャント心不全（non-high-output cardiac failure）
en-keyword=腎臓（kidney）
kn-keyword=腎臓（kidney）
END

start-ver=1.4
cd-journal=joma
no-vol=127
cd-vols=
no-issue=3
article-no=
start-page=175
end-page=178
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=20151201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2014 Incentive Award of the Okayama Medical Association in General Medical Science (2014 Yuuki Prize)
kn-title=平成26年度岡山医学会賞 総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=淺田騰
kn-aut-sei=淺田
kn-aut-mei=騰
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=127
cd-vols=
no-issue=2
article-no=
start-page=91
end-page=94
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=20150803
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2014 Incentive Award of the Okayama Medical Association in Cancer Research (2014 Hayashibara Prize and Yamada Prize)
kn-title=平成26年度岡山医学会賞 がん研究奨励賞（林原賞・山田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YanoShuya
en-aut-sei=Yano
en-aut-mei=Shuya
kn-aut-name=矢野修也
kn-aut-sei=矢野
kn-aut-mei=修也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=127
cd-vols=
no-issue=1
article-no=
start-page=25
end-page=29
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=20150401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Laparoscopic total colectomy with lymph node dissection for familial adenomatous polyposis with multiple colorectal cancers
kn-title=家族性大腸腺腫症（FAP）に合併した同時性５多発大腸癌に対してリンパ節郭清を伴う腹腔鏡下大腸全摘術を施行した１例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　A 49-year-old Japanese man visited our hospital with chief complaints of difficulty with and bleeding during defecation. After a detailed examination, he was diagnosed with familial adenomatous polyposis (FAP) with multiple (five) colorectal cancers. The tumors were located in the right-sided, left-sided, and sigmoid colon, and the lower rectum. Regional lymph node involvement was observed, but no metastasis to other organs was detected. We, therefore, performed a laparoscopic total colectomy with superior mesenteric artery (SMA) and inferior mesenteric artery (IMA) lymph node dissection. We were able to perform minimally invasive and cosmetically acceptable surgery using laparoscopy instead of highly-invasive open abdominal surgery. Our search of the literature revealed no reported cases of laparoscopic total colectomy with lymph node dissection for FAP with multiple colorectal cancers, making the present case the first to be reported in the literature.
en-copyright=
kn-copyright=

en-aut-name=KatoHiroshi
en-aut-sei=Kato
en-aut-mei=Hiroshi
kn-aut-name=加藤大
kn-aut-sei=加藤
kn-aut-mei=大
aut-affil-num=1
ORCID=

en-aut-name=OishiMasahiro
en-aut-sei=Oishi
en-aut-mei=Masahiro
kn-aut-name=大石正博
kn-aut-sei=大石
kn-aut-mei=正博
aut-affil-num=2
ORCID=

en-aut-name=KoderaMasahito
en-aut-sei=Kodera
en-aut-mei=Masahito
kn-aut-name=小寺正人
kn-aut-sei=小寺
kn-aut-mei=正人
aut-affil-num=3
ORCID=

en-aut-name=YamamuraMasao
en-aut-sei=Yamamura
en-aut-mei=Masao
kn-aut-name=山村方夫
kn-aut-sei=山村
kn-aut-mei=方夫
aut-affil-num=4
ORCID=

en-aut-name=IkedaHideaki
en-aut-sei=Ikeda
en-aut-mei=Hideaki
kn-aut-name=池田秀明
kn-aut-sei=池田
kn-aut-mei=秀明
aut-affil-num=5
ORCID=

en-aut-name=MizunoKenji
en-aut-sei=Mizuno
en-aut-mei=Kenji
kn-aut-name=水野憲治
kn-aut-sei=水野
kn-aut-mei=憲治
aut-affil-num=6
ORCID=

en-aut-name=YamashitaYutaka
en-aut-sei=Yamashita
en-aut-mei=Yutaka
kn-aut-name=山下裕
kn-aut-sei=山下
kn-aut-mei=裕
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=2
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=3
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=4
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=5
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=6
en-affil=
kn-affil=鳥取市立病院　外科

affil-num=7
en-affil=
kn-affil=鳥取市立病院　外科
en-keyword=家族性大腸腺腫症（FAP）（familial adenomatous polyposis）
kn-keyword=家族性大腸腺腫症（FAP）（familial adenomatous polyposis）
en-keyword=同時性多発大腸癌（synchronous colorectal cancer）
kn-keyword=同時性多発大腸癌（synchronous colorectal cancer）
en-keyword=大腸全摘術（colorectal surgery）
kn-keyword=大腸全摘術（colorectal surgery）
en-keyword=腹腔鏡下手術（laparoscopic surgery）
kn-keyword=腹腔鏡下手術（laparoscopic surgery）
END

start-ver=1.4
cd-journal=joma
no-vol=171
cd-vols=
no-issue=3
article-no=
start-page=492
end-page=498
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201409
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Cathelicidin antimicrobial peptide LL-37 augments interferon-beta expression and antiviral activity induced by double-stranded RNA in keratinocytes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Cathelicidin antimicrobial peptide LL-37 has the capacity to kill a wide range of microbes and to modify host immunity. Recently, our group observed that the activation of keratinocytes by LL-37 and DNA greatly increases interferon (IFN)-beta through Toll-like receptor (TLR) 9. However, the effect of LL-37 on the induction of IFN-beta through TLR3, a sensor of double-stranded (ds) RNA, in keratinocytes is not well known. 

Objectives To investigate whether LL-37 could affect TLR3 signalling and antiviral activity in normal human epidermal keratinocytes (NHEKs). 

Methods We investigated the production of IFN-beta in NHEKs stimulated with a TLR3 ligand, poly (I:C), in the presence of LL-37. To examine the effect of LL-37 and poly (I:C) on antiviral activity, a virus plaque assay using herpes simplex (HS) virus type-1 was carried out. The uptake of poly (I:C) conjugated with fluorescein isothiocyanate (FITC) into the keratinocytes was observed in the presence of LL-37. Immunostaining for TLR3 and LL-37 was performed using skin samples from HS. 

Results LL-37 and poly (I:C) synergistically induced the expression of IFN-beta in NHEKs. Furthermore, co-stimulation with LL-37 and poly (I:C) significantly decreased the viral plaque numbers compared with poly (I:C) or LL-37 alone. LL-37 enhanced the uptake of FITC-conjugated poly (I:C) into cells. Immunohistochemical analysis demonstrated that the expression of TLR3 and LL-37 is up-regulated in HS lesions. 

Conclusions Our findings suggest that LL-37 augments the antiviral activity induced by dsRNA in keratinocytes, which may contribute to the innate immune response to cutaneous viral infections such as HS.
en-copyright=
kn-copyright=

en-aut-name=TakiguchiT
en-aut-sei=Takiguchi
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorizaneS
en-aut-sei=Morizane
en-aut-mei=S
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoT
en-aut-sei=Yamamoto
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KajitaA
en-aut-sei=Kajita
en-aut-mei=A
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaK
en-aut-sei=Ikeda
en-aut-mei=K
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwatsukiK
en-aut-sei=Iwatsuki
en-aut-mei=K
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=2
en-affil=
kn-affil=Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=3
en-affil=
kn-affil=Kawasaki Med Univ, Dept Dermatol

affil-num=4
en-affil=
kn-affil=Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=5
en-affil=
kn-affil=Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=6
en-affil=
kn-affil=Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci
END

start-ver=1.4
cd-journal=joma
no-vol=52
cd-vols=
no-issue=2
article-no=
start-page=544
end-page=548
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Necessity for Reassessment of Patients with Serogroup 2 Hepatitis C Virus (HCV) and Undetectable Serum HCV RNA
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We encountered a patient positive for anti-hepatitis C virus (HCV) whose serum HCV RNA was undetectable with the Roche AmpliPrep/Cobas TaqMan HCV assay (CAP/CTM) version 1 but showed a high viral load with the Abbott RealTime HCV assay (ART). Discrepancies in the detectability of serum HCV RNA were investigated among 891 consecutive patients who were positive for anti-HCV. Specific nucleotide variations causing the undetectability of HCV RNA were determined and confirmed by synthesizing RNA coding those variations. Serum samples with the discrepancies were also reassessed by CAP/CTM version 2. Among the 891 anti-HCV-positive patients, 4 patients had serum HCV RNA levels that were undetectable by CAP/CTM version 1 despite having levels of > 5 log IU/ml that were detected by ART. All four patients had HCV genotype 2a and high titers of anti-HCV. Sequencing of the HCV 5' noncoding regions revealed 2 common variations, A at nucleotide (nt) 145 and T at nt 151. Synthesized RNAs of the HCV 5' noncoding region with standard (NCR145G151C) and variant nucleotides at nt 145 and nt 151 were quantified with CAP/CTM. RNAs of NCR145G151C and NCR145G151T were quantifiable with CAP/CTM version 1, while those of NCR145A151T and NCR145A151C went undetected. The substitution from G to A at nt 145 specifically conferred this undetectability, while this undetectability was reverted in synthesized HCV RNA with correction of this variation. Reassessment of these samples by CAP/CTM version 2 resulted in similar levels of HCV RNA being detected by ART. We conclude that HCV patients with undetectable HCV RNA by CAP/CTM version 1 should be reassessed for viral quantification.
en-copyright=
kn-copyright=

en-aut-name=MoritouYuki
en-aut-sei=Moritou
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SekiHiroyuki
en-aut-sei=Seki
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NanbaShintaro
en-aut-sei=Nanba
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwasakiYoshiaki
en-aut-sei=Iwasaki
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoKazuhide
en-aut-sei=Yamamoto
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=2
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=3
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=4
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=5
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci

affil-num=6
en-affil=
kn-affil=Okayama Univ, Hlth Serv Ctr

affil-num=7
en-affil=
kn-affil=Okayama Univ, Dept Gastroenterol & Hepatol, Grad Sch Med Dent & Pharmaceut Sci
END

start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=3
article-no=
start-page=187
end-page=190
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20141201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki Prize)
kn-title=平成25年度岡山医学会賞 総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=受賞対象論文: Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, Matsuo K, Kiura K, Miyoshi S, Matsuda F, Toyooka S：Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst (2014) 106, djt338
en-copyright=
kn-copyright=

en-aut-name=YamamotoHiromasa
en-aut-sei=Yamamoto
en-aut-mei=Hiromasa
kn-aut-name=山本寛斉
kn-aut-sei=山本
kn-aut-mei=寛斉
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　呼吸器・乳腺内分泌外科学
END

start-ver=1.4
cd-journal=joma
no-vol=68
cd-vols=
no-issue=5
article-no=
start-page=291
end-page=302
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Hepatitis C Virus-specific T-cell Response Correlates with Hepatitis Activity and Donor IL28B Genotype Early after Liver Transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At＞3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.
en-copyright=
kn-copyright=

en-aut-name=TsuzakiRyuichiro
en-aut-sei=Tsuzaki
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YagiTakahito
en-aut-sei=Yagi
en-aut-mei=Takahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KoikeKazuko
en-aut-sei=Koike
en-aut-mei=Kazuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwasakiYoshiaki
en-aut-sei=Iwasaki
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShirahaHidenori
en-aut-sei=Shiraha
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MiyakeYasuhiro
en-aut-sei=Miyake
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SadamoriHiroshi
en-aut-sei=Sadamori
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShinouraSusumu
en-aut-sei=Shinoura
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=UmedaYuzo
en-aut-sei=Umeda
en-aut-mei=Yuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YoshidaRyuichi
en-aut-sei=Yoshida
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NobuokaDaisuke
en-aut-sei=Nobuoka
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=UtsumiMasashi
en-aut-sei=Utsumi
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NakayamaEiichi
en-aut-sei=Nakayama
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YamamotoKazuhide
en-aut-sei=Yamamoto
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=2
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=3
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=4
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=5
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=6
en-affil=
kn-affil=Health Service Center, Okayama University

affil-num=7
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=8
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=9
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=10
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=11
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=12
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=13
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=14
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=15
en-affil=
kn-affil=Kawasaki University of Medical Welfare

affil-num=16
en-affil=
kn-affil=Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

affil-num=17
en-affil=
kn-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
en-keyword=interferon gamma
kn-keyword=interferon gamma
en-keyword=ELISPOT assay
kn-keyword=ELISPOT assay
en-keyword=single nucleotide polymorphisms
kn-keyword=single nucleotide polymorphisms
en-keyword=dendritic cell
kn-keyword=dendritic cell
en-keyword=CD4 T cell
kn-keyword=CD4 T cell
END

start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=6
article-no=
start-page=529
end-page=536
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2004
dt-pub=200406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Maintenance of glucose-sensitive insulin secretion of cryopreserved human islets with University of Wisconsin solution and ascorbic acid-2 glucoside
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Normal human islet cells are an ideal source for pancreas-targeted cell therapies, but the availability of human donor pancreata for islet isolation is severely limited. To effectively utilize such scarce donor organs for cell therapies, it is crucial to develop an excellent isolation, effective cryopreservation, and efficient gene transfer techniques for the transportation of isolated cells. In the present study, we investigate the effect of University of Wisconsin (UW) solution and ascorbic acid-2 glucoside (AA2G) on the cryopreservation of human islets. We also evaluate the gene transfer efficiency of a lentiviral vector expressing the E. coli LacZ gene, Lt-NLS/LacZ, in human islets. Human islets were isolated with a standard digestion method at the University of Alberta. Isolated islets were transported to Japan for 40 h and then subjected to cryopreservation experiments. The following preservation solutions were tested: UW solution with 100 mug/mL of AA2G, UW solution, 100% fetal bovine serum (FBS), and CMRL supplemented with 10% FBS. Following three months of cryopreservation, the islets were thawed and analyzed for viability, glucose-sensitive insulin secretion, proinsulin gene expression profile, and in vivo engraftment. The islets were also subjected to monolayer formation with 804G-cell-line-derived extracellular matrix (ECM), followed by Lt-NLS/LacZ transduction. The viability, morphology, glucose-sensitive insulin secretion, proinsulin gene expression, and monolayer formation efficiency of the thawed cryopreserved islets are significantly better maintained by the use of UW solution. When AA2G (100 mug/mL) is combined with UW, such parameters are further improved. The adequate engraftment of UW + AA2G-cryopreserved human islets is achieved in the liver of nude mice. Efficient Lt-NLS/LacZ transduction is identified in monolayered islets cryopreserved with UW solution with AA2G. The present work demonstrates that the combination of UW solution with AA2G (100 mug/mL) would be a useful cryopreservation means for human islets. Human islets monolayer-cultured with 804G-derived ECM are efficiently transduced with a lentiviral vector Lt-NLS/LacZ.
en-copyright=
kn-copyright=

en-aut-name=ArataT
en-aut-sei=Arata
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkitsuT
en-aut-sei=Okitsu
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FukazawaT
en-aut-sei=Fukazawa
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaH
en-aut-sei=Ikeda
en-aut-mei=H
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KobayashiK
en-aut-sei=Kobayashi
en-aut-mei=K
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YongC
en-aut-sei=Yong
en-aut-mei=C
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KosakaY
en-aut-sei=Kosaka
en-aut-mei=Y
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NarushimaM
en-aut-sei=Narushima
en-aut-mei=M
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsuokaJ
en-aut-sei=Matsuoka
en-aut-mei=J
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamamotoI
en-aut-sei=Yamamoto
en-aut-mei=I
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TanakaN
en-aut-sei=Tanaka
en-aut-mei=N
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=LakeyJRT
en-aut-sei=Lakey
en-aut-mei=JRT
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KobayashiN
en-aut-sei=Kobayashi
en-aut-mei=N
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=2
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=3
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=4
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=5
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=6
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=7
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=8
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=9
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry

affil-num=10
en-affil=
kn-affil=Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University

affil-num=11
en-affil=
kn-affil=Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University

affil-num=12
en-affil=
kn-affil=Univ Alberta, Surg Med Res Inst, Clin Islet Transplantat Program

affil-num=13
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
en-keyword=islets
kn-keyword=islets
en-keyword=University of Wisconsin solution
kn-keyword=University of Wisconsin solution
en-keyword=ascorbic acid-2 glucoside
kn-keyword=ascorbic acid-2 glucoside
en-keyword=cryopreservation
kn-keyword=cryopreservation
en-keyword=stimulation index
kn-keyword=stimulation index
END

start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=2
article-no=
start-page=155
end-page=157
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Guidelines for the treatment of dementia
kn-title=認知症の治療ガイドライン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KurataTomoko
en-aut-sei=Kurata
en-aut-mei=Tomoko
kn-aut-name=倉田智子
kn-aut-sei=倉田
kn-aut-mei=智子
aut-affil-num=1
ORCID=

en-aut-name=AbeKoji
en-aut-sei=Abe
en-aut-mei=Koji
kn-aut-name=阿部康二
kn-aut-sei=阿部
kn-aut-mei=康二
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学病院　神経内科

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　脳神経内科学
END

start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=2
article-no=
start-page=103
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Induction therapy followed by surgery for non small-cell lung cancer
kn-title=非小細胞肺癌に対する術前治療後外科切除療法
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=豊岡伸一
kn-aut-sei=豊岡
kn-aut-mei=伸一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　臨床遺伝子医療学
en-keyword=非小細胞肺癌
kn-keyword=非小細胞肺癌
en-keyword=導入療法
kn-keyword=導入療法
en-keyword=放射線化学療法
kn-keyword=放射線化学療法
en-keyword=外科切除
kn-keyword=外科切除
END

start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=2
article-no=
start-page=87
end-page=88
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara Prize and Yamada Prize)
kn-title=平成25年度岡山医学会賞 がん研究奨励賞（林原賞・山田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MiyaharaKoji
en-aut-sei=Miyahara
en-aut-mei=Koji
kn-aut-name=宮原孝治
kn-aut-sei=宮原
kn-aut-mei=孝治
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・肝臓内科学
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Pulmonary emphysema is characterized by alveolar destruction and persistent inflammation of the airways. Although IL-17A contributes to many chronic inflammatory diseases, it's role in the inflammatory response of elastase-induced emphysema remains unclear. 

Methods: In a model of elastase-induced pulmonary emphysema we examined the response of IL-17A-deficient mice, monitoring airway inflammation, static compliance, lung histology and levels of neutrophil-related chemokine and pro-inflammatory cytokines in bronchoalveolar lavage (BAL) fluid. 

Results: Wild-type mice developed emphysematous changes in the lung tissue on day 21 after elastase treatment, whereas emphysematous changes were decreased in IL-17A-deficient mice compared to wild-type mice. Neutrophilia in BAL fluid, seen in elastase-treated wild-type mice, was reduced in elastase-treated IL-17A-deficient mice on day 4, associated with decreased levels of KC, MIP-2 and IL-1 beta. Elastase-treated wild-type mice showed increased IL-17A levels as well as increased numbers of IL-17A+ CD4 T cells in the lung in the initial period following elastase treatment. 

Conclusions: These data identify the important contribution of IL-17A in the development of elastase-induced pulmonary inflammation and emphysema. Targeting IL-17A in emphysema may be a potential therapeutic strategy for delaying disease progression.
en-copyright=
kn-copyright=

en-aut-name=KurimotoEtsuko
en-aut-sei=Kurimoto
en-aut-mei=Etsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyaharaNobuaki
en-aut-sei=Miyahara
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanehiroArihiko
en-aut-sei=Kanehiro
en-aut-mei=Arihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WasedaKoichi
en-aut-sei=Waseda
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TaniguchiAkihiko
en-aut-sei=Taniguchi
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaGenyo
en-aut-sei=Ikeda
en-aut-mei=Genyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KogaHikari
en-aut-sei=Koga
en-aut-mei=Hikari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NishimoriHisakazu
en-aut-sei=Nishimori
en-aut-mei=Hisakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanimotoYasushi
en-aut-sei=Tanimoto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KataokaMikio
en-aut-sei=Kataoka
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IwakuraYoichiro
en-aut-sei=Iwakura
en-aut-mei=Yoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=GelfandErwin W.
en-aut-sei=Gelfand
en-aut-mei=Erwin W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TanimotoMitsune
en-aut-sei=Tanimoto
en-aut-mei=Mitsune
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=2
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=3
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=4
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=5
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=6
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=7
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=8
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=9
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=10
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med

affil-num=11
en-affil=
kn-affil=Univ Tokyo, Inst Med Sci, Ctr Expt Med & Syst Biol

affil-num=12
en-affil=
kn-affil=Natl Jewish Hlth, Dept Pediat, Div Cell Biol

affil-num=13
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol Allergy & Resp Med
en-keyword=IL-17
kn-keyword=IL-17
en-keyword=Elastase
kn-keyword=Elastase
en-keyword=Emphysema
kn-keyword=Emphysema
en-keyword=Chronic obstructive pulmonary disease
kn-keyword=Chronic obstructive pulmonary disease
END

start-ver=1.4
cd-journal=joma
no-vol=125
cd-vols=
no-issue=3
article-no=
start-page=217
end-page=220
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20131202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Th2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis
kn-title=Th２サイトカインはアトピー性皮膚炎患者における カリクレイン７の発現と機能を増強する
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MorizaneShin
en-aut-sei=Morizane
en-aut-mei=Shin
kn-aut-name=森実真
kn-aut-sei=森実
kn-aut-mei=真
aut-affil-num=1
ORCID=

en-aut-name=YamasakiKenshi
en-aut-sei=Yamasaki
en-aut-mei=Kenshi
kn-aut-name=山崎研志
kn-aut-sei=山崎
kn-aut-mei=研志
aut-affil-num=2
ORCID=

en-aut-name=KajitaAi
en-aut-sei=Kajita
en-aut-mei=Ai
kn-aut-name=梶田藍
kn-aut-sei=梶田
kn-aut-mei=藍
aut-affil-num=3
ORCID=

en-aut-name=IkedaKazuko
en-aut-sei=Ikeda
en-aut-mei=Kazuko
kn-aut-name=池田佳寿子
kn-aut-sei=池田
kn-aut-mei=佳寿子
aut-affil-num=4
ORCID=

en-aut-name=ZhanMaosheng
en-aut-sei=Zhan
en-aut-mei=Maosheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AoyamaYumi
en-aut-sei=Aoyama
en-aut-mei=Yumi
kn-aut-name=青山裕美
kn-aut-sei=青山
kn-aut-mei=裕美
aut-affil-num=6
ORCID=

en-aut-name=Richard L Gallo
en-aut-sei=Richard L Gallo
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IwatsukiKeiji
en-aut-sei=Iwatsuki
en-aut-mei=Keiji
kn-aut-name=岩月啓氏
kn-aut-sei=岩月
kn-aut-mei=啓氏
aut-affil-num=8
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学

affil-num=2
en-affil=
kn-affil=東北大学大学院医学系研究科　皮膚科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学

affil-num=7
en-affil=
kn-affil=米国カリフォルニア大学サンディエゴ校医学部　皮膚科学

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　皮膚科学
en-keyword=アトピー性皮膚炎
kn-keyword=アトピー性皮膚炎
en-keyword=Th２サイトカイン
kn-keyword=Th２サイトカイン
en-keyword=カリクレイン
kn-keyword=カリクレイン
en-keyword=表皮角化細胞
kn-keyword=表皮角化細胞
END

start-ver=1.4
cd-journal=joma
no-vol=125
cd-vols=
no-issue=3
article-no=
start-page=201
end-page=204
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20131202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Hydrogen as a treatment candidate for non-alcoholic steatohepatitis
kn-title=NASHに対する水素分子の有用性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KawaiDaisuke
en-aut-sei=Kawai
en-aut-mei=Daisuke
kn-aut-name=河合大介
kn-aut-sei=河合
kn-aut-mei=大介
aut-affil-num=1
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=高木章乃夫
kn-aut-sei=高木
kn-aut-mei=章乃夫
aut-affil-num=2
ORCID=

en-aut-name=YamamotoKazuhide
en-aut-sei=Yamamoto
en-aut-mei=Kazuhide
kn-aut-name=山本和秀
kn-aut-sei=山本
kn-aut-mei=和秀
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・肝臓内科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・肝臓内科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・肝臓内科学
en-keyword=酸化ストレス
kn-keyword=酸化ストレス
en-keyword=水素水
kn-keyword=水素水
en-keyword=NASH
kn-keyword=NASH
en-keyword=肝腫瘍
kn-keyword=肝腫瘍
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Chronic asthma is often associated with neutrophilic infiltration in the airways. Neutrophils contain elastase, a potent secretagogue in the airways, nonetheless the role for neutrophil elastase as well as neutrophilic inflammation in allergen-induced airway responses is not well defined. In this study, we have investigated the impact of neutrophil elastase inhibition on the development of allergic airway inflammation and airway hyperresponsiveness (AHR) in previously sensitized and challenged mice. 

Methods: BALB/c mice were sensitized and challenged (primary) with ovalbumin (OVA). Six weeks later, a single OVA aerosol (secondary challenge) was delivered and airway inflammation and airway responses were monitored 6 and 48 hrs later. An inhibitor of neutrophil elastase was administered prior to secondary challenge. 

Results: Mice developed a two-phase airway inflammatory response after secondary allergen challenge, one neutrophilic at 6 hr and the other eosinophilic, at 48 hr. PAR-2 expression in the lung tissues was enhanced following secondary challenge, and that PAR-2 intracellular expression on peribronchial lymph node (PBLN) T cells was also increased following allergen challenge of sensitized mice. Inhibition of neutrophil elastase significantly attenuated AHR, goblet cell metaplasia, and inflammatory cell accumulation in the airways following secondary OVA challenge. Levels of IL-4, IL-5 and IL-13, and eotaxin in BAL fluid 6 hr after secondary allergen challenge were significantly suppressed by the treatment. At 48 hr, treatment with the neutrophil elastase inhibitor significantly reduced the levels of IL-13 and TGF-beta 1 in the BAL fluid. In parallel, in vitro IL-13 production was significantly inhibited in spleen cells from sensitized mice. 

Conclusion: These data indicate that neutrophil elastase plays an important role in the development of allergic airway inflammation and hyperresponsiveness, and would suggest that the neutrophil elastase inhibitor reduced AHR to inhaled methacholine indicating the potential for its use as a modulator of the immune/inflammatory response in both the neutrophil-and eosinophil-dominant phases of the response to secondary allergen challenge.
en-copyright=
kn-copyright=

en-aut-name=KogaHikari
en-aut-sei=Koga
en-aut-mei=Hikari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyaharaNobuaki
en-aut-sei=Miyahara
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FuchimotoYasuko
en-aut-sei=Fuchimoto
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkedaGenyo
en-aut-sei=Ikeda
en-aut-mei=Genyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WasedaKoichi
en-aut-sei=Waseda
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OnoKatsuichiro
en-aut-sei=Ono
en-aut-mei=Katsuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanimotoYasushi
en-aut-sei=Tanimoto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KataokaMikio
en-aut-sei=Kataoka
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=GelfandErwin W.
en-aut-sei=Gelfand
en-aut-mei=Erwin W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanimotoMitsune
en-aut-sei=Tanimoto
en-aut-mei=Mitsune
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanehiroArihiko
en-aut-sei=Kanehiro
en-aut-mei=Arihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=2
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=3
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=4
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=5
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=6
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=7
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=8
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=9
en-affil=
kn-affil=Natl Jewish Hlth, Dept Pediat, Div Cell Biol

affil-num=10
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci

affil-num=11
en-affil=
kn-affil=Okayama Univ, Dept Hematol Oncol Allergy & Resp Med, Grad Sch Med Dent & Pharmaceut Sci
en-keyword=Neutrophil
kn-keyword=Neutrophil
en-keyword=Elastase
kn-keyword=Elastase
en-keyword=Airway
kn-keyword=Airway
en-keyword=Hyperresponsiveness
kn-keyword=Hyperresponsiveness
en-keyword=Asthma
kn-keyword=Asthma
END

start-ver=1.4
cd-journal=joma
no-vol=125
cd-vols=
no-issue=1
article-no=
start-page=77
end-page=78
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Genetic polymorphisms as susceptibility factors for drug response
kn-title=遺伝子多型と薬剤感受性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KurodaSatoshi
en-aut-sei=Kuroda
en-aut-mei=Satoshi
kn-aut-name=黒田智
kn-aut-sei=黒田
kn-aut-mei=智
aut-affil-num=1
ORCID=

en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=千堂年昭
kn-aut-sei=千堂
kn-aut-mei=年昭
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学病院　薬剤部

affil-num=2
en-affil=
kn-affil=岡山大学病院　薬剤部
END

start-ver=1.4
cd-journal=joma
no-vol=125
cd-vols=
no-issue=1
article-no=
start-page=69
end-page=71
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Guidelines for the treatment of Parkinson’s disease
kn-title=パーキンソン病の治療ガイドライン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KurataTomoko
en-aut-sei=Kurata
en-aut-mei=Tomoko
kn-aut-name=倉田智子
kn-aut-sei=倉田
kn-aut-mei=智子
aut-affil-num=1
ORCID=

en-aut-name=AbeKoji
en-aut-sei=Abe
en-aut-mei=Koji
kn-aut-name=阿部康二
kn-aut-sei=阿部
kn-aut-mei=康二
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学病院　神経内科

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　脳神経内科学
END

start-ver=1.4
cd-journal=joma
no-vol=125
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=12
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Telomerase-specific virotherapy targeting lymph node micrometastasis of human cancer
kn-title=癌微小リンパ節転移を標的とするテロメラーゼ特異的制限増殖型ウイルス製剤の開発
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KojimaToru
en-aut-sei=Kojima
en-aut-mei=Toru
kn-aut-name=児島亨
kn-aut-sei=児島
kn-aut-mei=亨
aut-affil-num=1
ORCID=

en-aut-name=WatanabeYuichi
en-aut-sei=Watanabe
en-aut-mei=Yuichi
kn-aut-name=渡邉雄一
kn-aut-sei=渡邉
kn-aut-mei=雄一
aut-affil-num=2
ORCID=

en-aut-name=HashimotoYuuri
en-aut-sei=Hashimoto
en-aut-mei=Yuuri
kn-aut-name=橋本悠里
kn-aut-sei=橋本
kn-aut-mei=悠里
aut-affil-num=3
ORCID=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=黒田新士
kn-aut-sei=黒田
kn-aut-mei=新士
aut-affil-num=4
ORCID=

en-aut-name=YamasakiYasumoto
en-aut-sei=Yamasaki
en-aut-mei=Yasumoto
kn-aut-name=山崎泰源
kn-aut-sei=山崎
kn-aut-mei=泰源
aut-affil-num=5
ORCID=

en-aut-name=YanoShuya
en-aut-sei=Yano
en-aut-mei=Shuya
kn-aut-name=矢野修也
kn-aut-sei=矢野
kn-aut-mei=修也
aut-affil-num=6
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=田澤大
kn-aut-sei=田澤
kn-aut-mei=大
aut-affil-num=7
ORCID=

en-aut-name=UnoFutoshi
en-aut-sei=Uno
en-aut-mei=Futoshi
kn-aut-name=宇野太
kn-aut-sei=宇野
kn-aut-mei=太
aut-affil-num=8
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=香川俊輔
kn-aut-sei=香川
kn-aut-mei=俊輔
aut-affil-num=9
ORCID=

en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=田中紀章
kn-aut-sei=田中
kn-aut-mei=紀章
aut-affil-num=10
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=浦田泰生
kn-aut-sei=浦田
kn-aut-mei=泰生
aut-affil-num=11
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=藤原俊義
kn-aut-sei=藤原
kn-aut-mei=俊義
aut-affil-num=12
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=2
en-affil=
kn-affil=オンコリスバイオファーマ

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=11
en-affil=
kn-affil=オンコリスバイオファーマ

affil-num=12
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学
en-keyword=telomerase
kn-keyword=telomerase
en-keyword=oncolytic adenovirus
kn-keyword=oncolytic adenovirus
en-keyword=lymph node metastasis
kn-keyword=lymph node metastasis
en-keyword=orthotopic colorectal cancer model
kn-keyword=orthotopic colorectal cancer model
en-keyword=<i>Alu</i> sequence
kn-keyword=<i>Alu</i> sequence
END

start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=3
article-no=
start-page=231
end-page=238
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=20121203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=HuH-7 cell line established from a highly differentiated human hepatocellular carcinoma
kn-title=高分化型ヒト肝癌由来細胞株“HuH-7”
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=高分化型ヒト肝癌由来細胞株“HuH-7”は，1982年にCancer Researchにその樹立を報告した．HuH-7は，当時の岡山大学医学部附属癌源研究施設病理部門（故佐藤二郎教授）の下で樹立し，これまで多くの研究分野で利用され，世界的に有名な肝癌細胞株となっている．本稿では，有用性の高い分化機能を有するヒト肝癌細胞株HuH-7について，肝細胞癌の腫瘍マーカーであるα-fetoprotein（AFP）を中心に，この細胞株を用いた研究分野に関する詳細を紹介する．
en-copyright=
kn-copyright=

en-aut-name=NakabayashiHidekazu
en-aut-sei=Nakabayashi
en-aut-mei=Hidekazu
kn-aut-name=中林秀和
kn-aut-sei=中林
kn-aut-mei=秀和
aut-affil-num=1
ORCID=

en-aut-name=TaketaKazuhisa
en-aut-sei=Taketa
en-aut-mei=Kazuhisa
kn-aut-name=武田和久
kn-aut-sei=武田
kn-aut-mei=和久
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=北海道情報大学　医療情報学科

affil-num=2
en-affil=
kn-affil=介護老人保健施設　仁和の里
en-keyword=肝細胞癌
kn-keyword=肝細胞癌
en-keyword=培養細胞
kn-keyword=培養細胞
en-keyword=α-フェトプロテイン
kn-keyword=α-フェトプロテイン
en-keyword=HuH-7
kn-keyword=HuH-7
END

start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=2
article-no=
start-page=137
end-page=143
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=20120801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Study for the structures of the HA complexes produced by Clostridium botulinum type A mutant strain
kn-title=ボツリヌスＡ型菌変異株が産生するHA複合体の構造に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Clostridium botulinum produces seven neurotoxin (NTX) serotypes, classified from as A to G. In culture, NTX forms protein complexes by association with non-toxic components, such as nontoxic-nonhemagglutinin (NTNH) and hemagglutinins (HA1, HA2, HA3). C. botulinum serotype A produces three types of toxin complexes, M-toxin (NTX and NTNH), L-toxin (M-toxin and HAs) and LL-toxin (dimer of L-toxin). In this study, I found three HA complexes in the culture of a nontoxigenic mutant serotype A lacking ntx and ntnh expression. The HA complexes displayed similar banding patterns on SDS-PAGE, but the staining intensities of the HA1 and HA2 bands were different. In addition, their native-PAGE banding profiles exhibited different behaviors. The large-molecular-size HA complex showed the highest activity, similar to that of an L-toxin. Based on the combined results of the PAGE and gel-filtration profiles, the differences in molecular size among the three HA complexes were thought to be caused by different numbers of HA1 and HA2 molecules. This paper reports for the first time the purification and characterization of a native HA complex of serotype A, and suggests that the HA can form complex structures without NTX and NTNH. This may help in understanding the toxin complex assembly pathway.
en-copyright=
kn-copyright=

en-aut-name=MaShaobo
en-aut-sei=Ma
en-aut-mei=Shaobo
kn-aut-name=馬少博
kn-aut-sei=馬
kn-aut-mei=少博
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　病原細菌学
en-keyword=ボツリヌス毒素（botulinum toxin）
kn-keyword=ボツリヌス毒素（botulinum toxin）
en-keyword=ボツリヌス菌（Clostridium botulinum）
kn-keyword=ボツリヌス菌（Clostridium botulinum）
en-keyword=血球凝集素（hemagglutinin）
kn-keyword=血球凝集素（hemagglutinin）
en-keyword=タンパク質複合体構造（protein complex structure）
kn-keyword=タンパク質複合体構造（protein complex structure）
END

start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=3
article-no=
start-page=187
end-page=192
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20070104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=原発性肺高血圧症の進行メカニズムの解明と治療薬の開発
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=小川愛子
kn-aut-sei=小川
kn-aut-mei=愛子
aut-affil-num=1
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=中村一文
kn-aut-sei=中村
kn-aut-mei=一文
aut-affil-num=2
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=松原広己
kn-aut-sei=松原
kn-aut-mei=広己
aut-affil-num=3
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=藤尾栄起
kn-aut-sei=藤尾
kn-aut-mei=栄起
aut-affil-num=4
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=池田哲也
kn-aut-sei=池田
kn-aut-mei=哲也
aut-affil-num=5
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=宮地克維
kn-aut-sei=宮地
kn-aut-mei=克維
aut-affil-num=6
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=三浦大志
kn-aut-sei=三浦
kn-aut-mei=大志
aut-affil-num=7
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=三浦綾
kn-aut-sei=三浦
kn-aut-mei=綾
aut-affil-num=8
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=永瀬聡
kn-aut-sei=永瀬
kn-aut-mei=聡
aut-affil-num=9
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=草野研吾
kn-aut-sei=草野
kn-aut-mei=研吾
aut-affil-num=10
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=伊達洋至
kn-aut-sei=伊達
kn-aut-mei=洋至
aut-affil-num=11
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=大江透
kn-aut-sei=大江
kn-aut-mei=透
aut-affil-num=12
ORCID=

affil-num=1
en-affil=
kn-affil=University of California, San Diego, Division of Pulmonary and Critical Care Medicine

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=3
en-affil=
kn-affil=国立病院機構岡山医療センター循環器科

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=6
en-affil=
kn-affil=国立病院機構岡山医療センター循環器科

affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科

affil-num=11
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科腫瘍・胸部外科

affil-num=12
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科循環器内科
en-keyword=原発性肺高血圧症
kn-keyword=原発性肺高血圧症
en-keyword=平滑筋細胞
kn-keyword=平滑筋細胞
en-keyword=prednisolone
kn-keyword=prednisolone
en-keyword=細胞周期
kn-keyword=細胞周期
END

start-ver=1.4
cd-journal=joma
no-vol=123
cd-vols=
no-issue=3
article-no=
start-page=227
end-page=230
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2011
dt-pub=20111201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Treatment and care of intractable neurological diseases
kn-title=神経内科領域の難治性疾患診療
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IkedaYoshio
en-aut-sei=Ikeda
en-aut-mei=Yoshio
kn-aut-name=池田佳生
kn-aut-sei=池田
kn-aut-mei=佳生
aut-affil-num=1
ORCID=

en-aut-name=AbeKoji
en-aut-sei=Abe
en-aut-mei=Koji
kn-aut-name=阿部康二
kn-aut-sei=阿部
kn-aut-mei=康二
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　脳神経内科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　脳神経内科学
en-keyword=神経難病
kn-keyword=神経難病
en-keyword=アルツハイマー病
kn-keyword=アルツハイマー病
en-keyword=パーキンソン病関連疾患
kn-keyword=パーキンソン病関連疾患
en-keyword=脊髄小脳変性症・多系統萎縮症
kn-keyword=脊髄小脳変性症・多系統萎縮症
en-keyword=筋萎縮性側索硬化症
kn-keyword=筋萎縮性側索硬化症
END

start-ver=1.4
cd-journal=joma
no-vol=123
cd-vols=
no-issue=3
article-no=
start-page=197
end-page=206
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2011
dt-pub=20111201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A new paradigm for the treatment of lifestyle-related diseases : Microinflammation as a novel therapeutic target
kn-title=生活習慣病治療のパラダイムシフト―慢性炎症を標的とした治療戦略―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ShikataKenichi
en-aut-sei=Shikata
en-aut-mei=Kenichi
kn-aut-name=四方賢一
kn-aut-sei=四方
kn-aut-mei=賢一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学病院　新医療研究開発センター
en-keyword=生活習慣病
kn-keyword=生活習慣病
en-keyword=メタボリック症候群
kn-keyword=メタボリック症候群
en-keyword=糖尿病
kn-keyword=糖尿病
en-keyword=炎症
kn-keyword=炎症
en-keyword=心血管疾患
kn-keyword=心血管疾患
END

start-ver=1.4
cd-journal=joma
no-vol=123
cd-vols=
no-issue=2
article-no=
start-page=103
end-page=109
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2011
dt-pub=20110801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Radiosensitization by telomerase-dependent oncolytic adenovirus
kn-title=テロメラーゼ依存的腫瘍融解アデノウイルス製剤による 放射線感受性増強作用
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=DNA修復機能阻害は放射線感受性を増強させるため，DNA修復に関与する因子の阻害剤は放射線増感剤となり得る．我々の開発したテロメラーゼ依存的腫瘍融解アデノウイルス製剤OBP-301（テロメライシン）は，アデノウイルスE1B55kDaタンパクを介して細胞のDNA修復に重要な役割を果たすMRN複合体（Mre11，Rad50，NBS1）を分解する機能を有する．このMRN複合体の分解によりATM（ataxia-telangiectasia mutated）の活性化が抑制され結果的にDNA修復機構が阻害される．我々はOBP-301と放射線との併用が強力な相乗効果を生み出すことをマウスの皮下腫瘍モデルおよび食道癌同所性モデルにおいて証明した．これらの結果はOBP-301が将来有望な放射線増感剤となり得ることだけでなく，E1B55kDaタンパクを産生する腫瘍融解アデノウイルス製剤と放射線との併用が悪性腫瘍に対する有力な治療戦略となり得ることを示す．
en-copyright=
kn-copyright=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=黒田新士
kn-aut-sei=黒田
kn-aut-mei=新士
aut-affil-num=1
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=藤原俊哉
kn-aut-sei=藤原
kn-aut-mei=俊哉
aut-affil-num=2
ORCID=

en-aut-name=ShirakawaYasuhiro
en-aut-sei=Shirakawa
en-aut-mei=Yasuhiro
kn-aut-name=白川靖博
kn-aut-sei=白川
kn-aut-mei=靖博
aut-affil-num=3
ORCID=

en-aut-name=YamasakiYasumoto
en-aut-sei=Yamasaki
en-aut-mei=Yasumoto
kn-aut-name=山崎泰源
kn-aut-sei=山崎
kn-aut-mei=泰源
aut-affil-num=4
ORCID=

en-aut-name=YanoSyuya
en-aut-sei=Yano
en-aut-mei=Syuya
kn-aut-name=矢野修也
kn-aut-sei=矢野
kn-aut-mei=修也
aut-affil-num=5
ORCID=

en-aut-name=UnoFutoshi
en-aut-sei=Uno
en-aut-mei=Futoshi
kn-aut-name=宇野太
kn-aut-sei=宇野
kn-aut-mei=太
aut-affil-num=6
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=田澤大
kn-aut-sei=田澤
kn-aut-mei=大
aut-affil-num=7
ORCID=

en-aut-name=HashimotoYuuri
en-aut-sei=Hashimoto
en-aut-mei=Yuuri
kn-aut-name=橋本悠里
kn-aut-sei=橋本
kn-aut-mei=悠里
aut-affil-num=8
ORCID=

en-aut-name=WatanabeYuichi
en-aut-sei=Watanabe
en-aut-mei=Yuichi
kn-aut-name=渡辺雄一
kn-aut-sei=渡辺
kn-aut-mei=雄一
aut-affil-num=9
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=野間和広
kn-aut-sei=野間
kn-aut-mei=和広
aut-affil-num=10
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=浦田泰生
kn-aut-sei=浦田
kn-aut-mei=泰生
aut-affil-num=11
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=香川俊輔
kn-aut-sei=香川
kn-aut-mei=俊輔
aut-affil-num=12
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=藤原俊義
kn-aut-sei=藤原
kn-aut-mei=俊義
aut-affil-num=13
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=7
en-affil=
kn-affil=岡山大学病院　遺伝子・細胞治療センター

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=11
en-affil=
kn-affil=オンコリスバイオファーマ株式会社

affil-num=12
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学

affil-num=13
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器外科学
en-keyword=アデノウイルス
kn-keyword=アデノウイルス
en-keyword=E1B55kDa
kn-keyword=E1B55kDa
en-keyword=MRN複合体
kn-keyword=MRN複合体
en-keyword=DNA修復
kn-keyword=DNA修復
en-keyword=放射線感受性
kn-keyword=放射線感受性
END

start-ver=1.4
cd-journal=joma
no-vol=71
cd-vols=
no-issue=12-1
article-no=
start-page=7879
end-page=7890
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1959
dt-pub=19591120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Electrocardiographic Study on Coronary Perfusion for Direct Vision Aortic Surgery Part I. Coronary Perfusion Under Selective Brain Cooling
kn-title=大動脈起始部直視下手術における冠灌流の心電図学的研究 第1編 選択的脳灌流冷却法下冠灌流における心電図学的考察
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Both retrograde perfusion via the coronary sinus and direct perfusion of the coronary artery during circulatory occlusion under selective brain cooling were studied and evaluated from the electrocardiographic standpoint. The following results were obtained. 1) Hypothermia is not applicable for this type of experiment because irritability of myocardium is increased by hypothermia resulting ventricular fibrillation. 2) Direct perfusion is more physiologic than retrograde perfusion and circulatory cessation is maintained over 50 minutes without deleterious effect to myocardium compared to only 15 minutes available in the latter method. 3) Perfusion pressure not exceeding 35 mm Hg. in retrograde perfusion and below 120 mm Hg. in direct perfusion are optimal to obviate mycardial damage which is manifested as ST-T deviation in electrecardiogram. It is safe to keep temperature of perfusion blood between 36 and 37°C. Blood containing over 7.2 gl/dl Hb is applicable for perfusion if oxygenation is satisfactorily attained.
en-copyright=
kn-copyright=

en-aut-name=IkedaJushin
en-aut-sei=Ikeda
en-aut-mei=Jushin
kn-aut-name=池田寿真
kn-aut-sei=池田
kn-aut-mei=寿真
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第2外科教室
END

start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=3
article-no=
start-page=209
end-page=213
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20101201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Development of innovative therapies for gastrointestinal cancer
kn-title=消化器がん治療における先端医療開発
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=藤原俊義
kn-aut-sei=藤原
kn-aut-mei=俊義
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学
en-keyword=消化器がん
kn-keyword=消化器がん
en-keyword=テロメラーゼ
kn-keyword=テロメラーゼ
en-keyword=アデノウイルス
kn-keyword=アデノウイルス
en-keyword=外科ナビゲーション
kn-keyword=外科ナビゲーション
END

start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=3
article-no=
start-page=203
end-page=208
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20101201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Development of novel detecting systems and therapies for micro cancer using replication-competent oncolytic adenovirus
kn-title=制限増殖型アデノウイルス製剤を用いた新たな微小がん病変の検出法の開発と治療への応用
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KojimaToru
en-aut-sei=Kojima
en-aut-mei=Toru
kn-aut-name=児島亨
kn-aut-sei=児島
kn-aut-mei=亨
aut-affil-num=1
ORCID=

en-aut-name=HashimotoYuuri
en-aut-sei=Hashimoto
en-aut-mei=Yuuri
kn-aut-name=橋本悠里
kn-aut-sei=橋本
kn-aut-mei=悠里
aut-affil-num=2
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=香川俊輔
kn-aut-sei=香川
kn-aut-mei=俊輔
aut-affil-num=3
ORCID=

en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=田中紀章
kn-aut-sei=田中
kn-aut-mei=紀章
aut-affil-num=4
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=浦田泰生
kn-aut-sei=浦田
kn-aut-mei=泰生
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=藤原俊義
kn-aut-sei=藤原
kn-aut-mei=俊義
aut-affil-num=6
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学

affil-num=5
en-affil=
kn-affil=オンコリスバイオファーマ

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・腫瘍外科学
en-keyword=telomerase
kn-keyword=telomerase
en-keyword=oncolytic adenovirus
kn-keyword=oncolytic adenovirus
en-keyword=GFP
kn-keyword=GFP
en-keyword=micrometastasis
kn-keyword=micrometastasis
en-keyword=circulating tumor cell
kn-keyword=circulating tumor cell
END

start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=2
article-no=
start-page=95
end-page=99
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20100802
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=TGF-β-Smad3 pathway activates Sox9-dependent chondrogenesis
kn-title=TGF-β-Smad3経路と転写因子Sox9による軟骨細胞分化調節
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FurumatsuTakayuki
en-aut-sei=Furumatsu
en-aut-mei=Takayuki
kn-aut-name=古松毅之
kn-aut-sei=古松
kn-aut-mei=毅之
aut-affil-num=1
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=尾﨑敏文
kn-aut-sei=尾﨑
kn-aut-mei=敏文
aut-affil-num=2
ORCID=

en-aut-name=AsaharaHiroshi
en-aut-sei=Asahara
en-aut-mei=Hiroshi
kn-aut-name=浅原弘嗣
kn-aut-sei=浅原
kn-aut-mei=弘嗣
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　整形外科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　整形外科学

affil-num=3
en-affil=
kn-affil=スクリプス研究所　分子実験医学
en-keyword=chondrogenesis
kn-keyword=chondrogenesis
en-keyword=epigenetic regulation
kn-keyword=epigenetic regulation
en-keyword=Smad3
kn-keyword=Smad3
en-keyword=Sox9
kn-keyword=Sox9
en-keyword=TGF-β
kn-keyword=TGF-β
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=2
article-no=
start-page=169
end-page=179
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1934
dt-pub=193409
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Uber den Einfluβ der Schilddruse und der Epithelkorperchen auf den Golgischen Apparat in den Epithelzellen der Magenschleimhaut.
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=<p>&lt;P&gt;1) Der Golgische Apparat in den Epithelzellen der Magenschleimhaut. In den parathyreoidektomierten Tieren zeigt der Apparat eine deutliche Veranderung. Der Apparat erweist sich namlich dicht uber dem Kerne als ein kleines Knauel, das aus dicht verwickelten feinen Faden besteht. Im Laufe der Zeit werden diese Faden immer dunner und die Maschen des Netzes werden immer etwas gro&#946;er, der ganze Apparat zerfallt schlie&#946;lich in kurze Stabchen, und sogar noch weiter in feine Kornchen. Derartige Kornchen finden sich im allgemeinen uber dem Kerne, obwohl sie nicht selten auch an der Zellbasis vorhanden sind. Dann nehmen die Kornchen an Zahl mehr oder weniger ab, um endlich fast ganzlich zu verschwinden. 2) Der Golgische Apparat der Hauptzellen. Nach Parathyreoidektomie zeigt er auch hier eine deutliche Veranderung, die zuerst an der dem Drusenhalsteil benechbarten Stellen beginnend, allmahlich in die Zellen der Drusenbasis ubergeht. Der Apparat bildet namlich im peripheren Abschnitte des Zelleibes, und zwar dicht neben dem Kern, ein Netzwerk, dessen Faden im Verlauf der Zeit immer dunner werden, um spater in kurze Stabchen und schlie&#946;lich in Kornchen zu zerfallen. 3) Der Apparat in den Belegzellen la&#946;t sich nachweisen.&lt;/P&gt; </p>

en-copyright=
kn-copyright=

en-aut-name=IkedaMasao
en-aut-sei=Ikeda
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama University
END

start-ver=1.4
cd-journal=joma
no-vol=1
cd-vols=
no-issue=1
article-no=
start-page=57
end-page=96
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1928
dt-pub=192812
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Uber die Veranderung der Schmidt-Lantermannschen Einkerbungen beim Regenerations-und Degenerations-Prozess der Nerven
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IkedaT.
en-aut-sei=Ikeda
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama University
END

start-ver=1.4
cd-journal=joma
no-vol=38
cd-vols=
no-issue=4
article-no=
start-page=341
end-page=347
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1984
dt-pub=198408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Partial purification of Simian virus 40 large T antigen by immunoaffinity chromatography and its detection by enzyme-linked immunosorbent assay.
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=<p>Simian virus 40 (SV40) large T antigen was partially purified from small amounts of SV40-infected and SV40-transformed cells by immunoaffinity chromatography with high recovery. T antigen, in both crude and partially purified states, was detected rapidly by a sensitive and quantitative enzyme-linked immunosorbent assay (ELISA). Stability of the partially purified T antigen was found to increase by addition of 0.01% bovine serum albumin (BSA).</p>

en-copyright=
kn-copyright=

en-aut-name=IkedaShogo
en-aut-sei=Ikeda
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HatsushikaMasao
en-aut-sei=Hatsushika
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShigeharaTsuguya
en-aut-sei=Shigehara
en-aut-mei=Tsuguya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeSekiko
en-aut-sei=Watanabe
en-aut-mei=Sekiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OmuraSachiko
en-aut-sei=Omura
en-aut-mei=Sachiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsutsuiKen
en-aut-sei=Tsutsui
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OdaTakuzo
en-aut-sei=Oda
en-aut-mei=Takuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=Okayama University

affil-num=2
en-affil=
kn-affil=Okayama University

affil-num=3
en-affil=
kn-affil=Okayama University

affil-num=4
en-affil=
kn-affil=Okayama University

affil-num=5
en-affil=
kn-affil=Okayama University

affil-num=6
en-affil=
kn-affil=Okayama University

affil-num=7
en-affil=
kn-affil=Okayama University 
en-keyword=SV40 T antigen
kn-keyword=SV40 T antigen
en-keyword=affinity chromatography
kn-keyword=affinity chromatography
en-keyword=ELISA
kn-keyword=ELISA
END

start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=1
article-no=
start-page=61
end-page=65
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20100401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Treatment strategy for chronic hepatitis B and C based on the guidelines
kn-title=ガイドラインに基づいたＢ型・Ｃ型慢性肝炎の治療方針
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KobashiHaruhiko
en-aut-sei=Kobashi
en-aut-mei=Haruhiko
kn-aut-name=小橋春彦
kn-aut-sei=小橋
kn-aut-mei=春彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　消化器・肝臓内科学
END

start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=16
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20100401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication
kn-title=DNA 損傷センサーATMキナーゼとChk2はＣ型肝炎ウイルスのRNA複製に必要である
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=AriumiYasuo
en-aut-sei=Ariumi
en-aut-mei=Yasuo
kn-aut-name=有海康雄
kn-aut-sei=有海
kn-aut-mei=康雄
aut-affil-num=1
ORCID=

en-aut-name=KurokiMisao
en-aut-sei=Kuroki
en-aut-mei=Misao
kn-aut-name=黒木美沙緒
kn-aut-sei=黒木
kn-aut-mei=美沙緒
aut-affil-num=2
ORCID=

en-aut-name=DansakoHiromichi
en-aut-sei=Dansako
en-aut-mei=Hiromichi
kn-aut-name=團迫浩方
kn-aut-sei=團迫
kn-aut-mei=浩方
aut-affil-num=3
ORCID=

en-aut-name=AbeKenichi
en-aut-sei=Abe
en-aut-mei=Kenichi
kn-aut-name=阿部健一
kn-aut-sei=阿部
kn-aut-mei=健一
aut-affil-num=4
ORCID=

en-aut-name=IkedaMasanori
en-aut-sei=Ikeda
en-aut-mei=Masanori
kn-aut-name=池田正徳
kn-aut-sei=池田
kn-aut-mei=正徳
aut-affil-num=5
ORCID=

en-aut-name=WakitaTakaji
en-aut-sei=Wakita
en-aut-mei=Takaji
kn-aut-name=脇田隆字
kn-aut-sei=脇田
kn-aut-mei=隆字
aut-affil-num=6
ORCID=

en-aut-name=KatoNobuyuki
en-aut-sei=Kato
en-aut-mei=Nobuyuki
kn-aut-name=加藤宣之
kn-aut-sei=加藤
kn-aut-mei=宣之
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学

affil-num=6
en-affil=
kn-affil=国立感染症研究所　ウイルス第二部

affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　腫瘍ウイルス学
en-keyword=HCV
kn-keyword=HCV
en-keyword=ATM
kn-keyword=ATM
en-keyword=Chk2
kn-keyword=Chk2
en-keyword=宿主因子
kn-keyword=宿主因子
en-keyword=DNA 損傷センサー
kn-keyword=DNA 損傷センサー
END

start-ver=1.4
cd-journal=joma
no-vol=97
cd-vols=
no-issue=5-6
article-no=
start-page=419
end-page=428
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1985
dt-pub=19850630
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Molecular cloning of the SV40 small t antigen gene and purification of the antigen
kn-title=SV40小型腫瘍抗原遺伝子のクローン化と抗原の精製
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The simian virus 40 (SV40) DNA fragment encoding small t antigen was cloned with expression vector pUC8 for the purification of small t-antigen. Small t antigen produced in Escherichia coli was a hybrid protein of 22,000 daltons which comprised about 6% of the total protein. Hybrid small t antigen maintained antigenic activity which was examined by Western-blotting and enzyme-linked immunoassay. Hybrid small t antigen was extracted from E. coli with urea and purified from a small t-antigen band in SDS-polyacrylamide gel. The purified antigen maintained antigenic activity.
en-copyright=
kn-copyright=

en-aut-name=IkedaShogo
en-aut-sei=Ikeda
en-aut-mei=Shogo
kn-aut-name=池田正五
kn-aut-sei=池田
kn-aut-mei=正五
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部癌源研究施設生化学部門
en-keyword=SV40 t 抗原
kn-keyword=SV40 t 抗原
en-keyword=遺伝子のクローン化
kn-keyword=遺伝子のクローン化
en-keyword=発現ベクター
kn-keyword=発現ベクター
en-keyword=ウエスタン・ブロッティング
kn-keyword=ウエスタン・ブロッティング
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=1
article-no=
start-page=33
end-page=39
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1998
dt-pub=19980930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The relation of Ikigai (the meaning of one's life) to one's behavioral pattern and belief, researched through the elderly persons at their discharge from hospital
kn-title=老人の退院時における生きがいと生活行動および生活信条との関連
en-subtitle=
kn-subtitle=
en-abstract=There have been few researches about Ikigai of the elderly at the time of leaving the hospital and about the ways of their home nursing care. The purpose of this study is to clarify the relation of Ikigai to one's behavioral pattern and belief. In three national university hospitals and a general hospital in Chugoku region and Shikoku region, ninety-two patients above the age of 70, ready to discharge, were interviewed and given a questionnaire. The questions were about their body condition, behavioral pattern, and belief, and their Ikigai. More than eighty percent of them seem to lead a life worth living at the time of leaving the hospital. The behavioral pattern scores on the "working as a volunteer" and "growing plants" are on a high level of Ikigai. The belief scores on
the "enjoy every day" is also on a high level of Ikigai. In this paper the result of this interview is reported and a better nursing care for them is discussed.
kn-abstract=退院を控えた老人が,どの程度生きがいを持って退院していくのか,老人自身のどのような生き方が生きがいに影響しているのかについて知るため,それまでの健康状態や,生活信条,生活行動について,退院許可の出た70歳以上の患者92名を対象として,独自の調査用紙に基づき面接調査を行った｡生きが
いとこれまでの健康度,生活信条,生活行動の関連性を,分散分析及びt検定により解析した｡生きがいの平均得点が高かった生活行動は｢ボランティア｣で,続いて｢植物｣であった。生きがいの平均得点が高かった生活信条は｢その日を楽しく生きる｣と回答した人が,回答しなかった人との間に有意差があり,老人の退院時の生きがいの得点が高い傾向を示すことが明らかとなった｡
en-copyright=
kn-copyright=

en-aut-name=WatanabeKumi
en-aut-sei=Watanabe
en-aut-mei=Kumi
kn-aut-name=渡辺久美
kn-aut-sei=渡辺
kn-aut-mei=久美
aut-affil-num=1
ORCID=

en-aut-name=NakanishiYoshiko
en-aut-sei=Nakanishi
en-aut-mei=Yoshiko
kn-aut-name=中西代志子
kn-aut-sei=中西
kn-aut-mei=代志子
aut-affil-num=2
ORCID=

en-aut-name=IkedaToshiko
en-aut-sei=Ikeda
en-aut-mei=Toshiko
kn-aut-name=池田敏子
kn-aut-sei=池田
kn-aut-mei=敏子
aut-affil-num=3
ORCID=

en-aut-name=TakataSetuko
en-aut-sei=Takata
en-aut-mei=Setuko
kn-aut-name=高田節子
kn-aut-sei=高田
kn-aut-mei=節子
aut-affil-num=4
ORCID=

en-aut-name=KondoMasuko
en-aut-sei=Kondo
en-aut-mei=Masuko
kn-aut-name=近藤益子
kn-aut-sei=近藤
kn-aut-mei=益子
aut-affil-num=5
ORCID=

en-aut-name=OhtaNiwa
en-aut-sei=Ohta
en-aut-mei=Niwa
kn-aut-name=太田にわ
kn-aut-sei=太田
kn-aut-mei=にわ
aut-affil-num=6
ORCID=

en-aut-name=InoshitaHikari
en-aut-sei=Inoshita
en-aut-mei=Hikari
kn-aut-name=猪下光
kn-aut-sei=猪下
kn-aut-mei=光
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医療技術短期大学部看護学科

affil-num=2
en-affil=
kn-affil=岡山大学医療技術短期大学部看護学科

affil-num=3
en-affil=
kn-affil=岡山大学医療技術短期大学部看護学科

affil-num=4
en-affil=
kn-affil=広島県立保健福祉短期大学

affil-num=5
en-affil=
kn-affil=岡山大学医療技術短期大学部看護学科

affil-num=6
en-affil=
kn-affil=岡山大学医療技術短期大学部看護学科

affil-num=7
en-affil=
kn-affil=香川医科大学医学部看護学科
en-keyword=老人 (the elderly)
kn-keyword=老人 (the elderly)
en-keyword=生きがい (Ikigai)
kn-keyword=生きがい (Ikigai)
en-keyword=生活信条 (belief)
kn-keyword=生活信条 (belief)
en-keyword=生活行動 (behavioral pattern)
kn-keyword=生活行動 (behavioral pattern)
END

start-ver=1.4
cd-journal=joma
no-vol=121
cd-vols=
no-issue=2
article-no=
start-page=85
end-page=90
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2009
dt-pub=20090803
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=CRTH2 plays an essential role in the pathophysiology of Cry j 1 -induced pollinosis in mice
kn-title=マウススギ花粉症モデルにおける CRTH2の役割
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NomiyaRie
en-aut-sei=Nomiya
en-aut-mei=Rie
kn-aut-name=野宮理恵
kn-aut-sei=野宮
kn-aut-mei=理恵
aut-affil-num=1
ORCID=

en-aut-name=OkanoMitsuhiro
en-aut-sei=Okano
en-aut-mei=Mitsuhiro
kn-aut-name=岡野光博
kn-aut-sei=岡野
kn-aut-mei=光博
aut-affil-num=2
ORCID=

en-aut-name=FujiwaraTazuko
en-aut-sei=Fujiwara
en-aut-mei=Tazuko
kn-aut-name=藤原田鶴子
kn-aut-sei=藤原
kn-aut-mei=田鶴子
aut-affil-num=3
ORCID=

en-aut-name=NishizakiKazunori
en-aut-sei=Nishizaki
en-aut-mei=Kazunori
kn-aut-name=西﨑和則
kn-aut-sei=西﨑
kn-aut-mei=和則
aut-affil-num=4
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　耳鼻咽喉・頭頸部外科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　耳鼻咽喉・頭頸部外科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　耳鼻咽喉・頭頸部外科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　耳鼻咽喉・頭頸部外科学
en-keyword=スギ花粉症
kn-keyword=スギ花粉症
en-keyword=モデルマウス
kn-keyword=モデルマウス
en-keyword=プロスタグランジンD(2)
kn-keyword=プロスタグランジンD(2)
en-keyword=CRTH(2)
kn-keyword=CRTH(2)
END

start-ver=1.4
cd-journal=joma
no-vol=121
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=15
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2009
dt-pub=20090401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Spa therapy as pulmonary rehabilitation for chronic obstructive pulmonary disease
kn-title=慢性閉塞性肺疾患における呼吸リハビリテーションとしての温泉療法
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MitsunobuFumihiro
en-aut-sei=Mitsunobu
en-aut-mei=Fumihiro
kn-aut-name=光延文裕
kn-aut-sei=光延
kn-aut-mei=文裕
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　老年医学
en-keyword=慢性閉塞性肺疾患
kn-keyword=慢性閉塞性肺疾患
en-keyword=呼吸リハビリテーション
kn-keyword=呼吸リハビリテーション
en-keyword=温泉療法
kn-keyword=温泉療法
en-keyword=肺機能
kn-keyword=肺機能
en-keyword=高分解能CT
kn-keyword=高分解能CT
END

start-ver=1.4
cd-journal=joma
no-vol=102
cd-vols=
no-issue=1-2
article-no=
start-page=177
end-page=188
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=199002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Exercise body surface maps in patients with left ventricular hypertrophy : Comparative study with stress thalliun scan (SPECT)
kn-title=左室肥大例における運動負荷QRST isointegral mapと運動負荷(201)Tℓ心筋シンチグラムの対比検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=For evaluating execise-induced myocardial ischemia in patients with ECG finding of left ventricular hypertrophy (LVH) with ST-T change, we recorded the body surface maps (QRST area maps) from 87 lead points before and after exercise and studied the patterns of the subtraction QRST area maps (S-maps) subtracting preexercise from postexercise maps in comparison with the findings of stress thallium (Tl) scans in 35 patients with hyertrophic cardiomyopathy (HCM) and 9 patients with essential hypertension (EH). All 21 patients whose S-maps revealed small changes less than -40μ VS or an increase only on the anterior chest region shoued no signigicant findings in the stress Tl scan. There were clear positive findings on the stress T1 scan in 7 of 8 patients with HCM (88%) whose S-maps revealed negative changes greater than -40μ VS on the wide precordial region and in 6 of 8 patients with HCM (75%) whose S-maps revealed increases on the anterior chest region but also had accompanying negative changes greater than -40μ VS somewhere on the precordial region. These results suggest that exercise QRST area maps may be useful in the identification of exercise-induced myocardial ischemia, especially in patients with HCM whose ECG showed LVH with ST-T changes. However, there were no significant findings on the stress T1 scan in 6 of 7 patients with EH whose S-maps revealed negative changes greater than -40μ VS on the precordial surfacre the same as those of HCM. These results suggest that factors other than exercise-induced myocardial ischemia such as the antonervous system may influence the ST-T cahanges in the EH cases. The specific mechanisms responsible for ischemic changes in patients with LVH (especialy in those with HCM) are not clear, although small vessel disease combined with myocardial hypertrophy or myocardial squeezing may be causative factors.
en-copyright=
kn-copyright=

en-aut-name=HagiharaHidenori
en-aut-sei=Hagihara
en-aut-mei=Hidenori
kn-aut-name=萩原秀紀
kn-aut-sei=萩原
kn-aut-mei=秀紀
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第一内科学教室
en-keyword=体表面電位図
kn-keyword=体表面電位図
en-keyword=左室肥大
kn-keyword=左室肥大
en-keyword=QRST isointegral map運動負荷(201)Tℓ心筋シンチグラム
kn-keyword=QRST isointegral map運動負荷(201)Tℓ心筋シンチグラム
END

start-ver=1.4
cd-journal=joma
no-vol=102
cd-vols=
no-issue=1-2
article-no=
start-page=165
end-page=176
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=199002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Magnetic resonance image database system and its clinical applications
kn-title=MR 画像データベースシステムの開発とその臨床応用に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A magnetic resonance (MR) image detabase system has been developed. The purpose of this paper is to present this system and its application. It consists of an image processing system and database system to handle data of clinical cases and a medical knowledge base. Using the image processing system and the database system with stored data of clinical cases, the MR image data of cases can be retrieved by diagnosis as well as ID number, patient's name, etc., and MR images can be processed. By using the database system with the medical knowledge base, differential diagnoses can be offered.
en-copyright=
kn-copyright=

en-aut-name=NoriyasuToshiaki
en-aut-sei=Noriyasu
en-aut-mei=Toshiaki
kn-aut-name=則安俊昭
kn-aut-sei=則安
kn-aut-mei=俊昭
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部放射線医学教室
en-keyword=MRI
kn-keyword=MRI
en-keyword=database
kn-keyword=database
en-keyword=medical image
kn-keyword=medical image
en-keyword=knowledge base
kn-keyword=knowledge base
en-keyword=PACS
kn-keyword=PACS
END

start-ver=1.4
cd-journal=joma
no-vol=102
cd-vols=
no-issue=1-2
article-no=
start-page=113
end-page=127
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=199002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The fate of toluene and its metabolites in mice organs after ingestion of (14)C-toluene
kn-title=マウスに経口投与した放射性標識トルエンの生体内運命
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Mice ingested (14)C-toluene orally, and the redioactivities of toluene and its metabolites in the blood, organs, urine, feces and exhaled air were determinated using liqid scintillation counter. Toluene absorbed from the digestive tract after 8 hours was caluculated by the ratio of subtracted amounts in digestive organs and feces from ingested toluene to ingested toluene was 98.92% and the ratio of amounts in mice excepting digestive organs, expired air and urine to ingested toluene was 92.09%. The ratio of toluene in expired air to ingested toluene after 8 hours was 31.15%, and of toluene as urinary metabolites was 16.64%. The concentration of toluene in the blood attained its maximum 60 minutes after ingestion and decreased with a half-life of 95 minutes. Concentration of toluene metabolites in the blood attained its maximun 120 minutes after ingestion and decreased with a half-life of 155 minutes. Amount of toluene in the exhaled air attained its maximum 60-75 minutes after ingestion and decreased with a 48 minute half-life. The concentration of toluene in blood and organs 180 minutes after ingestion was, in decreasing order, adipose tissue, kidneys, liver, cerebrum, and blood and concentration of toluene metabolites was, in decreasing order, kidneys, liver, blood, cerebrum and adipose tissue. Metabolites in blood and kidneys were identified as benzoic acid and hippuric acid, respectively. The metabolites in the liver was solely benzoic acid.
en-copyright=
kn-copyright=

en-aut-name=FujisawaKuniyasu
en-aut-sei=Fujisawa
en-aut-mei=Kuniyasu
kn-aut-name=藤澤邦康
kn-aut-sei=藤澤
kn-aut-mei=邦康
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部公衆衛生学教室
en-keyword=放射性標識トルエン
kn-keyword=放射性標識トルエン
en-keyword=経口投与
kn-keyword=経口投与
en-keyword=消化管吸収率
kn-keyword=消化管吸収率
en-keyword=トルエン代謝物
kn-keyword=トルエン代謝物
END

start-ver=1.4
cd-journal=joma
no-vol=102
cd-vols=
no-issue=1-2
article-no=
start-page=77
end-page=86
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=199002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Changes of extravascular lung water after hepatic ischemia by Pringle's maneuver Part 2. In regard to the effect of clamping of the superior mesenteric artery or portofemoral vein bypass
kn-title=Pringle 法急性肝流入血行遮断の肺血管外水分量におよぼす影響　第2編　上腸間膜動脈遮断と門脈一体循環シャント造設の効果を中心として
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To elucidate the effect of portal congestion on pulmonary interstitial edema after temporary hepatic ischemia by Pringle's maneuver, extravascular lung water (EVLW) was experimentally measured using a modified double indicator dilution method before and after interruption of the hepatic blood flow follwing clamping of the superior meaenteric artery or portofemoral vein bypass. The following results were obtained. 1) Compred with clamping of the superior mesenteric artery, the portofemoral vein bypass reduced the increase of EVLW after temporay hepatic ischemia by Pringle's maneuver. 2) The increase in EVLW had a tendency to be influenced by the degree of metabolic acidosis and portal congestion. These findngs suggest that the portofemoral vein bypass is more effective in the prolongation of the safe period of temporary hepatic ischemia by Pringle's maneuver than clamping of the superior mesenteric artery.
en-copyright=
kn-copyright=

en-aut-name=YokoyamaNobuji
en-aut-sei=Yokoyama
en-aut-mei=Nobuji
kn-aut-name=横山伸二
kn-aut-sei=横山
kn-aut-mei=伸二
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二外科学教室
en-keyword=Pringle 法急性肝流入血行遮断
kn-keyword=Pringle 法急性肝流入血行遮断
en-keyword=肺血管外水分量
kn-keyword=肺血管外水分量
en-keyword=上腸間膜動脈遮断
kn-keyword=上腸間膜動脈遮断
en-keyword=門脈一体循環シャント
kn-keyword=門脈一体循環シャント
END

start-ver=1.4
cd-journal=joma
no-vol=102
cd-vols=
no-issue=1-2
article-no=
start-page=63
end-page=76
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=199002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Changes of extravascular lung water after hepatic ischemia by Pringle's maneuver Part 1. In regard to the increase of the extravascular lunh water and its cause
kn-title=Pringle 法急性肝流入血行遮断の肺血管外水分量におよぼす影響　第1編　肺血管外水分量の増加とその成因を中心として
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To elucidate the effect of total hepatic ischemia on pulmonary organs, extravascular lung water (EVLW) was experimentally measured using a modified double indicator dilution method before and after interruption of the hepatic blood flow using Pringle's maneuver. The follow-ing results were obtained : 1) EVLW was significantlly increased more than one hour after temporary total hepatic ischemia. 2) Temporary hypotension resulted in little increase of EVLW by removing and replacing some blood volume through the femoral artery. 3) Pumonary interstitial edema was histologically and maroscopically observed in the Pringle's maneuver group. 4) Marked metabolic acidosis and elevation of serum transaminase were revealed after temporary hepatic ischemia. These findings auggest that pulmonary interstitial edema may result from sfter temporary total hepatic ischemia by Pringle's maneuver and the changes of EVLW are caused by increased permeability due to liver injury, metabolic acidosis and portal congestion.
en-copyright=
kn-copyright=

en-aut-name=YokoyamaNobuji
en-aut-sei=Yokoyama
en-aut-mei=Nobuji
kn-aut-name=横山伸二
kn-aut-sei=横山
kn-aut-mei=伸二
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二外科学教室
en-keyword=Pringle 法急性肝流入血行遮断
kn-keyword=Pringle 法急性肝流入血行遮断
en-keyword=肺血管外水分量
kn-keyword=肺血管外水分量
END

start-ver=1.4
cd-journal=joma
no-vol=103
cd-vols=
no-issue=4
article-no=
start-page=293
end-page=303
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=1991
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The level of lipid peroxide and the effect of human superoxide dismutase on cardiac ischemia/reperfusion injury
kn-title=心筋虚血・再灌流障害における過酸化脂質の動態と h-SOD 投与効果
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To clarify the role of free radicals and the efficacy of human superoxide dismutase (h-SOD) on cardiac ischemia/reperfusion injury, adult mongrel dogs were placed on a cardiopulmonary bypass (CPB). Aorta was cross clamped for 120 minutes and crystalloid cardioplegic solution was administered into the aortic root every 30 minutes. Sixteen dogs were divided into the control group and non cross clamped group (XCL(-)group). They were placed on total CPB for 130 minutes without an aortic cross clamp.
The control group showed higher thiobarbituric acid reactive substance (TBARS) release from heart in early reperfusion phase (P<0.05), and suppressed recovery of cardiac index (CI) and max dp/dt at 60 minutes after reperfusion (P<0.01 and P<0.05, respectively) than XCL (-) group. Eight dogs were administered saline and 32 dogs were administered saline and h-SOD into the aortic root just before reperfusion. Dogs, administered h-SOD, were devided into four groups by the dese of h-SOD, group I : 1mg/kg, group II : 3mg/kg, group III : 10mg/kg, and group IV : 20mg/kg. Between control and saline groups, no significant difference was found. Groups I and II showed suppressed TBARS release from the heart in the early reperfusion phase than the control group (P<0.01 and P<0.05, respectively). Groups II and III showed higher recovery of CI at 60 minutes after reperfusion than the control group (P<0.01 and P<0.05, respectively). In conclusion, significantly higher TBARS was released from the heart and recovery of cardiac function was suppressed in cardiac ischemia/reperfusion injury. The h-SOD administtation was effective to protect the heart from cardiac ischemia/reperfusion injury.
en-copyright=
kn-copyright=

en-aut-name=IkedaEiji
en-aut-sei=Ikeda
en-aut-mei=Eiji
kn-aut-name=池田英二
kn-aut-sei=池田
kn-aut-mei=英二
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二外科学教室
en-keyword=体外循環
kn-keyword=体外循環
en-keyword=心筋保護
kn-keyword=心筋保護
en-keyword=再灌流障害
kn-keyword=再灌流障害
en-keyword=TBA
kn-keyword=TBA
en-keyword=h-SOD
kn-keyword=h-SOD
END

start-ver=1.4
cd-journal=joma
no-vol=103
cd-vols=
no-issue=1-2
article-no=
start-page=209
end-page=221
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=1991
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Toxicokinetic study of several organic solvents
kn-title=有機溶剤の動態について
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Toxicokinetic study on organic solvents was carried out using the data obtained by controlled exposure experiments. Organic solvents used in the present study were chlorobenzene, toluene, m-xylene and trichloroethylene. Molar ratio urinary metabolites to organic solvents inhaled was different among solvents and was between 7.7% and 70.8%. The relationship between the amount of exposed toluene and the amount of hippuric acid was linear. However, for m-xylene, the amount of its urinary metabolites was not so much in comparison with the amount of exposed solvent at higher level exposure of 1400ppm × hour. Simulation of the excretion curves of urinary metabolites after cessation of exposure to organic solvents was fit for the two-compartment exponential model. Using the parameters of one compartment model of the single exposure to these organic solvents, the estimated metabolite level curve obtained by repeated exposures could be drawn, and relationship between biological half lives and critical sampling time was discussed. In respect to the urinary metabolites, the excretion rate of metabolites in the urine collected at the end of exposure depended on the period of time from the last urination to the end of exposure.
en-copyright=
kn-copyright=

en-aut-name=YunokiEmiko
en-aut-sei=Yunoki
en-aut-mei=Emiko
kn-aut-name=柚木恵美子
kn-aut-sei=柚木
kn-aut-mei=恵美子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部公衆衛生学講座
en-keyword=有機溶剤
kn-keyword=有機溶剤
en-keyword=尿中代謝産物
kn-keyword=尿中代謝産物
en-keyword=生物学的モニタリング
kn-keyword=生物学的モニタリング
en-keyword=生物学的半減期
kn-keyword=生物学的半減期
en-keyword=反復暴露
kn-keyword=反復暴露
END

start-ver=1.4
cd-journal=joma
no-vol=103
cd-vols=
no-issue=1-2
article-no=
start-page=183
end-page=197
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=1991
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Experimental study on pathogenesis and treatment of cerebral vasospasm Part 2. Effects of PGI2 analogue, thromboxane A2 synthetase inhibitor and Ca blocker on experimental delayed spasm models
kn-title=脳血管攣縮の発生機序と治療に関する実験的研究 第2編 実験的遅発性脳血管攣縮に対する PGI2 analogue, Thromboxane A2 合成酵素阻害剤, Ca 拮抗剤の効果
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The effects of a PGI2 analogue (OP-41483), a thromboxane A2 synthetase inhibitor (OKY-046) and a Ca blocker (nifedipine) on the diameter of constricted basilar arteries and on the regional cerebral blood flow (r-CBF) in the brain stem were investigated in the cat delayed spasm model. The experiment was performed three days (72 hours) after artificial subarachnoid hemorrhage. The basilar artery was exposed transclivally, and more advanced vasospasm was produced by topical application of a lysed erythrocyte solution for 5 to 6 hours which domonstrated no more vascular dilatation even by topical application of papaverine hydrochloride (0.01mg/ml). In the delayed spasm model, the intravenous administration of neither OP-41483 (8μg/kg), OKY-046 (60mg/kg) nor nifedipine (0.003mg/kg) affected the vascular diameter. OP-41483 increased r-CBF in the brain stem in 3, and nifedipine increased it in 4 out of the 5 studied delayed spasm models, whereas OKY-046 never increased r-CBF (n=5). There was no significant difference in the amount of fatty acids including arachidonic acid between normal and constricted arteries. This study suggested that thromboxane A2 is not the major factor of cerebral vasospasm and OKY-046 might not be effective on vascular diameter or r-CBF at the late spasm stage. However, the PGI2 analogue (OP-41483) and Ca blocker (nifedipine) may be effective in increasing r-CBF even at the late spasm stage.
en-copyright=
kn-copyright=

en-aut-name=MotokiMototsugu
en-aut-sei=Motoki
en-aut-mei=Mototsugu
kn-aut-name=元木基嗣
kn-aut-sei=元木
kn-aut-mei=基嗣
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部脳神経外科教室
en-keyword=cerebral vasospasm
kn-keyword=cerebral vasospasm
en-keyword=thromboxane A2
kn-keyword=thromboxane A2
en-keyword=OP-41483
kn-keyword=OP-41483
en-keyword=OKY-046
kn-keyword=OKY-046
en-keyword=nifedipine
kn-keyword=nifedipine
END

start-ver=1.4
cd-journal=joma
no-vol=103
cd-vols=
no-issue=1-2
article-no=
start-page=41
end-page=51
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=1991
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Experimental studies on the effects of plasma protein and nitrous oxide on sevoflurane minimum alveolar concentration (MAC) in dogs
kn-title=セボフルレン麻酔の Minimum Alveolar Concentration (MAC) に及ぼす血漿蛋白と笑気の影響に関する実験的研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The effects of plasma protein concentration (TP) on sevoflurane plasma protein/gas partition coefficient and of hematocrit values (Ht) on sevoflurane red cell/gas partition coefficient were examined in dogs. Furthermore, the effects of TP and inhalated nitrous oxide on sevoflurane MAC and sevoflurane concentration in blood at 1 MAC were studied in dogs during sevoflurane anesthesia. Snginificantly posotive correlations were noted in vitro between TP and plasma/gas partition coefficient, and between Ht and red cell/gas partition coefficient. However, the change in blood/gas partition coefficient appeared to be affected by TP. Sevoflurane MAC and seveflurane concentration in blood at 1 MAC rose in positive correlation with the rise of TP with or without nitrous oxide in combination, but there was no correlation with Ht. This seemed to be related to the predominancy of sevoflurane to dissolve into the plasma. The sevoflurane MAC and sevoflurane concentration in blood were significantly lower in the 33% nitrous oxide combined group than those in the oxygen alone group, but there was no significant difference between the 66% nitrous oxide combined group and the 33% nitrous oxide combined group. Furthermore, TP affected the sevoflurane MAC but not the nitrous oxide MAC.
en-copyright=
kn-copyright=

en-aut-name=MaetaMasato
en-aut-sei=Maeta
en-aut-mei=Masato
kn-aut-name=前田正人
kn-aut-sei=前田
kn-aut-mei=正人
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部麻酔・蘇生学教室
en-keyword=セボフルレン
kn-keyword=セボフルレン
en-keyword=血漿蛋白
kn-keyword=血漿蛋白
en-keyword=笑気
kn-keyword=笑気
en-keyword=MAC
kn-keyword=MAC
END

start-ver=1.4
cd-journal=joma
no-vol=105
cd-vols=
no-issue=5-6
article-no=
start-page=419
end-page=426
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1993
dt-pub=1993
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Adrenal secretion of catecholamines by inhalation of radon water in relation to an increase of the tissue perfusion rate in rabbits
kn-title=ラドン水吸入による家兎の副腎髄質カテコラミン分泌作用―組織循環増加作用との関わりについて―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To clarify the relationship between in the increase in subcutaneous tissue perfusion rate (TPR) upon inhalation of radon water and the vasoactive effects of radon, rabbits inhaled nebulized water containing 14,000-18,000 Bq/1 radon (radon group) taken from Ikeda Mineral Spring, Shimane Pref., Japan. Control rabbits inhaled radon water from the same springs which had been kept for over 10 radon half-life periods. TPR was evaluated 15 minutes after the beginning of inhalation by mass spectrometry. After inhalation for 90 minutes, plasma and adrenal glands were removed, and levels of adrenaline and noradrenaline were analyzed by high-performance liquid chromatography (THI mithod). Each group was divided into 4 subgroups according to intravenously injected medication as follows : 1) no medication (without adrenergic blocker), 2) phentolamine (α-blocker), 0.05mg/kg/min, 3) propranolol (non-selective β-blocker), 1mg/kg, and 4) atenolol (selective β1-blocker), 6mg/kg. In the radon group, plasma adrenaline and noradrenaline levels were significantly higher (p<0.01, p<0.05), and adrenaline and noradrenaline levels were significantly lower (p<0.01, P<0.01), than those in the control group. In the no medication and phentolamine subgroups, TPRs in the radon group were significantly higher than those in the control group (p<0.01, P<0.01). In the propranolol and atenolol subgroups, no significant change of TPR was found. It is suggested that catecholamines are secreted from the adrenal glands upon inhalation of radon water and that the β1-action of catecholamines contributes to the increase in tissue perfusion.
en-copyright=
kn-copyright=

en-aut-name=SuzukaIchio
en-aut-sei=Suzuka
en-aut-mei=Ichio
kn-aut-name=鈴鹿伊智雄
kn-aut-sei=鈴鹿
kn-aut-mei=伊智雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部心臓血管外科学教室
en-keyword=ラドン水
kn-keyword=ラドン水
en-keyword=副腎髄質
kn-keyword=副腎髄質
en-keyword=カテコラミン
kn-keyword=カテコラミン
en-keyword=組織循環
kn-keyword=組織循環
en-keyword=ホルミシス
kn-keyword=ホルミシス
END

start-ver=1.4
cd-journal=joma
no-vol=105
cd-vols=
no-issue=3-4
article-no=
start-page=381
end-page=394
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1993
dt-pub=1993
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Prepositus hypoglossi neurons projecting to the posterior vermis of the rat cerebellum
kn-title=ラット小脳虫部後葉に投射する舌下神経前位核ニューロン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Distribution of efferent neurons projecting to the posterior vermal lobules of the rat cerebellum was studied in the prepositus hypoglossi nucleus (PRH) and the nucleus of Roller (R) by retrograde labeling with wheat germ agglutinin-horseradish peroxidase (WGA-HRP). After a single injection of the tracer into each lobule of the anterior (lobule V) and posterior vermis (Lobules VI-IX), medium-sized to small neurons in the caudal half of the PRH and in the R were labeled. An abundance of labeled neurons were found after WGA-HRP infection into either lobule IX or VII, but were less numerous following injection into lobule VIII. Retrograde double labeling with fluorescent dyes showed that a considerable number of neurons in the caudal part of the PRH and in the R sent divergent axons to vermal lobule IX and the parafloccular lobe of the cerebellar hemisphere. Following retrograde neuronal labeling combined with immunohistochemistry, about 70% of the corticotropin releasing factor (CFR)-like immunopositive neurons which clustered in the caudal half of the PRH were found to project their axons to the posterior vermis.
en-copyright=
kn-copyright=

en-aut-name=KuroseKunihiko
en-aut-sei=Kurose
en-aut-mei=Kunihiko
kn-aut-name=黒瀬邦彦
kn-aut-sei=黒瀬
kn-aut-mei=邦彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第三解剖学教室
en-keyword=舌下神経前位核
kn-keyword=舌下神経前位核
en-keyword=小脳虫部
kn-keyword=小脳虫部
en-keyword=逆行性標識法
kn-keyword=逆行性標識法
en-keyword=Corticotropin releasing factor (CRF)
kn-keyword=Corticotropin releasing factor (CRF)
en-keyword=免疫組織化学
kn-keyword=免疫組織化学
END

start-ver=1.4
cd-journal=joma
no-vol=105
cd-vols=
no-issue=3-4
article-no=
start-page=365
end-page=380
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1993
dt-pub=1993
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Distribution of efferent neurons projecting to the superior colliculus and the cerebellar vermal lobule Ⅸ in the spinal and principal sensory trigeminal nuclei of the rat
kn-title=上丘と小脳虫部第Ⅸ小葉に投射するラット三叉神経脊髄路核および主知覚核ニューロン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Distributions of efferent neurons projecting to the superior colliculus (SC) and the posterior vermis of the cerebellum were studied in the rat trigeminal sensory nuclei by retrograde labeling with wheat germ agglutinin-horseradish peroxidase (WGA-HRP). After unilateral injection of the tracer into the SC, small to medium-sized neurons in the principal sensory (5SNPR) and spinal trigeminal nuclei (5SP) were contralaterally labeled. A large number of the labeled neurons were found in the border between the interpolar (5SPip) and the oralis subnucleus (5SPo) of 5SP and in the rostral part of 5SPo. Very few neurons were labeled in the rostral tip of the caudal subnucleus of 5SP (5SPc). Labeled neurons in the 5SNPR and 5SP were detected after WGA-HRP injection into the vermal lobule Ⅸ. The labeled neurons were densely distributed in the dorsomedial region of 5SPip and the caudal 5SPo, but less frequently in 5SNPR. No neurons were labeled in 5SPc. Retrograde double labeling by fluorescent dyes showed that a small number of neurons in the ventral part of 5SNPR sent divergent axons to both lobule Ⅸ and SC.
en-copyright=
kn-copyright=

en-aut-name=TanakaHideaki
en-aut-sei=Tanaka
en-aut-mei=Hideaki
kn-aut-name=田中秀昌
kn-aut-sei=田中
kn-aut-mei=秀昌
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第三解剖学教室
en-keyword=三叉神経脊髄路核
kn-keyword=三叉神経脊髄路核
en-keyword=三叉神経主知覚核
kn-keyword=三叉神経主知覚核
en-keyword=小脳虫部第Ⅸ小葉
kn-keyword=小脳虫部第Ⅸ小葉
en-keyword=上丘
kn-keyword=上丘
en-keyword=逆行性標識
kn-keyword=逆行性標識
END

start-ver=1.4
cd-journal=joma
no-vol=105
cd-vols=
no-issue=3-4
article-no=
start-page=353
end-page=364
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1993
dt-pub=1993
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Studies on the pathogenesis of lung cancer with interstitial pneumonia Part 2. Interleukin-2 receptor in peripheral blood of lung cancer patients
kn-title=肺癌のびまん性肺線維化病態に関する研究　第2編　肺癌における末梢血インターロイキン 2 レセプターの検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Interleukin-2 receptor (IL-2R) and lymphocyte subsets in peripheral blood were evaluated in patients with lung cancer. The level of sluble IL-2R (sIL-2R) in sera and the percentage of IL-2R positive lymphocytes in lung cancer patients were higher than that in normal subjects, but the lymphocytes reactivity to IL-2 was not different from that in normal subjects. There was no difference in the IL-2/IL-2R system of each histological type in patients with lung cancer. The serum sIL-2R level and the percentage of IL-2R positive lymphocytes increased in the advenced stage, but lymphocyte reactivity to IL-2 decreased. There was dissociation between expression of IL-2R and lymphocyte reactivity to IL-2 in lung cancer patients. Furthermore, serum sIL-2R level increased in relation to progression of fibrotic changes in lung cancer with interstitial pneumonia, although the percentage of IL-2R positive lymphocytes did not increase. Serum sIL-2R level showed no correlation with the percentage of IL-2R positive lymphocytes. These data suggest that the increased level of sIL-2R may be related to fibrotic changes in the lung and reflect the disorder of cellular immunity in lung cancer patients with interstitial pneumonia.
en-copyright=
kn-copyright=

en-aut-name=ShibayamaTakuo
en-aut-sei=Shibayama
en-aut-mei=Takuo
kn-aut-name=柴山卓夫
kn-aut-sei=柴山
kn-aut-mei=卓夫
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二内科学教室
en-keyword=Lung cancer
kn-keyword=Lung cancer
en-keyword=Soluble interleukin-2 receptor
kn-keyword=Soluble interleukin-2 receptor
en-keyword=Interleukin-2 receptor positive lymphocyte
kn-keyword=Interleukin-2 receptor positive lymphocyte
en-keyword=Response to recombinant human interleukin-2
kn-keyword=Response to recombinant human interleukin-2
en-keyword=Interstitial pneumonia
kn-keyword=Interstitial pneumonia
END

start-ver=1.4
cd-journal=joma
no-vol=105
cd-vols=
no-issue=1-2
article-no=
start-page=1
end-page=13
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1993
dt-pub=19930227
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Studies on the pathogenesis of PIE syndrome Part 1. Evaluation of cellular responses in bronchoalveolar lavage fluid of patients with PIE syndrome
kn-title=PIE症候群の病態に関する研究　第1編 PIE症候群の肺局所細胞反応の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The bronchoalveolar lavage (BAL) fluid of patients with PIE syndrome characterized by pulmonary eosinophilia was examined to determined the cellular response in the lungs. Evaluation of cellular components in the BAL fluid revealed an increased proportion not only of eosinophils but also of lymphocytes and neutrophils. In about half of the patients with PIE syndrome the level of eosinophilia was higher in the peripheral blood than in the BAL fluid. Patients with PIE syndrome were classified into prolonged PIE and PIE with asthma based on Crofton's classification. The percentage of neutorphils and eosinophils in BAL fluid were higher in patients with prolonged PIE than in PIE with asthma while the percentage of lymphocytes was higher in a group of PIE with asthma. On the other hand, the lymphocyte precentage in BAL fluid was higher in patients with PIE syndrome due to fungus antigen than in those with PIE syndrome due to drug allergy. These findings suggest that various cellular components play important roles in the pathogenesis of PIE syndrome and that the accumulation of the effector cells in the lungs is regulated by an allergic mechamism.
en-copyright=
kn-copyright=

en-aut-name=SatoKyo
en-aut-sei=Sato
en-aut-mei=Kyo
kn-aut-name=佐藤恭
kn-aut-sei=佐藤
kn-aut-mei=恭
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二内科学教室
en-keyword=bronchoalveolar lavage
kn-keyword=bronchoalveolar lavage
en-keyword=PIE syndrome
kn-keyword=PIE syndrome
en-keyword=eosinophil
kn-keyword=eosinophil
en-keyword=lymphocyte
kn-keyword=lymphocyte
en-keyword=neutrophil
kn-keyword=neutrophil
END

start-ver=1.4
cd-journal=joma
no-vol=108
cd-vols=
no-issue=9-10
article-no=
start-page=297
end-page=301
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1996
dt-pub=19961031
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Human heart mainly consisting of left-sided elements. Discussion based on the dissection of the left superior vena cava
kn-title=ヒトの心臓は主として左側の要素から成る左上大静脈の解剖に基づく考察
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A human heart with an unusual superior vena cava was dissected. This dissection suggested that the sinus coronarius and its branches (main veins of the heart) were left-sided vessels, and that the anterior cardiac veins were right-sided vessels. It was also suggested that the sinoatrial node near the right superior vena cava was the right-sided center of the conductive system, and that the atrioventricular node close to the sinus coronarius or left superior vena cava and descending into the ventricle was the left-sided center of this system. The left coronary artery was thicker than the right one, and issued circumflex and anterior interventricular arteries. These findings indicate that the human heart mainly consists of left-sided elements.
en-copyright=
kn-copyright=

en-aut-name=MurakamiTakuro
en-aut-sei=Murakami
en-aut-mei=Takuro
kn-aut-name=村上宅郎
kn-aut-sei=村上
kn-aut-mei=宅郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第二解剖学教室
en-keyword=Human heart
kn-keyword=Human heart
en-keyword=coronary arteries
kn-keyword=coronary arteries
en-keyword=sinus coronarius
kn-keyword=sinus coronarius
en-keyword=conductive system
kn-keyword=conductive system
en-keyword=left superior vena cava
kn-keyword=left superior vena cava
END

start-ver=1.4
cd-journal=joma
no-vol=108
cd-vols=
no-issue=1-2
article-no=
start-page=13
end-page=29
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1996
dt-pub=19960229
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The expansion and antitumoral activity of recombinant IL-2 activated tumor infiltrating lymphocytes from human cancers
kn-title=腫瘍内浸潤リンパ球の rIL-2 添加培養と細胞傷害活性の研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tumor infiltrating lymohocytes (TIL) were isolated from various human cancers and cultured. The expansion, cytotoxicity, phenotype, and perforin, which is considered the cytotoxic factor of killer cells, of TIL were examinel. TIL cultured in 1000u/ml recombinant interleukin-2 (rIL-2) with 20% conditioned medium (CoM) exhibited far better expansion capability than that of TIL cultured in rIL-2 1000u/ml alone, and continued to expand up to 14 weeks. The maximal expansion index (EI) was 23912. When TIL arrested expansion during the culture, the addition of PHA restored the ability to expand. The CoM was composed of spent medium from a 3-day culture of peripheral blood mononuclear cells from cancer patients. The lymphokine-activated killer (LAK) cells induced by the culture was utilized for clinical adoptive immunotherapy in our department. Cytotoxicity against K562 and Daudi target cells was highest at 2 to 3 weeks, and disappeared between 4 and 7 weeks of culture. The phenotype of fresh TIL was mainly CD3(+) T cells, predominantly CD4(+) cells, but CD8(+) cells became predominant in long term culture. The frequency of IL-2R(+) and HLA-DR+ cells was correlated with the expansiveness of TIL. The appearance and intensity of perforin positive cells were associated with the level of cytotoxicity of cultured TIL.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoMitsuaki
en-aut-sei=Matsumoto
en-aut-mei=Mitsuaki
kn-aut-name=松本三明
kn-aut-sei=松本
kn-aut-mei=三明
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部第一外科学教室
en-keyword=腫瘍内浸潤リンパ球
kn-keyword=腫瘍内浸潤リンパ球
en-keyword=recombinant interleukin-2
kn-keyword=recombinant interleukin-2
en-keyword=細胞傷害活性
kn-keyword=細胞傷害活性
en-keyword=リンパ球表面抗原
kn-keyword=リンパ球表面抗原
en-keyword=パーフォリン
kn-keyword=パーフォリン
END

start-ver=1.4
cd-journal=joma
no-vol=108
cd-vols=
no-issue=7-8
article-no=
start-page=253
end-page=266
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1996
dt-pub=19960831
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Analysis of dopamine receptor and dopamine transporter genes in schizophrenia
kn-title=ドパミン受容体とドパミントランスポーターの遺伝子多型に基づいた精神分裂病の分子遺伝学的研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Four studies on variants of the D2 receptor gene (Ser→Cys), Bal 1 polymorphism in D3, 48-nucleotide repeat polymorphism in D4, and 40-nucleotide repeat polymorphism in the dopamine transporter gene were carried out in patients with schizophrenia (n＝73), mood disorder (n＝11), neurological disease (n＝41) and controls (n＝29). Each polymorphism was typed by amplification of genomic DNA by PCR and agarose gel electrophoresis. Eight individuals were heterozygous for Cys/Ser 311 of D2 and three of these eight were schizophrenia patients and two of the three had family histories of the illness. Two patients with schizophrenia were homozygous for the mutant form of D3 and showed a stuporous state at disease onset. It was detected that four-fold and two-fold repeats in D4, and ten-fold, nine-fold and seven-fold repeats in the dopamine transporter gene. There was no evidence of association between any of these variants and reactivity to pharmacotherapy for schizophrenia.
en-copyright=
kn-copyright=

en-aut-name=YamaguchiKoji
en-aut-sei=Yamaguchi
en-aut-mei=Koji
kn-aut-name=山口耕司
kn-aut-sei=山口
kn-aut-mei=耕司
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部神経精神医学教室
en-keyword=ドパミン受容体
kn-keyword=ドパミン受容体
en-keyword=ドパミントランスポーター
kn-keyword=ドパミントランスポーター
en-keyword=遺伝子多型
kn-keyword=遺伝子多型
en-keyword=精神分裂病
kn-keyword=精神分裂病
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7-8
article-no=
start-page=717
end-page=730
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1994
dt-pub=199408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Cloning and structural analysis of mouse Apex gene encoding the major apurinic/apyrimidinic endonuclease
kn-title=マウス APEX ヌクレアーゼ遺伝子のクローニングと構造解析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The APEX nuclease is a mammalian multifunctional repair enzyme having 5' apurinic/apyrimidinic (AP) endonuclease, DNA 3' repair diesterase, 3'-5' exonuclease and DNA 3' phosphatase activities. The mouse Apex gene for the enzyme, was isolated from a mouse leukocyte genomic library by plaque hybridization with the mouse Apex cDNA as a probe. The nucleotide sequence of the Apex gene and its 5'-and 3'-flanking regions were determined. With reference to the published Apex cDNA sequence, the mouse Apex gene can be divided into five exons and four introns with a total length of about 2.6 kb. The boundaries between exon and intron follow the GT/AG rule. The translation initiation and termination sites are located in exons Ⅱ and Ⅴ, respectively. A part of the 5' flanking region belongs to a CpG island, which extends to intron Ⅱ. The CpG island is thought to be a putative transcription regulatory region of the Apex gene, a housekeeping gene.
en-copyright=
kn-copyright=

en-aut-name=NagaoKazutaka
en-aut-sei=Nagao
en-aut-mei=Kazutaka
kn-aut-name=長尾一孝
kn-aut-sei=長尾
kn-aut-mei=一孝
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部附属分子細胞医学研究施設病態分子生物学部門
en-keyword=APEX ヌクレアーゼ
kn-keyword=APEX ヌクレアーゼ
en-keyword=AP エンドヌクレアーゼ
kn-keyword=AP エンドヌクレアーゼ
en-keyword=DNA 修復酵素
kn-keyword=DNA 修復酵素
en-keyword=Apex 遺伝子（マウス）
kn-keyword=Apex 遺伝子（マウス）
en-keyword=CpG island
kn-keyword=CpG island
END

start-ver=1.4
cd-journal=joma
no-vol=109
cd-vols=
no-issue=7-12
article-no=
start-page=133
end-page=140
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1997
dt-pub=19971225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Expression of parathyroid-related peptide mRNA in the kidney
kn-title=腎臓における副甲状腺ホルモン関連ペプチドの局在の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=PTHrP mRNA was quantified by RT-PCR and the localization of PTHrP mRNA was determined by in situ hybridization in kidney. During development, the expression of PTHrP mRNA is much higher before 2 weeks of age while kidney is developing. In E16 fetal mice, PTHrP mRNA was strongly expressed in the collecting ducts, urothelium of the pelvis, tubles, the glomeruli and immature elements in the cortex of the developing kidney (nephrogenic zone). within 0-day-old-mice, it was dominantly expressed in collecting ducts, the urothelium of the pelvis and nephrogenic zone. These findings suggest that PTHrP plays a role in kidney development as an autocrine/ paracrine factor.
en-copyright=
kn-copyright=

en-aut-name=AyaKunihiko
en-aut-sei=Aya
en-aut-mei=Kunihiko
kn-aut-name=綾邦彦
kn-aut-sei=綾
kn-aut-mei=邦彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部小児科学講座
en-keyword=副甲状腺ホルモン関連ペプチド（PTHrP)
kn-keyword=副甲状腺ホルモン関連ペプチド（PTHrP)
en-keyword=腎臓
kn-keyword=腎臓
en-keyword=発達
kn-keyword=発達
en-keyword=in situ hybridization
kn-keyword=in situ hybridization
END

start-ver=1.4
cd-journal=joma
no-vol=112
cd-vols=
no-issue=3-8
article-no=
start-page=75
end-page=84
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2000
dt-pub=20000831
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Duration of fecal shedding in enterohemorrhagic Escherichia coli O157
kn-title=腸管出血性大腸菌O157感染者における菌陰性化に要する期間についての検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In June 1997, an outbreak of enterohemorrhagic Escherichia coli O157 occurred at a hospital of Okayama City, Japan. E. coli O157 was isolated from 86 patients (40 males and 46 females). Ages ranged from 14 to 96 years old with a mean of 53 years old. All the infected patients (59 asymptomatic carriers) were investigated in this study. The median duration of shedding (from starting therapy), among the 83 patients who received antimicrobial therapy, was 6 days. This result has paticular importance for taking appropriate measures during outbreaks among adults who have other diseases. Other factors (age,sex,etc) that might have affected the duration of shedding were aiso investigated, but were not found to be influential. Among the infected patients, elderly people, females and patients who had other diseases became symptomatic, and in paticular, patients who had severe malignancy became symptomatic. All asymptomatic carriers received antimicrobial therapy and no newly affected cases and no side effects among those patients were observed. these results indicate that antimicrobial therapy for asymptomatic carriers in facilities that have a large number of susceptible people is useful.
en-copyright=
kn-copyright=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=高尾総司
kn-aut-sei=高尾
kn-aut-mei=総司
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部衛生学講座
en-keyword=E. coli O 157
kn-keyword=E. coli O 157
en-keyword=asymptomaic carrier
kn-keyword=asymptomaic carrier
en-keyword=fecal shedding time
kn-keyword=fecal shedding time
en-keyword=antibiotics
kn-keyword=antibiotics
END

start-ver=1.4
cd-journal=joma
no-vol=113
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=16
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2001
dt-pub=20010428
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Establishment of an adriamycin-resistant human bladder cancer cell line (T-24/ADM) and analysis of the mechanism of resistance
kn-title=Adriamycin 耐性ヒト膀胱癌培養細胞株の樹立と耐性機序に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A human bladder cencer cell line resistant to adriamycin (ADM), T-24/ADM was establishied in vitro by exposing T-24 parent cells to a progressively higher concentration of the drug over an 18 month period. The T-24/ADM was 34.9 times more resistant to ADM than the T-24 parent. The T-24/ADM exhibited cross resistance to ADM derivatives, vinca alkaloid (vindesine, vincristine), etoposide and SN-38, but collateral sensitivity to methotrexate. The biological and biochemical characteristics of T-24/ADM were examined in terms of ADM-resistance.
Although a flow cytometric analysis showed that Pglycoprotein is not expressed on the T-24/ADM cells, lower accumalation of the drug caused by decreased uptake and increaced active efflux were observed. The cellular level of glutathione-S-transferase π was 1.8-fold higher than the parent cells and the activity of nuclear extracts of DNA topoisomerase Ⅱ for T-24/ADM assayed by decatenation of kinetoplast DNA was lower, about one-half that of the T-24 parent. Confocal laser microscopy revealed the difference in intracellular distribution of ADM in T-24/ADM; in particular, the accumlation of the drug in the nucleus decreased. Additionally western blot analysis showed an enhanced expression of multidrug resistance-associated protein (MRP) in the T-24/ADM cells.
This resistant cell may be used as an experimantal system to elucidate the mechanisum of ADM resistance and also as a model for developing new chemotherapeutic strategies against multi-drug resistant bladder cancer.
en-copyright=
kn-copyright=

en-aut-name=AkebiNaoki
en-aut-sei=Akebi
en-aut-mei=Naoki
kn-aut-name=野比直樹
kn-aut-sei=野比
kn-aut-mei=直樹
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部泌尿器科学教室
en-keyword=adriamycin resistance
kn-keyword=adriamycin resistance
en-keyword=human bladder cancer cell line
kn-keyword=human bladder cancer cell line
en-keyword=multidrug resistance
kn-keyword=multidrug resistance
END

start-ver=1.4
cd-journal=joma
no-vol=113
cd-vols=
no-issue=3
article-no=
start-page=289
end-page=294
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2001
dt-pub=20011231
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Ultrasound guided radio-frequency albation in human hepatocellular carcinoma
kn-title=肝細胞癌の超音波ガイド下ラジオ波焼灼療法による治療
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Hapatocellular carcinoma (HCC) is one of the most prevalent malignancies in Japan. Percutaneous ethanol injection therapy (PEIT) of microwave coagulation therapy (MCT) have been used to treat small HCC. These two methods are effective methods to treat HCC; however, they have weak points. A period of admission is long to treat patients with PEIT because it requires several sessions to kill HCC completely. The risk of complications of MCT is high because the needle is thick, although it can coagulate HCC completely in one session. Radio frequecy ablation (RFA) is a new method to treat HCC. RFA compensates these weak points and is thought to become a main modality to treat HCC. In this paper, we demonstrated two patients with HCC who were treated with RFA. The effect of the treatment was examined with helical computed tomography and contrast harmonic power doppler, and the results were satisfactory. We also mentioned the merits and demerits of RAF in Discussion.
en-copyright=
kn-copyright=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=能祖一裕
kn-aut-sei=能祖
kn-aut-mei=一裕
aut-affil-num=1
ORCID=

en-aut-name=KobayashiYoshiyuki
en-aut-sei=Kobayashi
en-aut-mei=Yoshiyuki
kn-aut-name=小林功幸
kn-aut-sei=小林
kn-aut-mei=功幸
aut-affil-num=2
ORCID=

en-aut-name=NakamuraShinichiro
en-aut-sei=Nakamura
en-aut-mei=Shinichiro
kn-aut-name=中村進一郎
kn-aut-sei=中村
kn-aut-mei=進一郎
aut-affil-num=3
ORCID=

en-aut-name=YumotoEiichiro
en-aut-sei=Yumoto
en-aut-mei=Eiichiro
kn-aut-name=湯本英一朗
kn-aut-sei=湯本
kn-aut-mei=英一朗
aut-affil-num=4
ORCID=

en-aut-name=SuzukiTakahiro
en-aut-sei=Suzuki
en-aut-mei=Takahiro
kn-aut-name=鈴木貴博
kn-aut-sei=鈴木
kn-aut-mei=貴博
aut-affil-num=5
ORCID=

en-aut-name=HakodaTomomi
en-aut-sei=Hakoda
en-aut-mei=Tomomi
kn-aut-name=箱田知美
kn-aut-sei=箱田
kn-aut-mei=知美
aut-affil-num=6
ORCID=

en-aut-name=TakumaYoshitaka
en-aut-sei=Takuma
en-aut-mei=Yoshitaka
kn-aut-name=詫間義隆
kn-aut-sei=詫間
kn-aut-mei=義隆
aut-affil-num=7
ORCID=

en-aut-name=TanakaHironori
en-aut-sei=Tanaka
en-aut-mei=Hironori
kn-aut-name=田中弘教
kn-aut-sei=田中
kn-aut-mei=弘教
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoEiji
en-aut-sei=Matsumoto
en-aut-mei=Eiji
kn-aut-name=松本栄二
kn-aut-sei=松本
kn-aut-mei=栄二
aut-affil-num=9
ORCID=

en-aut-name=TaniguchiHideaki
en-aut-sei=Taniguchi
en-aut-mei=Hideaki
kn-aut-name=谷口英明
kn-aut-sei=谷口
kn-aut-mei=英明
aut-affil-num=10
ORCID=

en-aut-name=FujikawaTatsuya
en-aut-sei=Fujikawa
en-aut-mei=Tatsuya
kn-aut-name=藤川達也
kn-aut-sei=藤川
kn-aut-mei=達也
aut-affil-num=11
ORCID=

en-aut-name=SuzukiMayumi
en-aut-sei=Suzuki
en-aut-mei=Mayumi
kn-aut-name=鈴木真由美
kn-aut-sei=鈴木
kn-aut-mei=真由美
aut-affil-num=12
ORCID=

en-aut-name=MoriyaAkio
en-aut-sei=Moriya
en-aut-mei=Akio
kn-aut-name=守屋昭男
kn-aut-sei=守屋
kn-aut-mei=昭男
aut-affil-num=13
ORCID=

en-aut-name=SakaguchiKousaku
en-aut-sei=Sakaguchi
en-aut-mei=Kousaku
kn-aut-name=坂口孝作
kn-aut-sei=坂口
kn-aut-mei=孝作
aut-affil-num=14
ORCID=

en-aut-name=TsujiTakao
en-aut-sei=Tsuji
en-aut-mei=Takao
kn-aut-name=辻孝夫
kn-aut-sei=辻
kn-aut-mei=孝夫
aut-affil-num=15
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=2
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=3
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=4
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=5
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=6
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=7
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=8
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=9
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=10
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=11
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=12
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=13
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=14
en-affil=
kn-affil=岡山大学医学部附属病院第一内科

affil-num=15
en-affil=
kn-affil=岡山大学医学部附属病院第一内科
en-keyword=肝細胞癌
kn-keyword=肝細胞癌
en-keyword=ラジオ波焼灼療法
kn-keyword=ラジオ波焼灼療法
en-keyword=腹部超音波
kn-keyword=腹部超音波
en-keyword=レボビスト
kn-keyword=レボビスト
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=3
article-no=
start-page=309
end-page=323
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2003
dt-pub=20030131
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=ヒト癌における遺伝子異常の検索と遺伝子診断
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=清水憲二
kn-aut-sei=清水
kn-aut-mei=憲二
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯学総合研究科　腫瘍制御学講座・分子遺伝学分野
en-keyword=癌遺伝子
kn-keyword=癌遺伝子
en-keyword=癌抑制遺伝子
kn-keyword=癌抑制遺伝子
en-keyword=遺伝子異常
kn-keyword=遺伝子異常
en-keyword=遺伝子診断
kn-keyword=遺伝子診断
en-keyword=早期発見
kn-keyword=早期発見
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=3
article-no=
start-page=275
end-page=281
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2003
dt-pub=20030131
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Long-term prognosis of the chronic hepatitis C patients with interferon: Comparison among virological responders, biochemical responders and non-responders
kn-title=インターフェロン治療後C型慢性肝炎患者の長期予後　―ウイルス学的著効例，生化学的著効例と無効例の比較―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To evaluate the prognosis of the sustained biochemical responder after interferon (IFN) therapy, we retrospectively studied 252 chronic hepatitis C patients who were treated with IFN. Patients were divided into four groups: group A, sustained virological responders (n=84); group B,sustained biochemical but not virological responders (n=43); group C, incomplete responders (n=64); group D, non responders (n=61). The levels of several liver function tests were evaluated at the end of the observation period (4.2±1.6 years, mean±SD) compared with those at just before IFN therapy. The levels of cholinesterase, albumin, γ-globulin, zinc sufate turbidity test, platelet count and clearance rate of indocyanine green test improved in group A (p<0.05), became worse in group D (p<0.05) and did not change in group B. The incidence of hepatocellular carcinoma was significantly higher in group D than in group B (p<0.01);Kaplan-Meier method, log-rank test). The hazard ratio for hapatocarcinogenesis of the patients in group A and B was significantly lower than that in group C and D (hazard ratio: 0.27, range of 0.08-0.98; p=0.046) adjusted for age, gender, stage and total alcohol consumption.
These results suggest that the progress of liver disease and liver carcinogenesis was more suppressed in sustained biochemical responders than in non reponders.
en-copyright=
kn-copyright=

en-aut-name=MiyakeMasanobu
en-aut-sei=Miyake
en-aut-mei=Masanobu
kn-aut-name=三宅正展
kn-aut-sei=三宅
kn-aut-mei=正展
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry
en-keyword=C型肝炎
kn-keyword=C型肝炎
en-keyword=インターフェロン
kn-keyword=インターフェロン
en-keyword=生化学的持続著効
kn-keyword=生化学的持続著効
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=2
article-no=
start-page=117
end-page=123
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2002
dt-pub=20020930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ikaros family とリンパ系腫瘍
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=中瀬浩一
kn-aut-sei=中瀬
kn-aut-mei=浩一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=愛媛県立中央病院
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=3
article-no=
start-page=253
end-page=259
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2003
dt-pub=20030131
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=癌抑制遺伝子 ING ファミリーの構造と機能
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=GunduzMehmet
en-aut-sei=Gunduz
en-aut-mei=Mehmet
kn-aut-name=グンデウズメーメット
kn-aut-sei=グンデウズ
kn-aut-mei=メーメット
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医歯学総合研究科　病態機構学講座，口腔病理病態学分野
en-keyword=ING 1
kn-keyword=ING 1
en-keyword=ING 3
kn-keyword=ING 3
en-keyword=ING ファミリー
kn-keyword=ING ファミリー
en-keyword=癌抑制遺伝子
kn-keyword=癌抑制遺伝子
en-keyword=LOH
kn-keyword=LOH
END

start-ver=1.4
cd-journal=joma
no-vol=116
cd-vols=
no-issue=2
article-no=
start-page=117
end-page=123
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2004
dt-pub=20040930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Direct in vivo observation of coronary capillaries with a high resolution CCD intravital videomicroscope
kn-title=高倍率CCD生体顕微鏡システムによる 心拍動 下冠毛細血管の直接観察
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We visualized the epicardial capillary network of the beating canine heart in vivo, using our high resolution intravital CCD videomicroscopy system, in order to elucidate its functional role under control conditions and during reactive hyperemia (RH). We used 10 hearts of open chest, anesthetized dogs. The pencil-lens videomicroscope probe was placed over capillaries fed by the left anterior descending artery in A-V blocked hearts paced at 60-90 beats per minute. In individual capillaries under control conditions flow was predominant either during systole or during diastole, indicating that the watershed between diastolic arterial and systolic venous flows is located within capillaries. The capillary flow increased rapidly during RH and reached a peak flow-velocity (2.0 ± 0.2 mm/s), twice as high as the control flow-velocity (1.0 ± 0.3 mm/s), with enhancement of intercapillary cross-connection flow. Furthermore, the mean diameter increased by 15% compared with the control value, additionally facilitating oxygen supply to myocardial cells, but there was a time lag of about 1.5 s for refilling the capillaries, indicating their function as capacitance vessels during RH. In conclusion, the coronary capillary network functions as 1) the major watershed between diastolic-dominant arterial and systolic-dominant venous flows, 2) a capacitor, and 3) a local flow amplifier and homogenizer of blood supply during RH.
en-copyright=
kn-copyright=

en-aut-name=KiyookaTakahiko
en-aut-sei=Kiyooka
en-aut-mei=Takahiko
kn-aut-name=清岡崇彦
kn-aut-sei=清岡
kn-aut-mei=崇彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯学総合研究科　循環器内科
en-keyword=冠微小循環
kn-keyword=冠微小循環
en-keyword=分水嶺
kn-keyword=分水嶺
en-keyword=unstressed volume
kn-keyword=unstressed volume
END

start-ver=1.4
cd-journal=joma
no-vol=116
cd-vols=
no-issue=2
article-no=
start-page=97
end-page=101
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2004
dt-pub=20040930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=動脈硬化発生に関わる血管内皮細胞のナノ／マイクロメカニクス解析―岡山大学医学賞 （砂田賞） を受賞して―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=片岡則之
kn-aut-sei=片岡
kn-aut-mei=則之
aut-affil-num=1
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=橋本謙
kn-aut-sei=橋本
kn-aut-mei=謙
aut-affil-num=2
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=梶谷文彦
kn-aut-sei=梶谷
kn-aut-mei=文彦
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院歯学総合研究科　システム循環生理学

affil-num=2
en-affil=
kn-affil=岡山大学大学院歯学総合研究科　システム循環生理学

affil-num=3
en-affil=
kn-affil=岡山大学大学院歯学総合研究科　システム循環生理学
en-keyword=動脈硬化
kn-keyword=動脈硬化
en-keyword=血管内皮細胞
kn-keyword=血管内皮細胞
en-keyword=単球
kn-keyword=単球
en-keyword=ナノ／マイクロメカニクス
kn-keyword=ナノ／マイクロメカニクス
END

start-ver=1.4
cd-journal=joma
no-vol=116
cd-vols=
no-issue=2
article-no=
start-page=89
end-page=96
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2004
dt-pub=20040930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=石灰沈着を伴うび漫性神経原線維変化病における α-Synuclein 陽性病変から分かること―岡山大学医学賞（新見賞）を受賞して―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=横田修
kn-aut-sei=横田
kn-aut-mei=修
aut-affil-num=1
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=寺田整司
kn-aut-sei=寺田
kn-aut-mei=整司
aut-affil-num=2
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=石津秀樹
kn-aut-sei=石津
kn-aut-mei=秀樹
aut-affil-num=3
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=黒田重利
kn-aut-sei=黒田
kn-aut-mei=重利
aut-affil-num=4
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　精神神経病態学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　精神神経病態学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　精神神経病態学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　精神神経病態学
en-keyword=α-synuclein
kn-keyword=α-synuclein
en-keyword=diffuse neurofibrillary tangles with calcification
kn-keyword=diffuse neurofibrillary tangles with calcification
en-keyword=NAC
kn-keyword=NAC
en-keyword=synucleinopathy
kn-keyword=synucleinopathy
en-keyword=tauopathy
kn-keyword=tauopathy
END

start-ver=1.4
cd-journal=joma
no-vol=117
cd-vols=
no-issue=3
article-no=
start-page=193
end-page=198
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=20060104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=シナプス小胞エンドサイトーシスの制御機構に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=吉田祐美
kn-aut-sei=吉田
kn-aut-mei=祐美
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 脳神経制御学
en-keyword=エンドサイトーシス
kn-keyword=エンドサイトーシス
en-keyword=ダイナミン
kn-keyword=ダイナミン
en-keyword=アンフィファイジン
kn-keyword=アンフィファイジン
END

start-ver=1.4
cd-journal=joma
no-vol=117
cd-vols=
no-issue=2
article-no=
start-page=109
end-page=118
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2005
dt-pub=20050901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=誘導性ヒスタミンはＨ(2)受容体刺激を介してP.ances-LPS 誘発性肝炎からマウスを保護する
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=横山穣
kn-aut-sei=横山
kn-aut-mei=穣
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科薬理学
en-keyword=内因性ヒスタミン
kn-keyword=内因性ヒスタミン
en-keyword=サイトカイン
kn-keyword=サイトカイン
en-keyword=マウス急性肝炎
kn-keyword=マウス急性肝炎
END

start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=3
article-no=
start-page=225
end-page=234
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20070104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=3-ニトロチロシン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=種々の機序により産生された活性窒素種 (reactive nitrogen species) によるチロシン残基のニトロ化による3-ニトロチロシン (3-NT) の生成は, 蛋白質の翻訳後修飾の一つとして広く認められている.種々の炎症性疾患組織では, 一酸化窒素・二酸化窒素・ペルオキシナイトライトといった活性窒素種が異なる機序で産生され, 3-NTの産生に関与している. チロシンニトロ化蛋白質の同定や, 蛋白質分子中のチロシンニトロ化部位が決定できるようになり, 蛋白質の寿命, 蛋白質問相互作用に対する悪影響, 蛋白質機能喪失との関連づけが可能になってきた. 測定法としては, 免疫組織化学的手法, ウェスタンブロッティングによる半定量法から, ELISA, HPLC-ECD, LC-MS/MS, GC-MS/MSを用いた定量的な方法がある. 本総説では, 3-NTについて, その生成機序, 測定方法, 予防医学的応用を述べる.
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=荻野景規
kn-aut-sei=荻野
kn-aut-mei=景規
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　公衆衛生学
en-keyword=3ﾝニトロチロシン
kn-keyword=3ﾝニトロチロシン
en-keyword=活性窒素種
kn-keyword=活性窒素種
en-keyword=翻訳後修飾
kn-keyword=翻訳後修飾
END

start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=3
article-no=
start-page=199
end-page=203
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20070104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=パーキンソン病におけるレビー小体形成のメカニズムに関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=村上哲郎
kn-aut-sei=村上
kn-aut-mei=哲郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院　神経内科
en-keyword=パーキンソン病
kn-keyword=パーキンソン病
en-keyword=レビー小体
kn-keyword=レビー小体
en-keyword=α-synucleinopathy
kn-keyword=α-synucleinopathy
en-keyword=多系統萎縮症
kn-keyword=多系統萎縮症
en-keyword=Pael-R
kn-keyword=Pael-R
END

start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=2
article-no=
start-page=99
end-page=103
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=20060901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=中枢神経疾患に対するカプセル化細胞移植
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=安原隆雄
kn-aut-sei=安原
kn-aut-mei=隆雄
aut-affil-num=1
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=新郷哲郎
kn-aut-sei=新郷
kn-aut-mei=哲郎
aut-affil-num=2
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=小林和樹
kn-aut-sei=小林
kn-aut-mei=和樹
aut-affil-num=3
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=竹内亮
kn-aut-sei=竹内
kn-aut-mei=亮
aut-affil-num=4
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=矢野昭正
kn-aut-sei=矢野
kn-aut-mei=昭正
aut-affil-num=5
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=村岡賢一郎
kn-aut-sei=村岡
kn-aut-mei=賢一郎
aut-affil-num=6
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=亀田雅博
kn-aut-sei=亀田
kn-aut-mei=雅博
aut-affil-num=7
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=元文姫
kn-aut-sei=元
kn-aut-mei=文姫
aut-affil-num=8
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=早瀬仁志
kn-aut-sei=早瀬
kn-aut-mei=仁志
aut-affil-num=9
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=上利崇
kn-aut-sei=上利
kn-aut-mei=崇
aut-affil-num=10
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=松井利浩
kn-aut-sei=松井
kn-aut-mei=利浩
aut-affil-num=11
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=三好康之
kn-aut-sei=三好
kn-aut-mei=康之
aut-affil-num=12
ORCID=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=伊達勲
kn-aut-sei=伊達
kn-aut-mei=勲
aut-affil-num=13
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=11
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=12
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科

affil-num=13
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科
en-keyword=カプセル化細胞移植
kn-keyword=カプセル化細胞移植
en-keyword=グリア細胞株由来神経栄養因子 (GDNF)
kn-keyword=グリア細胞株由来神経栄養因子 (GDNF)
en-keyword=血管内皮成長因子 (VEGF)
kn-keyword=血管内皮成長因子 (VEGF)
en-keyword=脳虚血
kn-keyword=脳虚血
en-keyword=パーキンソン病
kn-keyword=パーキンソン病
END

start-ver=1.4
cd-journal=joma
no-vol=119
cd-vols=
no-issue=3
article-no=
start-page=301
end-page=309
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2008
dt-pub=20080104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=IV Standard medical treatment of gastrointestinal carcinoma
kn-title=IV 消化器癌の内科的標準治療
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YagiToru
en-aut-sei=Yagi
en-aut-mei=Toru
kn-aut-name=八木覚
kn-aut-sei=八木
kn-aut-mei=覚
aut-affil-num=1
ORCID=

en-aut-name=KawaharaYoshiro
en-aut-sei=Kawahara
en-aut-mei=Yoshiro
kn-aut-name=河原祥朗
kn-aut-sei=河原
kn-aut-mei=祥朗
aut-affil-num=2
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=岡田裕之
kn-aut-sei=岡田
kn-aut-mei=裕之
aut-affil-num=3
ORCID=

en-aut-name=TakemotoKoji
en-aut-sei=Takemoto
en-aut-mei=Koji
kn-aut-name=竹本浩二
kn-aut-sei=竹本
kn-aut-mei=浩二
aut-affil-num=4
ORCID=

en-aut-name=KatoJun
en-aut-sei=Kato
en-aut-mei=Jun
kn-aut-name=加藤順
kn-aut-sei=加藤
kn-aut-mei=順
aut-affil-num=5
ORCID=

en-aut-name=KobayashiYoshiyuki
en-aut-sei=Kobayashi
en-aut-mei=Yoshiyuki
kn-aut-name=小林功幸
kn-aut-sei=小林
kn-aut-mei=功幸
aut-affil-num=6
ORCID=

en-aut-name=KawamotoHirofumi
en-aut-sei=Kawamoto
en-aut-mei=Hirofumi
kn-aut-name=河本博文
kn-aut-sei=河本
kn-aut-mei=博文
aut-affil-num=7
ORCID=

en-aut-name=YamamotoKazuhide
en-aut-sei=Yamamoto
en-aut-mei=Kazuhide
kn-aut-name=山本和秀
kn-aut-sei=山本
kn-aut-mei=和秀
aut-affil-num=8
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学

affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・肝臓・感染症内科学
en-keyword=消化器癌
kn-keyword=消化器癌
en-keyword=内科治療
kn-keyword=内科治療
en-keyword=化学療法
kn-keyword=化学療法
en-keyword=内視鏡治療
kn-keyword=内視鏡治療
END

start-ver=1.4
cd-journal=joma
no-vol=119
cd-vols=
no-issue=2
article-no=
start-page=119
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20070903
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Molecular biological studies of schizophrenia with a focus on genetics
kn-title=統合失調症の分子病態研究について - 遺伝子研究を中心に -
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MoritaYukitaka
en-aut-sei=Morita
en-aut-mei=Yukitaka
kn-aut-name=森田幸孝
kn-aut-sei=森田
kn-aut-mei=幸孝
aut-affil-num=1
ORCID=

en-aut-name=UjikeHiroshi
en-aut-sei=Ujike
en-aut-mei=Hiroshi
kn-aut-name=氏家寛
kn-aut-sei=氏家
kn-aut-mei=寛
aut-affil-num=2
ORCID=

en-aut-name=KurodaShigetoshi
en-aut-sei=Kuroda
en-aut-mei=Shigetoshi
kn-aut-name=黒田重利
kn-aut-sei=黒田
kn-aut-mei=重利
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 精神神経病態学

affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 精神神経病態学

affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 精神神経病態学
en-keyword=統合失調症
kn-keyword=統合失調症
en-keyword=遺伝子研究
kn-keyword=遺伝子研究
en-keyword=多因子遺伝
kn-keyword=多因子遺伝
en-keyword=NMDA仮説
kn-keyword=NMDA仮説
en-keyword=セリンラセメース
kn-keyword=セリンラセメース
END

start-ver=1.4
cd-journal=joma
no-vol=119
cd-vols=
no-issue=1
article-no=
start-page=33
end-page=39
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20070501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Aurora-A/STK15/BTAK overexpression induces centrosome amplification, chromosomal instability, and transformation in human urothelial cells
kn-title=ヒト膀胱上皮細胞におけるAurora-A遺伝子の過剰発現と中心体の異常複製, 染色体異常の研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aurora-A/STK15/BTAK kinase encoding gene, located on chromosome 20q13, is frequently amplified and overexpressed in human cancers. Sen et al. previously demonstrated that Aurora-A amplification and overexpression are associated with aneuploidy and clinically aggressive bladder cancer (J Natl Cancer Inst (2002) 94, 1320-1329). To examine if this association is the direct result of Aurora-A gene amplification and overexpression, an immortalized human urothelial cell line (SV-HUC) was infected with an adenoviral Aurora-A-green fluorescent protein (Ad-Aurora-A-GFP) fusion construct inducing ectopic expression of the resulting fusion protein. Controls included mock-infected and adenoviral-GFP infected cells. Ectopic expression of transduced Aurora-A did not alter the doubling time of the SV-HUC cells but significantly increased the number of cells with multiple centrosomes displaying aneuploidy and increased colony formation in soft agar. This is the first report demonstrating that overexpression of Aurora-A induces centrosome anomalies together with chromosomal instability and malignant transformation-associated phenotypic changes in immortalized human urothelial cells, thus supporting the hypothesis that this gene plays an important role in the development of aggressive bladder cancer.
en-copyright=
kn-copyright=

en-aut-name=TanakaNoriyoshi
en-aut-sei=Tanaka
en-aut-mei=Noriyoshi
kn-aut-name=田中規幹
kn-aut-sei=田中
kn-aut-mei=規幹
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 分子遺伝学
en-keyword=オーロラキナーゼ-A (Aurora-A)
kn-keyword=オーロラキナーゼ-A (Aurora-A)
en-keyword=中心体 (centrosome)
kn-keyword=中心体 (centrosome)
en-keyword=染色体不安定性 (chromosomal instability)
kn-keyword=染色体不安定性 (chromosomal instability)
en-keyword=膀胱癌 (bladder cancer)
kn-keyword=膀胱癌 (bladder cancer)
END

start-ver=1.4
cd-journal=joma
no-vol=120
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=34
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2008
dt-pub=20080501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Statins inhibit hepatitis C virus RNA replication in human hepatoma cells
kn-title=培養肝細胞を用いたスタチン剤のＣ型肝炎ウイルス抑制効果について
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IkedaMasanori
en-aut-sei=Ikeda
en-aut-mei=Masanori
kn-aut-name=池田正徳
kn-aut-sei=池田
kn-aut-mei=正徳
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科　分子生物学
en-keyword=HCV
kn-keyword=HCV
en-keyword=レプリコン
kn-keyword=レプリコン
en-keyword=スタチン
kn-keyword=スタチン
en-keyword=HMG-CoA reductase
kn-keyword=HMG-CoA reductase
en-keyword=ゲラニルゲラニル化
kn-keyword=ゲラニルゲラニル化
END

start-ver=1.4
cd-journal=joma
no-vol=36
cd-vols=
no-issue=1
article-no=
start-page=13
end-page=18
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1970
dt-pub=1970
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Studies on the Radiation Breeding in the genus Mentha : (VIII)Relation between the water content of mint seeds and their sensitivity to defferent dose of γ-rays
kn-title=放射線によるハッカ属植物の育種学的基礎研究 (8報)ハッカの種子含水量と放射線感受性に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=1. Relationship between the water content of dormant seeds of genus Mentha and their sensitivity to γ-rays (60Co) was studied. 2. Sensitivity of dormant seeds to radiations was at a minimum when they contained from about 11 to 20% water, except for M. arvensis L. (40KR) seeds. 3. Resistance of dormant M. arvensis (40KR) seeds to T-rays was at a maximum when they contained from 8 to 20% water. 4. In general, sensitivity of dormant seeds of genus Mentha to radiation is increased by either a low or a high water content.
en-copyright=
kn-copyright=

en-aut-name=OnoSeiroku
en-aut-sei=Ono
en-aut-mei=Seiroku
kn-aut-name=小野清六
kn-aut-sei=小野
kn-aut-mei=清六
aut-affil-num=1
ORCID=

en-aut-name=IkedaNagamori
en-aut-sei=Ikeda
en-aut-mei=Nagamori
kn-aut-name=池田長守
kn-aut-sei=池田
kn-aut-mei=長守
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学

affil-num=2
en-affil=
kn-affil=岡山大学
en-keyword=ハッカ属植物
kn-keyword=ハッカ属植物
en-keyword=育種学
kn-keyword=育種学
en-keyword=種子含水量
kn-keyword=種子含水量
en-keyword=放射線感受性
kn-keyword=放射線感受性
END